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GENERAL INTRODUCTION 
Explanation of Dissertation Format 
This dissertation is written in an alternate thesis format as 
permitted by the Graduate College. It includes a research objective, a 
background and literature review, a rationale, an experimental part, a 
discussion, a summary, a list of references cited in the background and 
literature review and in the discussion. The experimental part has five 
sections which correspond to the manuscripts submitted for publication. 
This dissertation contains the experimental results obtained by the 
author during his graduate study under the supervision of his major 
professor. Dr. Donald C. Dyer. A portion of the results included in 
Section I were obtained in collaboration with Dr. Miguel Isla. 
Research Objective 
The purpose of this research was to study the effects of the 
serotonergic agonists acting on the uterine and umbilical circulation in 
the near-term pregnant ewe/fetus. Maternal and fetal heart rate and 
blood pressure, uterine artery blood flow, and fetal umbilical artery 
blood flow were monitored following maternal administration of the 
serotonergic agonist and antagonist in the chronically instrumented 
ewe/fetus model. In addition, isolated uterine artery and umbilical 
vessels were used to explore in more detail agonist-antagonist receptor 
mechanisms. The significance of this research is that it documents 
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under in vivo conditions the ability of the serotonergic agonists to 
alter fetal hemodynamics, their dose-response relationship and, through 
the use of in vitro techniques, the receptor mechanisms involved. 
Background and Literature Review 
The uterine and umbilical vasculature are the potential sites at 
which drugs could affect the fetus by producing vasoconstriction. 
Serotonin causes contraction of most isolated large arteries (Cohen et 
al., 1981; Cohen et al., 1983; Van Nueten et al., 1982; Van Nueten et 
al., 1981; Van Nueten et al., 1984) including uterine and umbilical 
vessels (Altura et al., 1972; Dyer, 1970a; Dyer and Gough, 1971; Nair 
and Dyer, 1973). In this section the uterine and fetal circulation and 
serotonin receptors and vascular responses are briefly reviewed. 
Uteroplacental and fetal circulation 
Uterine circulatory anatomy The uterine artery is a 
continuation of the umbilical artery which originates from the internal 
iliac artery. In humans, the abdominal aorta divides into iliac 
arteries which subdivides into external and internal iliac arteries. In 
sheep the caudal end of the abdominal aorta trifurcate into two external 
iliac arteries and a common internal iliac artery. The common internal 
iliac artery subdivides into two internal iliac arteries that branch 
into the main uterine and sacral arteries. The main uterine artery is 
further subdivided into middle and dorsal uterine arteries (Fig. 1). 
The uterus receives its blood supply from both the uterine and 
Fig. 1. Arterial supply to the ewe uterus (From Fuller et al., 1978) 
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ovarian arteries. The functional importance of these two vessels varies 
among different species and within the same species during pregnancy. 
In guinea pigs, the ovarian artery is the major contributor to the total 
blood flow of the ovary-oviduct-uterus complex in the nonpregnant state 
and becomes the lesser contributor at day 11 of pregnancy (Chaichareon 
et al., 1976). In sheep, the uterus receives its blood supply 
predominantly from the uterine artery. Using electro-magnetic flow 
probes and microspheres, Rosenfeld et al. (1974) estimated that in sheep 
the uterine arteries contributes approximately 80% of the uterine blood 
flow. 
Adjustment of the uterine circulation to pregnancy 
Vascular adjustment to pregnancy The diameter of the 
uterine arteries enlarges several fold during pregnancy. In sheep, the 
external diameter increases from about 1 mm in the nonpregnant state to 
8 or 9 mm in the near-term pregnant state (Assail and Brinkman, 1972). 
The diameter reverts to the nonpregnant size within one week post 
partum. The mechanisms by which these reversible changes take place are 
not quite clear. Moll and Gotz (1985) suggested that the increased 
diameter of arteries supplying uterine tissue during pregnancy in the 
guinea pig were due to changes in the nonmuscular elements of the 
arterial wall and that estrogen may mediate these effects. Guenther et 
al. (1988) demonstrated that a decrease in the collagen to elastin ratio 
in the uterine artery in pigs during pregnancy was positively correlated 
with the observed Increase in arterial diameter (r-.69, p<.01) at 
physiological pressures. A significant positive correlation between 
estrogen concentration and uterine arterial diameter suggested that 
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increasing estrogenic exposure may induce these changes. On the other 
hand, the marked increase in uterine blood volume and flow during the 
pregnancy could also play an important role in bringing about the 
histological changes in the uterine vasculature. The development of the 
placental circulation which would decrease uterine vascular resistance 
through the production of estrogen could also contribute to an 
adjustment in the pattern and size of the uterine vasculature. Whatever 
the mechanism(s) of the alterations in the structure of the vessels may 
be, it is clear that the enormous enlargement of the uterine vascular 
supply is extremely important to the progressively enlarging uterus and 
developing fetus in order to provide adequate nutrition at all times 
during pregnancy. 
Uterine hemodynamic adjustment to nrepnancv Among the 
various adjustments that take place in the maternal organism to 
pregnancy two events are considered of paramount importance for both 
maternal and fetal homeostasis. First is the increase in maternal 
cardiac output and blood volume (Rosenfeld, 1977). Second is the 
tremendous rise in uterine blood flow which, near term, reaches 17 to 20 
times the nonpregnant values (Assali and Brinkman, 1972). The blood 
flow to the uterus increases during pregnancy to satisfy the metabolic 
demands of the conceptus. This is accompanied by an increase in cardiac 
output in most species. In humans, cardiac output increases 
approximately 30%-40% in early gestation and then plateaus (Lees et al., 
1967). In sheep and goats, the cardiac output increases progressively 
and reach the maximum in late gestation (Rosenfeld, 1977). Dilts et al. 
(1969) demonstrated that sheep uterine blood flow increased from about 
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1.5 ml/min/kg in the nonpregnant state to about 17 ml/min/kg near term 
pregnancy. The fraction of cardiac output to the uterus increased by 
about the same magnitude. Using the microsphere technique, Rosenfeld 
(1977) estimated that the uteroplacental blood flow in sheep received 
16% of its cardiac output. 
On the other hand, the development of the uteroplacental 
circulation can be regarded as a low resistance circulatory network 
which brings about nearly a 10-fold decrease in uterine vascular 
resistance (Dilts et al., 1969). This decrease in the uterine vascular 
resistance facilitates the marked increase in uterine blood flow that 
occurs during pregnancy. The overall systemic vascular resistance of 
the mother falls by about 30% during pregnancy because of this low 
uteroplacental vascular resistance (Dilts et al., 1969). The decrease 
in systemic resistance assists in accommodating the Increase in maternal 
cardiac output during pregnancy. 
Regulation of uterine circulation The uterine vascular 
plexus receives a rich, vasomotor innervation (Bell, 1972) which has 
been demonstrated to be capable of altering uterine blood flow (Clark et 
al., 1980). Adrenergic innervation of the uterus is present in every 
species examined, whereas cholinergic innervation is either scarce or 
absent (Thorbert et al., 1977). Adrenergic nerves of the uterus 
originate from peripheral ganglia. In guinea pigs, approximately half 
of the cervix and a third of the uterine horns receive adrenergic nerve 
innervation. However, the density of the adrenergic innervation in the 
uterus progressively decreases during pregnancy (Thorbert et al., 
1978). The disappearance of adrenergic nerves starts early in gestation 
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in those parts of the uterus in close proximity to a fetus and then 
spreads to the whole organ. It is thought that the response of the 
uterine adrenergic nerves to pregnancy is part of a regulatory mechanism 
mediated by steroid hormones. The independent and interdependent 
actions of both steroid hormones and catecholamine on uterine vascular 
regulation have been reported (Clark et al., 1978; Ford et al., 1977). 
It seems that the uterine vasculature becomes insensitive to 
neuroadrenergic stimulation as pregnancy progresses and simultaneously 
becomes hypersensitive to circulatory catecholamine (Ryan et al., 1974). 
However, no substantial difference between nonpregnant and pregnant 
sheep in the sensitivity of the uterine blood flow response to neural 
stimulation and catecholamine injection has been observed (Meschia, 
1983). Marked vasoconstriction and reduced uterine blood flow in 
pregnant sheep has been observed by both nerve stimulation of the 
uterine artery (Fuller et al., 1979) and infusion of catecholamine into 
pregnant sheep (Anderson et al., 1977; Rosenfeld et al., 1977). 
However, it seems that the uterine blood flow is not tonically regulated 
by the alpha^ receptor since administration of phenoxybenzamine failed 
to change the uterine blood flow (Chez et al., 1978). During gestation 
in sheep, the uterine vasculature is more sensitive to catecholamine 
than are other vascular beds in the systemic circulation and the a^-
adrenoceptor mediated contractile responses to norepinephrine (NE) of 
uterine arteries increased during pregnancy (Martensson and Carter, 
1982). 
Placental circulation The placentas of sheep, goats and cattle 
represent the cotyledonary variety of epitheliochorial placenta. A 
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crosscurrent arrangement between the maternal and fetal circulation was 
proposed for the ovine placenta (Meschia, 1983). Data on oxygen 
transfer indicate that the ovine placenta is an inefficient organ of 
diffusional exchange (Rankin et al., 1971). In the fetal lamb the 
umbilical venous Pog is consistently lower than the uterine venous Pog 
over a wide range of maternal Pog values (Rankin et al. , 1971). 
In sheep, blood flow to the uterus and its placenta have been 
measured throughout pregnancy (Rosenfeld et al,, 1974). In the early 
part of gestation, myometrium and endometrium still form the bulk of 
uterine weight and receive the largest fraction, approximately 73%, of 
uterine blood flow. Blood flow to the formation sites of the placental 
cotyledons (caruncles), however, is remarkably high in relation to their 
size. Consequently, in the 2nd month of ovine pregnancy, placental 
blood flow becomes the largest fraction (approximately 63%) of the total 
uterine flow. In the final 2 months of pregnancy fetal weight increases 
exponentially while at the same time placental weight decreases 
slightly. Despite the decrease in placental weight, placental blood 
flow increases several folds from approximately 300 ml/min to as much as 
2 liters/min. In the last month of gestation, caruncula flow becomes 
approximately 82% of uterine flow. It is obvious that any reduction in 
uterine blood flow will considerably affect placental circulation. 
As discussed above, the formation and growth of the placenta 
vascular bed generates a low vascular resistance in the uterine vessels 
which brings about a large increase of blood flow to the uterus during 
pregnancy. Therefore, influencing the development of the placental 
circulation could modify the magnitude of uterine blood flow. This 
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would be a chronic regulatory mechanism of the uterine blood flow. On 
the other hand, rapidly changing the diameter of the placental 
circulatory channels can act as a short-term regulatory mechanism. It 
is generally thought that nerves are absent in the umbilical cord and 
placenta and for this reason attention has been focused on the role of 
humoral autacoid in the control of placental vascular tone. Most 
studies have been conducted in vitro because of the technical 
difficulties of in vivo investigations during pregnancy. In vitro 
studies have included perfusion of the umbilical vessels (Boura et al., 
1979) and recording the vasoconstriction of helical strips of umbilical 
artery or vein (Dyer, 1970a, 1983; Tulenko, 1979), Mak et al. (1984) 
demonstrated that thromboxane A2 in the placenta and thromboxane Aj, 5-
HT and bradykinin in the umbilical vein could contribute to control of 
vascular smooth muscle tone. Their vasoconstrictor effects are partly 
indirect and affected by the concomitant local release/formation-of 
eicosanoids. These autacoid may normally have important influences on 
blood flow in the fetal extracorporeal circulation. Epinephrine (EPI), 
NE and histamine have, if any, minimal influences on the placental 
circulation. 
Fetal circulation 
Anatomv of the fetal cardiovascular circulation The fetus 
takes up nutritional substances and excretes metabolic wastes into the 
maternal circulation through the placenta. Thus, the placenta serves as 
the "lung and kidney" for fetus. The major circulatory features of the 
fetal lamb are diagrammed in Fig. 2. The human fetus differs from the 
sheep fetus in having one umbilical vein rather than two. The right and 
Fig. 2. Schematic representation of cardiovascular circulation of fetal 
lamb (From Assali et al., 1968) 
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left ventricles of the fetus operate in parallel because of the foramen 
ovale between the right and left atria. The patent ductus arteriosus 
connects the pulmonary artery and the aorta. Therefore, blood is pumped 
into the aorta at different sites and the lungs are almost entirely 
bypassed. 
The combined output of the left and right ventricle is about 
equally divided between the placenta and the body of the fetus itself. 
The placental circulation is supplied by the umbilical arteries and has 
a relatively low vascular resistance. The rate of blood flow in the 
descending aorta of the fetus is very high (490 ml/kg fetal weight/min), 
about half of which goes to the placenta via the umbilical arteries 
(Rudolph and Heymann, 1974). Most oxygenated blood returning from 
placental circulation enters the inferior vena cava; about 40% traverses 
through the foramen ovale to the left heart. Therefore, the left-sided 
heart chambers are supplied with more highly oxygenated blood from the 
placenta. Since the lungs are collapsed and the pulmonary vascular 
resistance is high, about 90% of the output of the right ventricle 
traverses the patent ductus arteriosus to reach the descending aorta, 
and only about 7% traverses the lungs in the fetus of the sheep near 
term (Rudolph and Heymann, 1974). 
The blood oxygen saturation is about 58% in the umbilical artery 
and about 80% in the umbilical vein. Part of the oxygenated blood in the 
umbilical vein bypasses the liver through the ductus venosus and enters 
the inferior vena cava, where it joins blood from the lower trunk and 
extremities (25% saturated) and from the liver. Mixed blood reaching 
the left atrium has an oxygen saturation of 60-65%. 
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The pulmonary arterial pressure is about 5 mmHg above that in the 
aorta. Therefore, most of the right ventricular output flow enters the 
aorta through the ductus arteriosus. The blood enters the aorta at a 
point distal to the origins of the arteries to the head and upper limbs, 
and is thus directed to the posterior body and umbilical arteries. More 
highly oxygenated blood from the left ventricle is pumped into the 
ascending aorta to reach the arteries supplying the cerebral 
circulation, the heart, and the upper extremities. 
Regulation of the fetal circulation Fig. 3 shows a block 
diagram of the factors that enter into play to control arterial blood 
pressure. It has been demonstrated that the fetal heart has limited 
ability to increase stroke volume (Rudolph and Heymann, 1974) and this 
limitation could be explained by the lower compliance (Romero et al., 
1972) and contractility (Friedman, 1973) of the fetal cardiac muscle. 
Furthermore, since the two ventricles effectively function in parallel 
as discussed above, the Frank-Starling mechanism would not be as 
important as it is in the adult. The fetal cardiac output is thus 
regulated predominantly by changes in heart rate (Rudolph and Heymann, 
1974). In sheep, the fetal heart rate ranges from 170 to 220 and this 
fast heart rate is important to provide the fetus with the high cardiac 
output necessary to meet its metabolic activities. In general, 
sustained bradycardia is thought to reflect fetal distress (Assali et 
al., 1968). 
The fetal systemic arterial pressure is relatively low compared to 
the adult, which could be caused by the low fetal systemic vascular 
resistance. The major factor which contributes to the low fetal 
Fig. 3. Block diagram of the factors affecting arterial blood pressure 
(From Assali et al., 1968) 
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systemic vascular resistance is the umbilicoplacental circulation 
(Assail et al., 1968). This vascular bed accepts about the half of the 
fetal cardiac output and has a relatively low vascular resistance. 
Therefore, any increase in the vascular resistance of the 
umbilicoplacental circulation promptly increases fetal systemic vascular 
resistance and produces an increase in arterial pressure and a decrease 
in cardiac output. It has been demonstrated by Assali et al. (1968) 
that compression of the whole umbilical cord produces bradycardia along 
with a transitory hypertension. If the umbilical arteries alone are 
compressed, similar changes are observed. If the umbilical veins are 
compressed, a prompt bradycardia with hypotension occurred. These 
changes are probably vagal in origin and are related to many factors 
such as hypoxia, decreased right heart filling, cardiac output, and so 
forth. 
The autonomic nervous system supplying the vascular bed is fully 
developed in the term fetus (Assali et al., 1968). It appears that 
parasympathetic innervation precedes sympathetic innervation in the 
fetus (Rudolph and Heymann, 1974). Baroreflex activity has been 
demonstrated to be present in the fetal lamb by observing a fall in the 
heart rate following an increase in arterial blood pressure (Maloney et 
al., 1977; Shineboume et al., 1972) and its sensitivity progressively 
increased with advancing gestation until term, but there was no further 
change after birth (Rudolph and Heymann, 1974). 
Sympathetic innervation starts in the fetal lamb at about 0.5 of 
gestation (Lebowitz et al., 1972). It seems that there is greater 
sympathetic control of blood pressure in the term fetus and newborn than 
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in the adult (Woods et al., 1977). From studies of the development of 
adrenergic nerve control of various organs a general principle has been 
proposed: the function of the post-synaptic component can generally be 
demonstrated before the presynaptic elements are fully functional 
(Rudolph and Heymann, 1974). The studies indicate that alpha and beta 
adrenergic receptors and parasympathetic receptors are present in the 
myocardium and many vascular structures at an early gestational age 
(Rudolph and Heymann, 1974; Vapaavuori et al., 1973). 
It has been well established that NE is present in the circulation 
of near-term fetuses and is derived from the adrenal gland as well as 
the sympathetic nervous system (Cheung and Brace, 1987; Lewis et al., 
1982). Administration of exogenous NE to the fetal lamb produced an 
increase in arterial pressure and a decrease in heart rate (Cheung and 
Brace, 1987, 1988; Lewis et al., 1982). In chronically catheterized 
sheep fetuses, acute hypoxia caused an increase in arterial pressure and 
a decrease in heart rate (Iwamoto et al., 1983; Lewis et al., 1984). It 
has been suggested that these cardiovascular changes may be mediated by 
the concomitant increase in plasma NE and EPI concentrations (Cohen et 
al., 1984; Jones and Ritchie, 1983; Lewis et al., 1982). 
Arginine vasopressin (AVP) may also play an important role in 
maintaining homeostasis of the fetal cardiovascular system (Stark et 
al., 1982; Stegner et al., 1984; Wiriyathian et al., 1983). There was a 
large increase in plasma AVP concentration during fetal stress and acute 
hypoxia (Stark et al., 1982; Stegner et al., 1984). It has been 
demonstrated that infusion of AVP produced a marked increase in fetal 
arterial pressure and a decrease in heart rate (Robillard and Weitzman, 
19 
1980; Wiriyathian et al., 1983). The autonomie nervous system may 
modulate the fetal arterial pressure and heart rate responses to AVP 
(Tomita et al., 1985). 
Serotonin receptors and vascular responses 
Biochemistry of serotonin 
Distribution of serotonin Most of the serotonin in the 
body is found in enterochromaffin cells of the intestine, the central 
nervous system, and blood. Platelets contain about 90% of the 5-HT in 
the blood. The concentration of free 5-HT in the plasma is about 20 
ng/ml. The gastrointestinal tract in mice, rats and guinea pigs has 
been reported to possess serotonergic neurons (Gershon et al., 1977). 
Other tissues containing significant amounts of 5-HT are the heart, 
kidney, spleen and thyroid. The significance of the presence of 
serotonin in these tissues is not yet understood. 
Biosynthesis of serotonin Serotonin is synthesized from 
the essential amino acid L-tryptophan by two enzymatic reactions (Fig. 
4). The amount of 5-HT synthesized daily is about 10 mg. The rate-
limiting step in the synthesis of serotonin from tryptophan is the first 
reaction catalyzed by tryptophan hydroxylase, which is present only in 
cells synthesizing serotonin. The second enzyme, L-aromatic amino acid 
decarboxylase, is widely distributed in tissues and is not specific. It 
will catalyze the decarboxylation of all aromatic amino acids, including 
L-3,4-dihydroxyphenylalanine, the precursor of the catecholamine. 
Metabolism of serotonin The major pathway of metabolism of 
serotonin is by oxidative deamination with the production of the 
unstable intermediate 5-hydroxyindoleacetaldehyde, which can undergo 
Fig'. 4. Biosynthesis of serotonin (From Tyce, 1985) 
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oxidation catalyzed by the enzyme aldehyde dehydrogenase with the 
formation of 5-hydroxyindoleacetic acid, or undergo reduction catalyzed 
by aldehyde reductase with the formation of 5-hydroxytryptophol (Fig. 
5). Under normal circumstances the predominant pathway is oxidation to 
5-hydroxyindoleacetic acid. 
Classification of serotonin receptors 
Overview The first classification of 5-HT receptors came 
from the work of Gaddum and Picarelli (1957) who demonstrated the 
existence of two pharmacologically distinct types of receptors (D and 
M) for 5-HT in the guinea-pig ileum. The D receptor is sensitive to 
Dibenzyline (phenoxybenzamine) and mediates contraction of the smooth 
muscle. The M receptor is sensitive to morphine and mediates 
depolarization of the cholinergic nerves. Since Dibenzyline and 
morphine are not specific 5-HT receptor blocking drugs, they are of 
little or no value as tools for the overall classification of 5-HT 
receptors. Recently, two classification schemes of 5-HT receptors have 
been proposed (Bradley et al., 1986; Peroutka and Snyder, 1979). Based 
on radioligand binding study, Peroutka and Snyder (1979) demonstrated 
that there were two distinct 5-HT binding sites (S-HT^ and 5-HT2) in the 
central nervous system (CNS), while Bradley et al. (1986), based largely 
on data from the functional studies in isolated peripheral tissues, 
proposed three distinct groups of 5-HT receptors which have been named 
"5-HTi-like", 5-HT2 and 5-HT3. 5-HTi binding sites in CNS the have been 
further subdivided into four subtypes (Heuring and Peroutka, 1987; Pazos 
et al., 1984b; Pedigo et al., 1981). More recently, Hartig (1989) 
proposed a classification scheme for 5-HT receptors based primarily on 
Fig, 5. Metabolism of serotonin (From Tyce, 1985) 
24 
Serotonin - 0 - Glucuronide Seroionin-O-Sulfote 
g/ucuronyl 
transferase 
serotonin 
'^sulfotransferase 
HQ 
CHg-CHg-NHg CHg-CH^H 
H 
Serofon/n 
serotonin 
N-acetyl- transferase 
H 
5-Hydroxytryptophol 
monoamine 
oxidase 
CHz'CHg'NH-CO'CHs HO 
aldehyde 
reductase 
CHg-CHO 
N-Acetylserotonin 5 - Hydroxyindoleacetaldehyde 
aldehyde 
dehydrogenase 
hydroxy/ndo/e-
0-methyltransferase 
iCHg-CH^-NH-CO-CH^ HO 
H 
Melatonin 
H 
5'Hydroxyindole Acetic Acid 
25 
the molecular structure of the receptor proteins and second messenger 
systems. 
5-HTi receptors S-HTj binding sites first proposed by 
Peroutka and Snyder (1979) were defined by nanomolar affinity for 5-HT 
and could be labeled with [®H]5-HT. Later it has been found that 5-HTi 
binding sites labeled by [^H]5-HT were heterogeneous (Table 1). The 
different affinities to spiperone at [^H]5-HT binding sites led to the 
suggestion that the sites with high affinity for spiperone should be 
designated sites, while the sites with relatively low affinity 
for spiperone should be designated S-HT^b sites (Pedigo et al., 1981; 
Schnellmann, 1984). A third subtype of S-HT^ recognition sites (the 5-
HTic sites) was identified in the choroid plexus and cortex of various 
species (Pazos et al., 1984a, 1984b; Peroutka, 1986). Most recently, 
the studies of the pharmacology and biochemistry of the S-HT^q receptor 
(Hartig, 1989; Pazos and Palacios, 1985; Yagaloff and Hartig, 1985) 
suggest that it should be more appropriately placed in the S-HTg family 
of receptors. 
The 5-HT]^ receptor was the second 5-HT receptor that was 
successfully cloned. The transfection of the G-21 clone into monkey 
kidney cells produces a protein that exhibits the ligand binding 
characteristics of the 5-HTij^ and beta-adrenergic receptors (Fargin et 
al., 1988). Both labeled cyanopindolol, a radioligand that labels 
beta-adrenergic receptors, and the S-HT^^ agonist [^H]8-hydroxy-(2-di-
N-propylamino)-tetralin (8-OH-DPAT) have a high affinity to G-21-
transfected monkey kidney cell membranes. The possible relationship 
between S-HT^j^ receptors and ^-adrenergic receptors are supported by the 
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Table 1. Characteristics of 5-HT receptor subtypes (From Schmidt and 
Peroutka, 1989) 
5-HTi receptors 
5-HTiA 5-HTIB 5-HTiD 
Molecular Cloned ? ? 
biology 
Radiolabeled [3H]5-HT [3H]5-HT [3H]5-HT 
by [3H]8-0H-DPAT labeled CYP 
[®H]Ipsapirone (Rat and mouse 
[3H]WB 4101 only) 
[®H]Buspirone 
[3H]PAPP 
[ ^H]Spiroxatrine 
[3H]5-MeO-DPAC 
labeled BH-8-MeO-N-PAT 
High density Raphe nuclei Substantia nigra Basal 
regions Hippocampus Globus pallidus ganglia 
Selective 
Potent phar­ 8-OH-DPAT No agents No agents 
macologic Ipsapirone available available 
agents 
(<10nM) 
Nonselective 
5-HT 5-HT 5-HT 
5-CT 5-CT 5-CT 
RU 24969 RU 24969 Metergoline 
d-LSD ( - )Pindolol 
(-)Pindolol 
Second Inhibition of adenylate Inhibition of Inhibition 
messenger cyclase adenylate of adenyla­
cyclase te cyclase 
Membrane Hyperpolarization via an ? ? 
effects opening of potassium 
channels 
Other Basilar artery Autoreceptor Autoreceptor 
functional Thermoregulation 
correlates Hypotension 
Sexual behavior 
5-HT Syndrome 
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Table 1. continued 
S-HTg receptors 5-HT3 receptors 
5-HTic 5-HT2A 5-HT2B 5-HT3 
Cloned ? Cloned ? 
[3H]5-HT [3H]D0B [^H]Spiperone [%]GR 65630 
[ j Mesulergine ["Br]R(-)DOB [ i Mesulergine i^HjlCS 205-930 
i®H]Mianserin labeled DOI "^I-labeled LSD [^H]Quipazine 
labeled LSD [^HJKetanserin [®H]Ketanserin [^H]Zacopride 
[^HJSCH 23390 [^H]Mianserin [3H]BRL 43694 
labeled SCH ^^'l-labeled [3H]QICS 205-930 
23892 methyl-LSD 
[ ]N-me thy1-sp ip erone 
Choroid plexus Layer IV cortex Layer IV cortex Peripheral neuron 
Entorhinal cortex 
Area postrema 
Selective 
No agents DOB No agents GR 65630 
available DOI available Zacopride 
ICS 205-930 
Granisetron 
Ondansetron 
Nonselective 
Mesulergine Mesulergine Mesulergine 
Metergoline Metergoline Metergoline 
Methysergide Methysergide 
Mianserin Mianserin 
Ketanserin Ketanserin 
Spiperone Spiperone 
PI turnover ? PI turnover ? 
Depolarization ? Depolarization Depolarization 
via an opening 
mf r»Vi1 nfî He 
channels 
Vascular contraction 
Platelet shape change 
Platelet aggregation 
Paw edema 
Tryptamine seizures 
Head twitches 
Transmitter 
release 
von Bezold-
Jarisch reflex 
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similarity in amino acid sequence shared by these two receptors. In 
several amino acid stretches, the receptor more closely resembles 
the ^^-adrenoceptor than it does the other cloned 5-HT receptors. The 
5-HTia receptor and the /^^adrenoceptor are identical in 20 out of 27 
amino acids, while the receptor only shares a maximum of ten out 
I 
of 27 amino acids with either of the other two cloned 5-HT receptors 
(Fargin et al., 1988; Julius et al., 1988; Pritchett et al., 1988), 
This raises intriguing questions about the functional and evolutionary 
relationships among these different receptors. 
5-HTia receptors can be labeled by a number of radioligands. 
Although the S-HT^y^ site can be labeled with [^H]5-HT, it can be more 
directly labeled with [^H]8-OH-DPAT (Gozlan et al., 1983; Hall et al., 
1985; Hoyer et al., 1985; Peroutka, 1986), [^H]ipsapirone (Dompert et 
al., 1985), [^H]buspirone (Moon and Taylor, 1985) and [^H]l-(2-(4-
aminophenyl)ethyl)-4-(3-trifluro-methylphenyl)piperazine (PAPP) (Asarch 
et al., 1985). A selective a^-adrenergic radioligand, [^H]WB 4101, has 
also been demonstrated to label the S-HT^^ site (Norman et al., 1985). 
8-OH-DPAT potently binds at the 5-HTia site (IG50 - 6.3 nM) but is 
essentially inactive (IC50 - 3800 nM) at both the 5-HTig and 5-HT2 
binding sites (Arvidsson et al., 1981; Gozlan et al., 1983; 
Marcinkiewicz et al., 1984). 
The dense areas for S-HT^^^ binding sites in the brain are the CA 1 
region, the denate gyrus of the hippocampus and the raphe nuclei (Hoyer 
et al., 1986; Pazos and Palacios, 1985). The involvement of S-HTi* 
receptor in 5-HT behavioral syndrome (Smith and Peroutka, 1986; 
Tricklebank, 1985), seminal emissions and/or ejaculations (Kwong et al., 
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1986) and the thermoregulation (Tricklebank, 1985) has been proposed. 
In the periphery, 5-HT-induced contractions of the canine basilar artery 
have been proposed to be a functional correlate of the S-HT^^ receptor 
(Peroutka et al., 1986; Taylor et al., 1986). 
labeled cyanopindolal directly labeled S-HT^g binding sites in 
the rat brain (Hoyer et al., 1985). Other radioligands for 5-HTiB 
binding sites have also been reported (Table 1). Three arylpiperazines 
related compounds, m-trifluoromethyl-phenylpiperazine (TFMPP), l-(3-
chlorophenyl)piperazine (mCPP) and l-(2-methoxyphenyl)piperazine (2-
MPP) have been identified as relatively selective ligands for the 5-
HT^g binding sites (Fuller et al., 1980; Glennon, 1987; Sills et al., 
1984). The affinities of these three compounds were much higher at 5-
HTib binding sites than they were at 5-HTij^ and S-HT^c binding sites. 
TFMPP has values of 1950 and 30 nM for the S-HT^^ and 5-HTib binding 
sites, respectively (Glennon, 1987). mCPP has values of 2400 and 75 
nM for the 5-HTij^ and 5-HTib binding sites, respectively (Glennon, 1987). 
2-MPP possesses a 100-fold selectivity for 5-HTi vs. 5-HT2 sites and an 
affinity for 5-HTi sites comparable to that of TFMPP (Glennon, 1987). 
The 5-HTiB receptor binding sites appear to be species specific. 
To date, the 5-HTig binding sites have been identified only in rat and 
mouse brains but not in guinea pig, cow, chicken, turtle, frog, or human 
brain membranes (Heuring et al., 1986; Hoyer et al., 1986). In the rat 
brain, the highest density of S-HT^g binding is in globus pallidus, 
dorsal subiculum, and substantia nigra (Hoyer et al., 1986). The 5-
HTig site has been associated with 5-HT and noradrenergic neurons 
"autoreceptors" in the CNS and periphery (Engel et al., 1986; Raiteri et 
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al., 1986). No functional correlates of the S-HT^g receptor in blood 
vessels have been reported. 
The 5-HTiQ site was originally identified in bovine brain membranes 
(Hearing and Peroutka, 1987) and found in many other species, including 
pig, calf, and human brain membranes (Schmidt and Peroutka, 1989). 
These [^H]5-HT labelled sites display nanomolar affinity for 5-
carboxyamidotryptamine (5-CT), 5-methoxytryptamine, metergoline, and 5-
HT but display a low affinity to S-HT^^, S-HTm, S-HTjci S-HTg and S-HTj 
selective agents (Heuring and Peroutka, 1987). 5-HTuj binding sites 
exist in all regions of bovine brain but are most dense in the basal 
ganglia (Heuring and Peroutka, 1987). To date, a specific physiological 
effect of 5-HT has not been correlated with S-HT^g binding sites. 
As discussed above, the S-HT^ radioligand binding site is clearly 
not a homogeneous entity. Since no selective antagonists have yet been 
described, it is a considerable handicap to the definition of these 
sites related to functional studies. In this sense, Bradley et al. 
suggested a term "5-HTi-like" receptors which may not necessarily be 
identical to S-HT^ recognition sites as described above. Some currently 
used 5-HTi antagonists like methiothepin and methysergide bind to both 
5-HTi and S-HTg receptors (Bradley et al., 1986; Engel et al., 1983; 
Martin and Sanders-Bush, 1982). The criteria for a response to be 
defined as mediated through "5-HTi-like" receptors have been proposed 
(Bradley et al., 1986) in which the response should be susceptible to 
antagonism by methiothepin and/or methysergide and should be resistant 
to antagonism by selective S-HTj receptor antagonists such as ketanserin 
and cyproheptadine and by S-HTg receptor antagonists such as MDL 72222 
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or ICS 205-930. Also the response should be mimicked by the selective 
5-HTi agonist 5-CT at concentrations equal to or less than those of 5-
HT, 
According to these criteria, 5-HT-induced contractile responses in 
the saphenous vein of the dog and the basilar artery from rabbit and man 
have been defined as "5-HTi-like" receptor mediated (Apperley et al., 
1986; Bradley et al., 1986a, 1986b; Feniuk et al., 1985; Forster and 
Whalley, 1982; Peroutka, 1984). There is also evidence that such 
receptors mediate vasoconstriction in the arteriovenous anastomoses 
located in the carotid circulation in vivo (Verdouw et al., 1985). The 
5-HT-induced relaxation of some vascular and gastrointestinal smooth 
muscle could also be mediated by "5-HTi-like" receptors (Cohen et al., 
1983; Feniuk et al., 1983, 1984), 
5-HTo receptors 5-HT2 receptors have first been proposed 
by Peroutka and Snyder (1979) to describe a 5-HT recognition site in the 
brain with a low affinity for 5-HT but with a high affinity for 
spiperone and other 5-HT receptor antagonists such as methysergide and 
cyproheptadine. Other radioligands that have been used to label S-HTg 
sites include [^H]ketanserin, [^H]mesulergine, [^"l]LSD, and [^"l]MIL 
(Hoffman et al., 1985; Leysen et al., 1982; Yagaloff and Hartig, 1985). 
Ketanserin, a 5-HT antagonist, possesses a high affinity (K^ < 1 nM) for 
5-HT2 sites and a negligible affinity for S-HT^ recognition sites 
(Arvidsson et al., 1981; Leysen et al., 1981; Leysen et al., 1982). In 
general, 5-HT2 binding sites have high affinity for the agents that are 
usually considered as being serotonin antagonists. On the other hand, 
classical 5-HT agonists generally display a relatively low affinity for 
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5-HT2 sites. One of the good examples is 5-HT. The affinity (K^) of 5-
HT for [^H] ketanserin-labeled 5-HT2 sites is in the 400-1000 nM range 
(Glennon, 1987). The highest level of 5-HT2 binding sites is in layer 
IV of the cerebral cortex and caudate. Other brain regions have 
substantially fewer binding sites (Hoyer et al., 1986; Pazos and 
Palacios, 1985). 
It was thought that S-HTg sites were homogeneous (Peroutka, 1988). 
However, recent studies have provided data to suggest that subtypes 
exist within the 5-HT2 receptor family (Lyon et al., 1987; Peroutka et 
al., 1988; Pierce and Peroutka, 1989). It has been demonstrated that 5-
HT competition curves with [^H]ketanserin in rat and human cortical 
membranes are shallow (Hill slopes - 0.67, 0.69, respectively), 
suggesting that [®H] ketanserin labels more than one population of 5-HT 
receptors, while in bovine cortical membranes, 5-HT competition curves 
are steep (Hill slope - 0.97) indicating that a single site is labeled 
by [^H] ketanserin (Pierce and Peroutka, 1989). In addition, it was 
shown that [^H]DOB (4-bromo-2,5-dimethoxy-amphetamine) does not label an 
agonist state of the S-HTg recognition site, but rather a distinct 
subtype of the 5-HT2 receptor (Lyon et al., 1987). Also [^^Br] R(-
)DOB-labeled sites comprise only 19% of the density of 5-HT2 sites in 
rat cortex and are not eliminated by the addition of lO'^M GTP (Peroutka 
et al., 1989). In accordance with these data it has been proposed that 
the high affinity component of [^H]ketanserin binding site was 
designated the 5-HT2A binding site, while the low affinity component was 
designated the 5-HT2B site (Pierce and Peroutka, 1989) (Table 1). 
Further elaboration on the classification of the 5-HT2 receptors will 
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depend on the development of selective agents that can distinguish 
subtypes of the S-HTg receptors. 
Based on the similarities in amino acid structure and the second 
messenger pathway, the 5-HTiq receptor has recently been proposed to 
belong to the 5-HT2 receptor family (Hartig, 1989; Hoyer, 1988; Pierce 
and Peroutka, 1989; Pritchett et al., 1989). Similarities in ligand 
binding properties and second messenger coupling of the S-HTg and 5-
HTic receptors have been apparent (Hoyer, 1988). The high homology 
between the S-HTg and S-HT^; receptor clones is obvious and they share 
78% sequence homology with 141 out of 180 amino acids being identical 
(Fargin et al., 1988; Julius et al., 1988; Pritchett et al., 1988). 
The identification of ketanserin as a S-HTg antagonist provided a 
particularly useful tool with which to characterize these receptors 
pharmacologically. This compound shows negligible affinity for S-HT^ 
binding sites and is not a potent calcium antagonist (Leysen et al., 
1981; Van Nueten and Vanhoutte, 1981). However, it should be noted that 
ketanserin does show appreciable affinity for o-adrenoceptors (Kalkman 
et al., 1982; Leysen et al., 1981; Leysen et al., 1982; Van Nueten et 
al., 1981; Wenting et al., 1984) and it is imperative to dissociate 
those effects of 5-HT which are mediated via stimulation of specific 5-
HT receptors from those effects which may be mediated via a-
adrenoceptors (Feniuk, 1984). Therefore, before the receptor subserving 
a given response can be characterized as being of the S-HTg type, it 
should be necessary to exclude the possible involvement of alpha-
adrenergic receptor activity in 5-HT-induced responses or to determine 
the antagonistic potencies of both ketanserin and methysergide which has 
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appreciable affinity for 5-HTi receptors but has negligible affinity for 
a-adrenoceptors. The criteria for the characterization of 5-HT2 
receptors have been proposed by Bradley et al. (1986) in which the 5-
HT-induced response should be susceptible to antagonism by ketanserin 
and/or methysergide but not by MDL 72222 and ICS 205-930. 
The characterization of 5-HT2 receptors with the corresponding 
pharmacological responses has been investigated in various tissues, 
including blood vessels. Vasoconstriction in many arteries has been 
found to be mediated by a receptor similar to the S-HTg binding site 
(Leysen et al., 1984; Maayani et al., 1984; Van Nueten et al., 1981, 
1984). Similarly, drug antagonism of tracheal smooth muscle 
contraction, in vivo bronchoconstriction and contraction of guinea pig 
ileum is consistent with mediation by S-HTg receptors (Leysen et al., 
1984). 5-HT induction of platelet shape changes and aggregation may 
also be mediated by S-HTg receptors (Leysen et al., 1984). A number of 
CNS effects of 5-HT have also been attributed to 5-HT2 receptors 
(Glennon et al., 1983; Leysen et al., 1982, 1984; Peroutka et al., 
1981). 
5-HT3 receptors The recognition of 5-HT3 receptors is 
based on the identification of the selective S-HTg receptor antagonists 
cocaine and MDL 72222 (Fozard et al., 1979; Fozard, 1984a). With the 
availability of these specific antagonists, 5-HT3 receptors have been 
identified in a variety of locations on peripheral efferent and afferent 
neurons (Fozard, 1984b). Lately, a more potent S-HTg antagonist ICS 
205-930 and a selective 5-HT3 agonist, 2-methyl-5HT, were identified by 
Richardson et al. (1985). The criteria for the characterization of 5-
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HTg receptors have been proposed (Bradley et al., 1986a). For a 
response to be defined as being mediated by S-HTg receptors it should be 
susceptible to antagonism by cocaine, MDL 72222 or ICS 205-930, but 
resistant to antagonism by ketanserin or methiothepin. Also this 
response should be mimicked by the selective S-HTg agonist 2-methyl-5-
HT, which has a potency similar to that of 5-HT itself. 
Although 5-HT3 receptors were originally demonstrated on peripheral 
neurons where they were responsible for eliciting the depolarizing 
action of 5-HT, recent data show that S-HTg binding sites are also 
identified in the rat brain with [^H]GR 65630 and a variety of other 
radioligands (Kilpatrick et al., 1987) (Table 1). S-HTg agonists such 
as 5-HT, 2-methyl-5-HT, and phenylbiguanide have a moderate affinity (K^ 
value approximately 150 nM) for this site. The 5-HT3 antagonists such 
as granisetron, ICS 205-930, and zacopride display subnanomolar affinity 
(Ki values - 0.1-0.8 nM) for this site (Schmidt and Peroutka, 1989). In 
rat brains, 5-HT3 binding sites are most dense in cortical areas and the 
area postrema. The possibility that 5-HT3 receptors may also be found 
in non-neuronal locations should not be excluded. 
It also appears that heterogeneity may exist within the 5-HT3 class 
of receptors. Both MDL 72222 and ICS 205-930, which are potent and 
selective 5-HT3 antagonists, have been demonstrated to possess 
significantly different potencies in various physiological systems 
(Donatsch et al., 1984; Richardson et al., 1985). Three subtypes of the 
5-HT3 receptors have been suggested (Richardson et al., 1985), but more 
rigorous studies with selective antagonists are needed for their proper 
characterization. 
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Second messenger systems linked to 5-HT receptors Most recently 
it has been suggested that neurotransmitter receptors fall into two 
broad superfamilies: the G protein receptor superfamily and the ligand-
gate ion channel superfamily (Lester, 1988). S-HT^^, S-HT^g, 5-HTic, 5-
HTju and S-HTg receptors are coupled to G proteins and belong to the G 
protein receptor superfamily (Hartig, 1989). The S-HTg receptors are 
unique among 5-HT receptors because activation of S-HTg receptors 
invariably results in a "nicotine-like" fast depolarization (Fozard, 
1984a; Mawe et al., 1986). Therefore, it is conceivable that these 
sites may be very tightly coupled to ion channels and indeed these 
channels may be part of the receptor as is the case for the nicotine 
receptor (Neijt et al., 1988). In this sense, S-HTg receptors appear to 
belong to the ligand-gate ion channel superfamily (Hartig, 1989). 
The 5-HTi receptor family has been linked to the modulation of 
adenylate cyclase. S-HT^^ receptors are indisputably linked to 
adenylate cyclase in brain tissue although whether activation (via 
stimulatory guanosine triphosphate binding protein, G,) or inhibition 
(via inhibitory guanosine triphosphate binding protein, G^) of the 
enzyme occurs depends on the pre-existing state of activation (Fozard, 
1987). Both activation and inhibition of adenylate cyclase activity by 
the 5-HTu^ receptor has been shown in the S-HT^j^ receptor clone 
transfected functional response system (De Vivo and Maayani, 1986; 
Markstein et al., 1986; Shenker et al., 1985; Weiss et al., 1986). In 
the rat hippocampus, S-HT^^ sites are also coupled to neuronal 
channels by a pertussis toxin-sensitive G protein which is neither G, 
nor Gi (Andrade et al., 1987). In contrast, S-HT^g sites appear to be 
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linked in a negative way to adenylate cyclase in rat substantia nigra 
(Bouhelal et al., 1988; Neale et al., 1987). S-HT^j receptor also 
appears to mediate the inhibition of adenylate cyclase activity 
(Schoeffter et al., 1988). 
The 5-HTic receptor, unlike other S-HTj receptors, is linked to 
the phosphatidylinositol (PI) turnover. The 5-HTic receptors are 
densely present in choroid plexus in brain. It has been demonstrated 
that the midpoints for the binding and phosphoinositide activation by 5-
HT are nearly identical in this area and the response is inhibited by 
mianserin, ketanserin and spiperone (Conn et al., 1986; Sanders-Bush and 
Conn, 1987). These data suggest that S-HT^c receptors in choroid plexus 
mediate 5-HT-induced PI turnover and there is a single ligand binding 
site on this single-subunit receptor (Conn et al., 1986; Sanders-Bush 
and Conn, 1987). 
It has been well demonstrated that 5-HT2 receptors are coupled to 
PI hydrolysis in the CNS (Berridge et al., 1982; Brown et al., 1984; 
Conn and Sanders-Bush, 1984, 1987; Kendall and Nahorski, 1985; Pierce 
and Peroutka, 1988) and in peripheral tissues (Coughlin et al., 1984; de 
Coureelles et al., 1985; Doyle et al., 1986; Roth et al., 1984). 
Stimulation of 5-HT2 receptors leads to activation of phospholipase C. 
The breakdown of phosphoinositides generates inositol 1,4,5-triphosphate 
(IP3), which is known to mobilize calcium from intra-cellular stores and 
1,2-diacylglycerol, which activates the Ca^^-sensitive, phospholipid-
dependent protein kinase C. On the other hand, extracellular calcium 
has also been proposed to play an important role in the vascular 
contractions produced by S-HTg receptor activation (Berta et al., 1986; 
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Capponi et al., 1987; Nakaki et al., 1985). It has been shown that 5-
HT stimulated phosphatidylinositol turnover in rat aorta and that in 
this tissue the mechanism of the 5-HT-induced contraction required the 
participation of the opening of a voltage-gate calcium channel and the 
stimulation of a phosphatidylinositol-specific phospholipase C (Nakaki 
et al., 1985; Roth et al., 1986). It has been reported that 5-HT 
stimulated depolarization of the smooth muscle membranes (Fuj iwara et 
al., 1982), which could open the voltage-dependent calcium channel and 
induce an influx of extracellular calcium. Recent evidence indicates 
that a rise in cytosolic calcium also activates the phospholipase C 
(Eberhard and Holz, 1987; Fisher and Agranoff, 1981; Kendall and 
Nahorski, 1984, 1985). Small increases in cytosolic Ca^ "*" induced by Ca^ '*' 
influx across the plasma membrane may result in higher cytosolic Ca^ "*" 
concentration due to activation of phospholipase C which in turn 
increases IP3 turnover and release of Ga^"*" from intracellular stores. 
The IP3 produced in this way could also act in the plasma membrane to 
increase Ca^"*" influx as it does on the membrane of the responsive 
fraction of endoplasmic reticulum (Kuno and Gardner, 1987; Slack et al., 
1986) . The role of IP3 in eliciting Ca^^ entry by emptying an 
intracellular pool is also proposed (Putney et al., 1989). 
Diacylglycerol is also generated by the activation of phospholipase C 
following Ca^^ influx, which will stimulate protein kinase C activation. 
The extracellular calcium can traverse the cell membrane and gain 
access to the contractile apparatus through two distinct pathways. One 
is the receptor-operated calcium channel system; the other is the 
voltage-dependent calcium channel system (Bolton, 1979; Meisheri et al., 
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1981; VanBreeman et al., 1982). The voltage-dependent calcium channel 
is voltage sensitive and as membrane potential is made increasingly more 
positive the inward calcium current will rise progressively until it 
reaches a peak magnitude (Brown et al., 1981), A number of calcium 
entry blocking agents can affect voltage-dependent calcium channels. 
These compounds have been divided into three groups (Spedding, 1985). 
Group I consists of nifedipine and related 1,4-dihydropyridines. Group 
II contains the calcium blockers verapamil, D600, diltiazem and 
diclofurime which, for the most part, have unrelated chemical 
structures. Group III is made up of diphenylalkylamine compounds such 
as cinnarizine, fendiline, flunarizine and prenylamine. The compounds 
in groups I and II are potent and selective on calcium channels in 
cardiac muscle. The compounds in group III appear to be less selective 
and can act on both calcium and sodium channels in cardiac muscle. It 
has been shown, moreover, that verapamil, D600, and diltazem, namely 
group II compounds, have approximately equiactive effects on calcium 
channels in cardiac muscle and vascular smooth muscle. However, 
nifedipine and related dihydropyridines exert preferential effects on 
vascular smooth muscle (Janis and Triggle, 1983). It has been known for 
many years that many isolated smooth muscle preparations can be 
stimulated to contract by exposing them to a membrane-depolarizing high 
potassium bathing medium. These potassium-induced tension changes are 
usually quite sensitive to the inhibitory action of calcium entry 
clocking agents (Godfraind, 1983; Hurwitz et al., 1980). Contractions 
produced by high concentrations of potassium can be blocked by adding a 
calcium entry blocking agent to the high potassium bathing solution or 
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aborted by adding such an agent after the contraction has been induced 
(Godfraind, 1983; Hurwitz et al., 1982). Potassium induced contraction 
can also be abolished by removing calcium ions from the high potassium 
bathing solution and reinstated by adding calcium ions back to the 
solution (Hurwitz et al., 1980). These findings indicate that an 
essential step in the development of a potassium-induced contraction is 
the influx of calcium ions from the extracellular environment. 
Although receptor-operated calcium channels play an important role 
in the functional behavior of smooth muscle, they have received much 
less study than have votage-dependent calcium channels. Meisheri et al. 
(1981) demonstrated in the rabbit aorta that D600 preferentially 
inhibited potassium induced calcium influx, whereas amrinone 
preferentially inhibited NE induced calcium influx. They also observed 
that the calcium fluxes stimulated by the high potassium medium and by 
norepinephrine were additive. Stice et al. (1987) also demonstrated in 
pig uterine arteries that D600 or amrinone selectively inhibited ''^Ca 
uptake and contraction induced by either high-K^ or phenylephrine. 
Moreover, the blockade of Ca^^ uptake by D600 and amrinone was additive. 
In sum, these experimental results favor the proposal that receptor-
operated calcium channels constitute one population and that voltage-
dependent calcium channels constitute another population of membrane 
calcium channels. Whether or not membrane potential exerts any 
essential or modulating influence on the activation of receptor-operated 
calcium channels is still unresolved. 
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5-HT and cardiovascular responses 
Cardiovascular effects of central serotonergic neuronal 
activation It has been demonstrated that activation of an ascending 
serotonergic system by stimulation of the midbrain raphe produces an 
increase in blood pressure which is mediated in part by the hypothalamus 
and which requires transmission toward the spinal cord to enhance 
sympathetic activity (Robinson, 1982). Administration of serotonin into 
the rat lateral or the third ventricle also produces an increase in 
arterial blood pressure and this pressor response can be antagonized by 
intraventricular administration of the serotonergic antagonists 2-
bromolysergic acid diethylamide (BOL) and methysergide (Kristic and 
Djurkovic, 1980; Lambert et al., 1978). The pressor response to 
intraventricular administration of serotonin is antagonized by the 
systemic administration of «-adrenergic antagonists such as 
phenoxybenzamine and tolazoline, suggesting that the pressor response 
produced by serotonin probably involves the discharge of the sympathetic 
nervous system (Kristic and Djurkovic, 1980). 
Serotonin and vascular responses Serotonin has complex and 
multiple actions on cardiovascular function. In an intact animal, it 
causes either increases or decreases in blood pressure, depending on the 
species studied and the dose used. The local effect of 5-HT on blood 
flow can be affected by many factors. Depending on the species, the 
vascular bed, the experimental conditions, the degree of sympathetic 
tone, and the route of administration, serotonin can augment or reduce 
blood flow. It has been demonstrated that 5-HT can produce constriction 
or dilation of blood vessels (Vanhoutte, 1982a, 1982b; Van Nueten, 1983; 
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Van Nueten and Vanhoutte, 1984). 
Serotonin causes contraction of many isolated large arteries, which 
can be inhibited by ketanserin, spiperone, methysergide, and a number of 
other serotonergic antagonists (Cohen et al., 1981; Cohen et al., 1983; 
Van Nueten et al., 1982; Van Nueten et al., 1981; Van Nueten et al., 
1984). There is a good correlation between the affinity of these 
serotonergic antagonists for S-HTg binding sites in brain tissue and 
their potency to antagonize contractions of isolated blood vessels to 5-
HT, suggesting that vasoconstrictions produced by 5-HT are mediated by 
S-HTg receptors on the vascular smooth muscle (Leysen et al., 1982; Van 
Nueten et al., 1981; Van Nueten et al., 1984). However, there are large 
differences in sensitivity to 5-HT in different blood vessels. Serotonin 
is more potent than norepinephrine in coronary, cerebral, umbilical, and 
pulmonary arteries (Cohen et al., 1983; Dyer, 1970a; Edvinsson et al., 
1983; Van Nueten, 1983). Vasoconstrictions produced by 5-HT in . 
cutaneous and subcutaneous arteries are inhibited by a-adrenergic 
antagonists, indicating that activation of «-adrenergic receptors is 
involved in the responses produced by 5-HT in these vessels (Apperley et 
al., 1976; Maggi et al., 1983; Winkelmann et al., 1976). In certain 
pathological states in animals and in humans the vasoconstriction 
responses in some vascular beds become hypersensitive to serotonin 
(Hollenberg, 1988; Winquist and Bohr, 1983). 
Many large veins constrict when exposed to 5-HT, which is mediated 
by S-HTg receptors. In the rat jugular vein the response to 5-HT is 
inhibited competitively by ketanserin, spiperone, and methysergide 
(Cohen et al., 1981). However, in canine cutaneous veins the 
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contractions produced by 5-HT are mediated by a-adrenergic receptors 
(Clement et al., 1969; Curro et al., 1978). 
It has been proposed that the contractions evoked by serotonin can 
be attributed to the activation of S-HTg receptors on the smooth muscle 
or to the amplification of the contractile response to other 
vasoconstrictor neurohumoral mediators (Vanhoutte, 1985). In some 
vessels, direct activation of alpha-adrenoceptors or displacement of 
other endogenous vasoconstrictors, mainly NE from adrenergic nerves can 
also be involved in the response produced by 5-HT (Vanhoutte, 1985). 
Although 5-HT produces a vasoconstriction effect on most vascular 
smooth muscle, it can cause relaxation in coronary arteries, cerebral 
arteries, saphenous veins, pulmonary vein, the canine nasal circulation, 
and the perfused vascular bed of the guinea pig stomach (Cohen et al., 
1983; Edvinsson et al., 1983; Eyre, 1975; Feniuk et al., 1983; Fu and 
Toda, 1983; Van Nueten et al., 1981; Zhang and Dyer, unpublished data). 
Activation of /9-adrenergic receptors may be involved in the relaxation 
produced by 5-HT in cerebral arteries (Edvinsson et al., 1983). 
However, in many other blood vessels in which 5-HT produces relaxation, 
serotonergic receptors appear to be involved. These receptors differ 
from 5-HT2 receptors of the vascular smooth muscle which mediate the 
contractions. Indeed, the relaxation of many vascular smooth muscles 
obtained in vitro with 5-HT can be inhibited by methiothepin, 
methysergide, pizotifen, and cyproheptadine, but not by ketanserin 
(Cohen et al., 1983; Feniuk et al., 1983; Van Nueten et al., 1981; Van 
Nueten et al., 1984). Serotonergic receptors mediating relaxation could 
be located on the vascular smooth muscle cells themselves or the 
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endothelial cells on vascular smooth muscle which could release 
endothelium dependent relaxing factor (EDRA) upon the activation of 
serotonergic receptors (Vanhoutte, 1985). 5-HT can also activate the 
prejunctional S-HT^ receptors with a resulting reduction of the evoked 
release of NE or cause release of inhibitory transmitters from 
peptidergic nerves (Vanhoutte, 1985). 
5-HT may play a role in regulation of the heart rate. Indeed, the 
monoamine produces a positive chronotropic effect in atria of the kitten 
which is not reversed by ketanserin (Kaumann, 1983) . The receptor 
involved is different from 5-HTi and S-HTg binding sites. 5-HT also has 
a positive inotropic effect on the mammalian heart (Buccino et al., 
1967). One of the mechanisms could be that 5-HT stimulates the 
serotonergic receptors on nerve terminals and triggers the release of 
the adrenergic neurotransmitter (Thandroyen et al., 1985). It has also 
been reported that 5-HT can inhibit the reuptake of NE by sympathetic 
nerve terminals (Thandroyen et al., 1985). However, 5-HT does not 
regulate cardiac contractility under basal conditions (Sole et al., 
1979). 
5-HT during pregnancy 5-HT has been implicated in a number 
of physiological and pathophysiological conditions associated with 
pregnancy and uterine hemodynamics. These include pre-eclampsia, 
abortion, and parturition. It has been demonstrated that 5-HT 
concentration increased in whole blood during normal pregnancy (Carter 
et al., 1982; Carl, 1985; Krupp and Krupp, 1960). Because the fetal 
content of 5-HT is high, the excess 5-HT might originate in the fetus 
(Jones and Rowesel, 1973). In rats and mice, placental content of 
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serotonin has been found to increase throughout gestation (Robson and 
Senior, 1964). Placental serotonin falls sharply just prior to the time 
of parturition in the rat, but not in mice. In the rat, administration 
of a monoamine oxidase inhibitor increased placental serotonin and 
caused a delay in parturition but this action was not observed in mice 
(Lesinski et al., 1967). The source of serotonin is unknown. It seems 
unlikely that 5-HT originates from mast cells since the rat placenta 
does not contain mast cells. The biosynthetic pathway for serotonin 
also has been described and approximately 20 ng of serotonin can be 
formed from 5-hydroxytryptophan per gram of human placenta per hour 
(Klinge et al., 1964). 
Direct investigations into the effect of 5-HT on the uterine 
vasculature have been extremely limited. 5-HT has been observed to 
produce death of fetal mice when it was given to the mother. 5-HT 
produces such an action presumably by reducing the blood supply to the 
placenta (Robson and Sullivan, 1966). Dyer and Gough (1971) 
demonstrated that 5-HT and LSD potently constrict human uterine arteries 
obtained from non-pregnant uteri. With main uterine arterial blood flow 
monitored via electromagnetic flow transducers, Clark et al. (1980) 
demonstrated in chronically catheterized ewes that 5-HT produced dose 
related decreases in uterine blood flow in both pregnant and non­
pregnant ewes. The vasoconstrictor responses to 5-HT were significantly 
attenuated by the 5-HT antagonist, methylsergide. In contrast, 
responses to NE were not modified by methylsergide, suggesting that 
specific 5-HT receptors existed and mediated the vasoconstriction 
produced by 5-HT in the ovine uterine vasculature. 
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It has been well documented that 5-HT produces a potent 
vasoconstriction on the umbilical vasculature in humans and in animals 
(Dyer, 1970a; Bjoro and Stray-Pederson, 1986; Mak et al., 1984; McGrath 
et al., 1985; Tuncer et al., 1985). These responses are inhibited by 
cinanserin, bromlysergic acid diethylamide (BOL), ketanserin, mianserin, 
and methysergide (Dyer, 1974, 1983; McGrath et al., 1985; Tuncer et al., 
1985), suggesting that 5-HT2 receptors are involved in 5-HT-induced 
vasoconstriction. Contractions to 5-HT can be potentiated 8-10 fold by 
cocaine and the magnitude of the potentiation was linearly related to an 
Inhibition of 5-HT uptake by the ovine umbilical artery (Dyer, 1970b). 
Contractions to 5-HT were not associated with changes in either cAhP or 
cGMP levels (Fiscus and Dyer, 1981). Indomethacin effectively blocked 
contractions Induced by arachldonlc acid and adenosine triphosphate 
(ATP) in sheep umbilical vasculature but did not antagonize contractions 
to 5-HT, suggesting that release of prostaglandins is not involved in 
the response to 5-HT but may be for ATP (Fiscus and Dyer, 1982). Sheep 
umbilical veins and arteries contain 0.38 and 0.13 /ig/g wet weight of 5-
HT, respectively (Dyer and Weber, 1971). 
Involvement of 5-HT receptors in the action of 2.5-dimethoxv-4-
methvl-amphetamine Certain phenalkylamlne hallucinogens possess a 
high affinity for 5-HT receptors in the isolated rat fundus preparation 
(Glennon et al., 1980; Glennon and Hack, 1978). There also appears to 
be a correlation between 5-HT receptor affinity and hallucinogenic 
potency in these hallucinogens. The more potent agents usually possess a 
higher affinity for 5-HT receptors (Glennon et al., 1980; Glennon et 
al., 1982). 2,5-Dimethoxy-4-methyl-amphetamlne (DOM) is a prototypic 
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phenalkylamlne hallucinogen and has been shown to produce a vasopressor 
action in humans (Snyder et al., 1967), cats (Tadepalli et al., 1975), 
rats (Huang and Ho, 1972) and dogs (Cheng et al., 1973) which was 
antagonized by serotonergic antagonists. Dyer et al. (1973) found that 
DOM produced a potent vasoconstriction on isolated sheep umbilical blood 
vessels. The vasoconstriction to DOM is effectively antagonized by the 
serotonergic antagonists cinanserin and BOL (Dyer, 1974, 1983). 
Recent evidence suggests that DOM acts via S-HTg receptors (Glennon 
et al., 1984; Titeler et al., 1985). Both ketanserin and pirenperone 
are effective in attenuating the discriminative stimulus effects of DOM 
(Glennon et al., 1983). In radioligand binding studies, an excellent 
correlation was found between the affinities of hallucinogens at the 5-
HTg binding site and their potencies to substitute for DOM as a 
discriminative cue (Glennon et al., 1984). DOM displays a relatively 
low affinity for 5-HTi sites (K^ - 3550 nM) but high affinity for 5-HT2 
binding sites (K^ - 60 nM) (Glennon, 1987). More recently, Sanders-
Bush et al. (1988) demonstrated that DOM stimulated phosphoinositide 
hydrolysis in the cerebral cortex with a maximum effect that is 76% of 
that produced by 5-HT. This effect of DOM was blocked by the 5-HT2 
antagonists ketanserin and spiperone, but not by antagonists of other 
phosphoinositide hydrolysis-linked receptors (a^ adrenergic, 
histaminergic and muscarinic cholinergic). Taken together, these 
studies suggest that DOM might produce its hallucinogenic effects via a 
direct agonistic interaction at 5-HT2 sites. 
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Rationale 
Serotonergic agonists potentially are harmful to the fetus in that 
they activate serotonergic receptors and produce vasoconstriction in the 
umbilical vasculature. Another potential site at which these drugs 
could affect the fetus is via constriction of the uterine vasculature 
during pregnancy. 5-HT can constrict human uterine vascular smooth 
muscle obtained from nonpregnant uteri. However, information is lacking 
on the effects of 5-HT agonists on uterine arteries from pregnant 
animals, While most studies have been carried out on isolated tissues, 
it is important to study the effects of serotonergic agonists on uterine 
and umbilical artery blood flow hemodynamics in the living animal. The 
establishment of the chronically instrumented pregnant ewe/fetus model 
in Dr. Dyer's laboratory allows us to ascertain whether selected 
serotonergic agonists will alter the maternal and fetal heart rate and 
arterial blood pressure, the maternal uterine artery blood flow and the 
fetal umbilical artery blood flow when they are administrated to the 
mother. Vascular resistances of the uterine and umbilical arteries can 
then be ascertained, which permits the determination of whether 
serotonergic agonists exert a vasoconstrictor effect on these vessels. 
By monitoring fetal arterial blood Pog, Pcog and pH values, it can be 
determined whether the serotonergic agonists cause stress to the fetus. 
The use of isolated uterine and umbilical vascular smooth muscle in 
association with modern pharmacological receptor analysis techniques 
permits an in-depth analysis of receptor mechanisms involved in the 
vasoconstriction produced by the agonists. The application of specific 
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vasoconstriction produced by the agonists. The application of specific 
serotonergic agonists and antagonists in the methodology and the 
determination of the dissociation constants for the agonists and 
antagonists permit the generation of fundamental information which is 
needed for classification of serotonergic receptors. These data will 
also provide the information necessary for a proper comparison of 
serotonergic receptors reported in other tissues. Fundamental 
information on the signal transduction system coupling to serotonergic 
receptors can be obtained in part by using uptake techniques. 
The methodology and techniques described above permit correlation 
of in vivo and iji vitro studies, which allows an understanding of the 
effects of serotonergic agonists in the pregnant animal and the receptor 
mechanisms involved. 
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SECTION I, CARDIOVASCULAR ACTION OF R(-) 2,5-DIMETH0XY-4-METHYL-
AMPHETAMINE (DOM) IN THE PREGNANT EWE AND FETAL LAMB^ 
Abstract 
Pregnant ewes and their fetuses were instrumented between 110 to 
120 days of gestation (term, 145 days) for monitoring heart rate, blood 
pressure, uterine artery blood flow, and fetal intra-abdominal umbilical 
artery blood flow and arterial blood gases. DOM (2,5-dimethoxy-4-
methyl-amphetamine) was administered intravenously to the ewe in doses 
of 1, 2.5, 5, 10, or 20 fig/kg. Maternal administration of DOM produced 
dose-dependent increases in maternal blood pressure and a fall in the 
heart rate. Uterine blood flow was dramatically decreased by DOM and 
uterine vascular resistance increased by 6.8, 16.7 and 19.6 fold after 
DOM at 5, 10, and 20 ftg/kg, respectively. These responses were 
accompanied by fetal hypoxemia, combined metabolic and respiratory 
acidosis, hypertension and bradycardia. The changes in blood flow and 
vascular resistance were always smaller in the fetal umbilical artery 
than those in the maternal uterine artery. The maximal rise in vascular 
resistance in the fetal umbilical artery was 2.6 fold after DOM (20 
fig/kg). Ketanserin (1 mg/kg), administrated 30 minutes prior to the 
administration of DOM, inhibited maternal and fetal cardiovascular and 
blood gas responses to DOM. The conclusions are: (1) the fetus is 
distressed following maternal administration of DOM brought about by a 
^Submitted to J. Pharmacol. Exp. Ther. as a research paper by Lubo 
Zhang, Donald C. Dyer, Frederick B. Hembrough and Miguel Isla. 
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reduction in the uterine blood flow and impairment of oxygen transfer to 
the fetus, (2) the cardiovascular responses to DOM may be mediated by 5-
HTg receptors. 
Introduction 
2,5-Dimethoxy-4-methyl-amphetamine (DOM) has a hallucinogenic 
effect in humans. It is about 50-100 times more potent than mescaline, 
but is 30-50 times less active than lysergic acid diethylamide (LSD) 
(Snyder et al,, 1967; Hollister et al., 1969). The hallucinogens 
related to DOM have a peripheral action on the cardiovascular system 
that must be considered when they are studied. In human subjects DOM (5 
mg) elicited an increase in systolic blood pressure and pulse rate 
(Snyder et al., 1967). The vasopressor action of DOM has also been 
shown in cats, rats and dogs and was antagonized by serotonergic 
antagonists (Tadepalli et al., 1975; Huang and Ho, 1972; Cheng et al., 
1973). DOM enhanced vasopressor responses to tyramine, norepinephrine 
(NE) and epinephrine (EPI) but reduced the pressor responses to 
bilateral carotid artery occlusion (Cheng et al., 1973). Recent 
evidence suggests that DOM can act on S-HTg receptors (Dyer, 1983; 
Glennon et al., 1984; Titeler et al., 1985). 
We have shown that DOM potently constricts sheep uterine and 
umbilical blood vessels in vitro (Zhang and Dyer, 1989a, 1989b). 
Contractions to DOM were effectively antagonized by the ketanserin, a 
specific 5-HT2 antagonist (Leysen et al., 1981; Leysen et al., 1982; Van 
Nueten et al., 1981). The pAg values for ketanserin vs. DOM in the 
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uterine artery and umbilical artery were 8.33 and 9.10, respectively 
(Zhang and Dyer, 1989a, 1989b). During pregnancy, uterine blood vessels 
supplying oxygen and nutrients to the developing fetus are maximally 
dilated, but readily constricted in the presence of vasoconstrictors 
(Meschia, 1983). Another potential site at which drugs could affect the 
fetus is via constriction of the umbilical vasculature. In general, 
drugs which have good lipid solubility cross the placenta with ease. A 
positive correlation has been established for psychotomimetic potency 
and increased lipid solubility (Nichols et al., 1977). 
To date, there are no published reports of the effects of DOM on 
fetal cardiovascular function and oxygenation. The purpose of this 
study was to investigate the cardiovascular and blood gas responses in 
the pregnant ewe and her fetus to maternal intravenous administration of 
DOM. Maternal uterine artery blood flow and fetal intra-abdominal 
umbilical artery blood flow were continuously monitored with the 
ultrasonic pulsed Doppler flow transducers. Additionally, ketanserin 
was administrated to the ewe prior to DOM injection to determine the 
inhibitory effect of ketanserin on the maternal and fetal cardiovascular 
and blood gas responses to DOM. 
Methods 
Abbreviations 
MBP maternal arterial blood pressure 
FBP fetal arterial blood pressure 
MHR maternal heart rate 
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FHR fetal heart rate 
MUABF maternal uterine artery blood flow 
FUmABF fetal intra-abdominal umbilical artery blood flow 
PCVR percent change in vascular resistance 
Animal preparation and surgical procedures 
Mixed-breed ewes were obtained from a local source and bred by 
natural mating. The gestational age was based on the day of mating. 
Robillard et al. (1979) found a good correlation between fetal weight 
and gestational age using this technique (fetal body weight (Kg) -
[0.096 X gestational age (days)] -9.2228). Pregnant ewes of known 
gestational age (110-120 days) were instrumented during surgery as 
described below. 
Prior to surgery the animals were deprived of food for 48h and water 
for 24h. General anaesthesia was induced by intravenous injection of 
thiopental sodium (20mg/kg). The ewe was incubated and maintained on a 
halothane/oxygen mix (1-2% halothane, approx. 3L/min). The animal was 
then placed on her right lateral recumbancy. Dorsally at the level of 
the tuber coxae, a vertical incision (approx. 25 cm) was made about 3 cm 
cranial to the tuber coxae on the left flank. The left main uterine 
artery was located in the broad ligament of the uterus. A length of the 
vessel (approx. 2 cm) was cleared by blunt dissection and a Doppler flow 
transducer was placed around the vessel. Lidocaine was applied to the 
blood vessels to help prevent contraction brought on by manipulation. 
The transducer leads were then sutured to the broad ligament to minimize 
twisting. Thereafter, the uterine horn was exposed and, through a small 
uterine incision, the fetal hind limbs were located. The upper part of 
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the fetus was kept inside the uterus. During fetal surgery, lidocaine 
was applied to the blood vessels as described above. Polyvinyl 
catheters (I.D., 0.66 mm; O.D., 1.3 mm) were inserted into the fetal 
femoral artery and vein for a distance of approximately 5 cm and secured 
with silk ligatures. Through a midline abdominal incision, using blunt 
dissection as much as possible, both left and right intra-abdominal 
umbilical arteries were exposed. Doppler flow transducers were then 
attached to both vessels. After the incision was closed, the leads of 
the Doppler flow transducers were secured with silk sutures and anchored 
to the skin. A catheter was secured to the abdominal skin for access to 
the amniotic cavity for measuring intrauterine fluid pressure and 
administration of antibiotics to the fetus. After securing all the 
fetal catheters and transducers, the uterine incision was closed in two 
layers. Thereafter, the ewe abdominal wall was closed in separate 
layers and all catheters and leads of Doppler flow transducers were 
exteriorized through a subcutaneous tunnel and placed in a cloth pouch 
on the ewe's flank, after which the skin was closed. For maternal 
instrumentation, an incision (approx. 4 cm) was made parallel to the 
tracheal on the left side of the neck. The left carotid artery and 
jugular vein (approx. 2 cm) were cleared by blunt dissection. Another 
incision (approx. 2 cm) was made in the middle of the two shoulders and 
a stainless steel tube was pushed underneath the skin from the incision 
on the shoulders to the one on the neck. Two tygon catheters (I.D., 
1mm; O.D. 1.8 mm) for the carotid artery and jugular vein were 
introduced through the stainless steel tube from the side of the 
shoulders to that of the neck. The stainless steel tube was then 
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removed from the side of the neck. The ends of the catheters on the 
side of the shoulders, which were connected with a piece (approx. 4 cm) 
of thick wall tygon tube (I.D., 0.8 mm), were sutured to the skin. The 
tygon tubes were plugged by a blunt 18 gauge needle with one end sealed. 
The other ends of the catheters in the side of the neck were ready for 
inserting into the vessels. For catheterizing the carotid artery, a 
small hole was made in the vessel by puncture using an 18 gauge needle. 
The catheter was introduced through the hole into the carotid artery and 
advanced to the ascending aorta for blood pressure monitoring and 
arterial blood sampling. The catheter was fixed to the carotid artery 
by making a purse suture around the catheter. Similarly, a catheter was 
introduced into the jugular vein and passed to the superior vena cava. 
This catheter was used for drug administration. The neck incision was 
then closed. Ampicillin 2 g was given to each ewe i.m. just prior to 
the surgery and injected into the amniotic cavity at the end of surgery. 
Before using, all catheters were soaked in 7% TDMAC heparin complex 
(Polysciences, Inc., Warrington, PA) to prevent blood clot formation. 
The catheters were then sterilized with ethyleneoxide. Following 
surgery, all catheters were filled with heparinized saline solution (20 
units heparin/ml). Ewes were housed in individual pens and provided 
with water and a standard diet. The animals were usually standing and 
eating within 1 h after surgery. Ampicillin (2 g every day) was given 
intramuscularly for the first 3 days following surgery and after every 
experiment. Initial experiments were performed five days or more after 
surgery to allow for surgical recovery. 
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Physiological measurements 
Fetal and maternal systemic blood pressures were continuously 
measured, except during arterial blood sampling, in all experiments by 
attaching the arterial catheters to Beckman low-volume displacement 
pressure transducers. Changes in both maternal uterine artery and fetal 
intra-abdominal umbilical artery blood flow were monitored continuously 
using the ultrasonic pulsed Doppler flow meter modified from the 
original design of Hartley and Cole (1974) and constructed by the 
University of Iowa Bioengineering Resource Facility (Haywood et al., 
1981). The pulsed Doppler flow probe consisted of a Silastic cuff 
around a 1-mm-diam piezoelectric crystal that emits a 20-mHz ultrasonic 
signal. The same crystal receives the reflected signal from the passing 
blood cells in the intervals between ultrasonic pulses. The signals are 
then recorded either as pulsatile or mean flow velocity of a Doppler 
shift (kHz) on a Beckman Dynograph. The techniques for construction and 
use of the probes and application of the flow meter have been described 
in detail (Haywood et al., 1981; Van Orden et al., 1984). The 
electronic amplifiers in the system are extremely stable, and the 
changes in the velocity signals recorded from the flow probes are 
directly and reliably proportional to changes in the true volume flow 
(Haywood et al., 1981; Van Orden et al., 1984). 
Drug induced changes in blood flow (BF) velocity of the maternal 
uterine artery and fetal intra-abdominal umbilical artery are expressed 
as a percentage of the control (% BF) and percent changes in vascular 
resistance (PCVR), using the Doppler flow probe, were calculated using 
the following formulas (Robillard et al., 1986): 
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% BF •= [Egg/Bpg] X 100 
VR = mBP/DS 
PCVR - [(VRE-VRb)/VRB] X 100 
Eqs is the Doppler shift (kH,) during experimental periods (different 
doses of DOM); Egg is the Doppler shift (kH^) during the control period; 
VR is the vascular resistance (expressed arbitrarily in mmHg/kHj.) ; raBP 
is the mean systemic blood pressure (mmHg). DS is the Doppler shift 
(kHg) ; and VRg and VRg are the VR during experimental and control 
periods, respectively. 
Blood pressures and blood flows were recorded continuously on an 
eight-channel recorder (Beckman Type R Dynograph). Maternal and fetal 
heart rates were calculated from the pulsatile blood pressure tracing. 
Arterial blood gas values were determined by removing 0.9 ml of 
blood anaerobically from the fetal or maternal arterial catheters into a 
1.0-ml heparinized plastic syringe and analyzed for oxygen pressure 
(Pog), pH, and carbon dioxide pressure (Pcoj) , using a pH/blood gas 
analyzer (813, Instrumentation Laboratory). Base excess (BE) was 
calculated from Siggaard-Andersen curve nomogram incorporated in the 
blood gas analyzer. 
Maternal rectal temperature was monitored by a scanning tele-
thermometer (Model 47, Yellow Springs Instrument Co., Inc.). 
DOM and ketanserin doses 
DOM was obtained from the National Institute of Drug Abuse, 
Rockville, MD and ketanserin tartrate from Janssen, Beerse, Belgium. 
DOM was administered at 1, 2.5, 5, 10 or 20 /ig/kg of maternal weight and 
at 2.5, 5, 10, 20 and 40 pg/kg after ketanserin 1 mg/kg administration. 
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These doses permitted quantifiable changes in fetal and maternal 
cardiovascular and arterial blood gas values without endangering the 
sheep preparation. Since the fetus grows rapidly from 100 days to term, 
we feel that the blood flow transducer will partially occlude blood flow 
as the fetus grows, thereby altering the blood flow hemodynamics. 
Therefore no more than two experiments within 2 weeks after surgery were 
performed on each ewe to minimize the reduction of umbilical artery 
blood flow through the Doppler flow probe due to fetal growth. The dose 
of DOM was dissolved in 3.0 ml of physiological saline (0.9%) and 
injected into the maternal jugular vein catheter over a 3-minute period. 
The dose of ketanserin was dissolved in 10 ml of distilled water and 
injected into the maternal jugular vein over a 10-minute period. 
Experimental protocol 
Each ewe and its fetus were monitored for a baseline period of 60 
minutes before DOM administration in order to establish a baseline. 
During this period, arterial blood samples were withdrawn from the fetal 
and maternal arterial catheters 10 minutes before DOM administration in 
order to determine the baseline fetal and maternal blood gas values. 
The interval between any two doses of DOM was 40 minutes. Fetal and 
maternal arterial blood samples were withdrawn 20 minutes after each 
dose of DOM. MBP, FBP, MUABF and FUmBF were monitored throughout the 
experimental period following DOM administration. MHR and FHR were 
monitored at the peak of blood pressure response by increasing the speed 
of the recording paper and counting the pulses. 
In order to study the blocking effect of ketanserin on the response 
produced by DOM, ketanserin (1 mg/kg) was infused over 15 minutes into 
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the maternal jugular vein catheter after the 60-minute period of 
calibration. Thirty minutes after infusion of ketanserin, different 
doses of DOM were injected into the maternal jugular vein catheter using 
the same injection sequence as for DOM alone. Cardiovascular monitoring 
was the same as above except that HR and blood gases were monitored at 
two additional periods, the first at the peak blood pressure response to 
ketanserin and the second 25 minutes after ketanserin infusion. 
Data analysis 
Regression lines were determined with the least-squares formula. 
Student's paired t test was employed to compare control to DOM treatment 
values and group t test was employed to compare DOM treatments before 
and after ketanserin. The term significant is used throughout to 
describe changes with a P value of less than 0.05. The results are 
presented as means ± SE. 
Results 
The mean (±SE) gestational age of ewes receiving DOM alone or 
ketanserin plus DOM were 124.4 ±1.5 days and 122.8 ±0.8 days, 
respectively. There was no significant difference in the gestational 
ages between the two groups. The control values for maternal and fetal 
cardiovascular parameters and arterial blood gas values for all studies 
obtained at 10 minutes before injection of DOM or ketanserin/DOM are 
presented in Table 1. A comparison of these control values indicated no 
significant differences between the two groups. 
Table 1. Control fetal and maternal cardiovascular parameters and blood gas values prior to ewes 
receiving DOM or DOM plus ketanserin 
Fetal Maternal 
Variable DOM (n-5) Ketanserin/DOM (n-8) DOM (n-5) Ketanserin/DOM (n-8) 
mBP*(mmHg) 53.800 ± 1.10 51.000 ± 2.17 107.900 ± 5.00 99.700 ± 2.70 
HR*(min-i) 158.300 ± 12.10 163.300 ± 6.70 110.000 ± 5.80 99.300 ± 9.10 
PH 7.409 ± 0.01 7.385 ± 0.02 7.482 ± 0.02 7.494 ± 0.01 
Pco2*(mmHg) 42.400 ± 0.83 45.100 ± 1.29 32.200 ± 0.76 30.300 ± 1.40 
Po2*(mmHg) 17.900 ± 1.08 18.900 ± 1.44 90.300 ± 5.26 92.400 ± 2.59 
BE*(mEq/l) 3.790 ± 0.90 3.250 ± 1.07 1.600 ± 1.41 1.480 ± 1.21 
MRT*(°C) 40.000 ± 0.30 40.400 ± 0.20 
*mBP indicates mean arterial blood pressure; HR, heart rate; PCO2 arterial blood carbon 
dioxide partial pressure; P02, arterial blood oxygen partial pressure; BE, arterial blood base 
excess; MRT, maternal rectal temperature. Values are means ± SE. 
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Effects of DOM on arterial blood pressure and heart rate 
Intravenous injections of DOM (1 pg/kg to 20 pg/kg) to the mother 
produced a dose-dependent rise in maternal and fetal arterial blood 
pressure (Fig. 1) which was accompanied by a fall in heart rate (Fig. 
2). This was associated with an increase in pulse pressure. Peak blood 
pressure responses were obtained within 5 minutes following the 
administration of DOM (Fig. 3) and the duration of action was dependent 
upon the dose. The blood pressure returned to near control values 
within 30 minutes following the 20 Mg/kg dose. There was a 2-3 minute 
delay in the increase of fetal arterial blood pressure following the 
increase of maternal arterial blood pressure. Tachyphylaxis to DOM in 
the doses used was not observed. 
Fetal and maternal heart rate decreased immediately as the 
pressures rose. The maximal fall in fetal and maternal heart rates 
occurred at DOM 10 pg/kg even though the arterial blood pressures still 
increased at DOM 20 /ig/kg. Fig. 4 illustrates the linear relationship 
between the fall in heart rate and the increase in mean arterial blood 
pressure. The significant difference in the slopes of the regression 
lines indicated that heart rate decrease in the fetus was more 
pronounced than that in the ewe. When arterial blood pressure increased 
1 mmHg, FHR and MHR decreased 3.4 beats/min and 1.4 beats/min, 
respectively. 
Effects of DOM on maternal uterine artery and fetal umbilical artery 
hemodynamics 
A significant and dose-dependent decrease was observed in MUABF and 
FUmABF following DOM administration (Fig. 5). The threshold dose of DOM 
Fig. 1. Dose-response curves for changes in the mean arterial blood pressure produced by intravenous 
administration of DOM to the mother in the conscious chronically instrumented pregnant ewe 
preparation. Solid lines indicate the results with DOM treatment before ketanserin 
administration. Dash lines indicate the results with DOM treatment after ketanserin 
administration. Ketanserin (1 mg/kg) was administrated intravenously to the ewe 30 minutes 
before beginning the administration of DOM. K indicates ketanserin. Results are illustrated 
as the X ± SE. of 5 to 8 animals. Asterisk indicates the comparison of the result at each 
dose of DOM to the control. *, P < 0.05; ** P < 0.01. Cross indicates the comparison 
between the two results at the same dose of DOM before and after ketanserin administration. 
+, P < 0.05; ++, P < 0.01 
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# Fetal 
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Dose of DOM ( j j g / kg )  
20 40 
Fig. 2. Dose-response curves for changes in the heart rate produced by intravenous administration of 
DOM to the mother in the conscious chronically instrumented pregnant ewe preparation. Solid 
lines indicate the results with DOM treatment before ketanserin administration. Dash lines 
indicate the results with DOM treatment after ketanserin administration. Ketanserin (1 
mg/kg) was administrated intravenously to the ewe 30 minutes before beginning the 
administration of DOM. K indicates ketanserin. Results are illustrated as the x + SE. of 5 
to 8 animals. Asterisk indicates the comparison of the result at each dose of DOM to the 
control. *, P < 0.05; **, P < 0.01. Cross indicates the comparison between the two results 
at the same dose of DOM before and after ketanserin administration. +, P < 0.05; ++, P< 
0.01 
o Maternai 
• Fêtai 
++ 
Dose of DOM (fjg/Kg) 
Fig. 3. Segment of a record showing the response of the maternal and 
fetal arterial blood pressure and the blood flow velocity of 
maternal uterine artery and fetal intra-abdominal umbilical 
artery to maternal intravenous administration of DOM (20 /ig/kg) 
in the conscious chronically instrumented pregnant ewe 
preparation. DOM was injected at the arrow. The time scale is 
indicated at the bottom. The blood flow velocity was 
continuously monitored with the ultrasonic pulsed Doppler flow 
meter as described in Methods. The Doppler flow meter was 
calibrated for 0.5 volts per kHg shift 
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Fig. 4. The relationship between an increase in the arterial blood pressure and a decrease in the 
heart rate for the conscious pregnant ewes and the fetal lambs when the arterial blood 
pressure was altered by intravenous administration of DOM to the ewe. The slopes of two 
regression lines were significantly different (P < 0.05) 
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Fig. 5. Effects of intravenous administration of DOM to the mother, before and after ketanserin 
administration, on the blood flow (BF) of the maternal uterine artery and the fetal intra­
abdominal umbilical artery in the conscious chronically instrumented pregnant ewe 
preparation. Ketanserin (1 mg/kg) was administrated intravenously to the ewe 30 minutes 
before beginning the administration of DOM. K indicates ketanserin. Results are illustrated 
as the X ± SE. of 5 to 8 animals. Asterisk indicates the comparison of the result at each 
dose of DOM to the control. *, P < 0.05; **, P < 0.01; ***, P < 0.005. Cross indicates the 
comparison between the two results as the same dose of DOM before and after ketanserin 
administration. +, P < 0.05; ++, P < 0.01 
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to produce these decreases was 2.5 /ig/kg. The peak MUABF response was 
obtained at about the same time as the peak MBP response. The duration 
of action was dependent upon the dose and was clearly associated with 
the MBP response. The peak FUmABF response occurred after a 2-3 mln 
delay from administration, and it correlated with the peak FBP response. 
The duration of the FUmABF response was shorter than the MUABF response. 
A maximal reduction of 92% in MUABF was observed within 5 minutes after 
DOM (20 /ig/kg) and this peak response lasted for about 30 sec. The 
MUABF tracing then developed a spasmodic pattern and this lasted for 
more than an hour (Fig. 3). The maximal reduction in FUmABF was only 
40% and the spasmodic pattern of blood flow was not observed. 
Reflecting the changes in mean blood pressure and blood flow, DOM 
significantly and dose-dependently Increased both maternal uterine 
artery (Fig. 6) and fetal umbilical artery (Fig. 7) vascular resistance. 
However, the change in vascular resistance was always smaller in. the 
fetal umbilical artery than in the maternal uterine artery. The maximal 
rise in vascular resistance (19.6 ±1.7 - fold) in the maternal uterine 
artery was observed within 5 minutes after DOM (20 pg/kg) which was 
significantly (P < 0.01) greater than that in the fetal umbilical artery 
(2.6 ± 0.4 - fold). 
Effects of DOM on arterial blood gas and oH values and on the maternal 
rectal temperature 
In all dosage groups, maternal blood gas values (Pog, Pcog and pH) 
did not vary significantly from baseline values after DOM 
administration. The responses of fetal pH, Pcog, Pog and BE to 
maternally administered DOM are presented in Table 2. A significant 
Fig. 6. Effects of intravenous administration of DOM to the mother, before and after ketanserin 
administration, on the maternal uterine artery resistance in the conscious chronically 
instrumented pregnant ewe preparation. Ketanserin (1 mg/kg) was administrated intravenously 
to the ewe 30 minutes before beginning the administration of DOM. K indicates ketanserin. 
PCVR indicates percent change in vascular resistance calculated as described in Methods. 
Results are illustrated as the x ± SE. of 5 to 8 animals. Asterisk indicates the comparison 
of the result at each dose of DOM to the control. *, P < 0.05; **, P < 0.01; ***, P < 0.005. 
Cross indicates the comparison between the two results at the same dose of DOM before and 
after ketanserin administration. ++, P < 0.01; +++, P < 0.005 
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Fig. 7. Effects of intravenous administration of DOM to the mother, before and after ketanserin 
administration, on the fetal intra-abdominal umbilical artery resistance in the conscious-
chronically instrumented pregnant ewe preparation. Ketanserin (1 mg/kg) was administrated 
intravenously to the ewe 30 minutes before beginning the administration of DOM. K indicates 
ketanserin, PCVR indicates percent changein vascular resistance calculated as described in 
Methods. Results are illustrated as the x ± SE. of the 5 to 8 animals. Asterisk indicates 
the comparison of the result at each dose of DOM to the control. * < 0.05; **, P < 0.01. 
Cross indicates the comparison between the two results at the same dose of DOM before and 
after ketanserin administration. +, F <0.05, ++, P < 0.01 
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Table 2. Effects of DOM pre and/or after ketanserin administration on fetal arteri 
DOM Pre ketanserin (n - 5) After ketanse 
dose 
(Mg/kg) 
pH Pco2^(nunHg) Po2^(mniHg) BE^(mEq/l) pH PcogfmmHg) 
0, .0 7, .409+0. ,01 42. ,4±0. 83 • 17, ,9±1.08 +3, .79+0.90 7, .385±0, .02 45, ,1±1, ,29 
2. 5 7, .400±0. ,02 43. 2+1. 00 17. ,4+1.07 +3, .46±1.45 7, .378±0, ,02 44, ,6+1, ,10 
5, .0 7, .383±0. ,01 45. 1±0. 90* 17, .5+0.51 +3, .30±1.37 7. 375±0. 01 46, ,0±1, ,20 
10. 0 7, .370+0. 02* 45. 6±1. 05* 15. ,3±1.09* +2, .70±1.15 7, .366±0, ,02 46, .8+1. ,60 
20, 0 7, .335+0. ,01* 47, .9±1. ,10* 14. ,0±0.90* +1. 30+0.40* 7, 345+0, 02* 48, ,3+1, ,40 
40, .0 7, .32410, 03* 50, 3+2, ,10" 
^Tcog indicates carbon dioxide partial pressure; P02, oxygen partial près: 
Values are means ± SE. 
Changes are significantly different from the control values (P<0.05). 

or after ketanserin administration on fetal arterial blood values 
erin (n - 5) After ketanserin (n - 8) 
Po2^(nmiHg) BE^(mEq/l) pH Pco2(nimHg) Po2(nunHg) BE(mEq/l) 
17, ,9+1.08 +3, ,79±0, ,90 7, 385±0. 02 45, , 1±1. , 2 9  18, ,9±1. 44 +3, ,25+1, ,07 
17, 4+1.07 +3, ,46±1, ,45 7, 378±0. ,02 44, ,6±1, ,10 18, ,9+1. 60 +2, ,48+1, 00 
17, .5±0.51 +3, .30±1. ,37 7. ,375+0, ,01 46, ,0+1, ,20 20, ,0±1. 80 +2, ,85±0, 90 
15, .3+1.09'' +2, .70±1, .15 7, 366±0. ,02 46, .8±1, ,60 19, ,5±1. ,60 +2, ,60+0, 80 
14, .0+0.90* +1, .30+0, .40* 7, 345±0, ,02* 48 .3±1, ,40 17, 7±1. ,60 +1, ,86+0, 80* 
7, .324±0, ,03* 50 .3±2, 10* 16, .5+2, 10* +1, .35±1, 50* 
Loxide partial pressure; P02, oxygen partial pressure; BE, base excess. 
Ly different from the control values (P<0.05). 
F 
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reduction (P < 0.05) in pH was observed 20 minutes after maternal DOM 
doses of 10 and 20 /ig/kg. PCO2 significantly increased at the doses 5, 
10 and 20 /ig/kg, while a reduction in BE was observed at the 20 /ig/kg 
dose. Pog decreased to 15.3 ± 1.09 and 14.0 ± 1.07 after DOM 
administration of 10 and 20 /tg/kg, respectively, which were 
significantly different (P < 0.05) from the control of 17.9 ± 1.08 
(Table 2). 
There were no changes in maternal rectal temperature 20 minutes 
after maternal DOM administration at all the doses studied. 
Effect of ketanserin on arterial blood pressure and heart rate responses 
to DOM 
Ketanserin, infused into the maternal jugular vein at 1 mg/kg over 
a 15-minute period, produced a fall in MBP from 99.7 ± 2.7 mmHg to 69.4 
± 3.9 mmHg (P < 0.01) (Fig. 1). The peak reduction of MBP was obtained 
within 5 minutes after the infusion of ketanserin. MBP returned to 
baseline values by 25 minutes. MHR was 78 ± 15 after ketanserin 
infusion and was not significantly different from the baseline value (P 
> 0.05) (Fig. 2). The fall in FBP from 50.9 ± 2.2. mmHg to 43.8 ± 2.0 
(P < 0.05) was less than that in the mother (Fig. 1). No significant 
changes were observed in FHR after ketanserin infusion (Fig. 2). 
Thirty minutes after ketanserin infusion, MBP and FBP responses to 
DOM (5, 10 and 20 /ig/kg) were significantly (P < 0.05) inhibited (Fig. 
1). A significant (P < 0.05) increase in MBP and FBP was only observed 
at the higher dose of DOM (40 /ig/kg). MHR and FHR did not vary 
significantly from baseline values at any dose of DOM after ketanserin 
(Fig. 2). 
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Effect of ketanserln on maternal uterine artery and fetal umbilical 
artery hemodynamic responses to DOM 
Following the infusion of ketanserln (1 mg/kg) there was a decrease 
in MUABF of 32 ± 5.9% (P < 0.05) (Fig. 5) which corresponded to the 
reduction in MBP. MUABF and MBP returned to baseline values at the same 
time. The reduction in FUmABF (19 ± 4.1%) was significant (P < 0.05) 
but less than the reduction in MUABF (Fig. 5). Since ketanserln 
decreased both arterial blood pressure and blood flow simultaneously, 
there were no significant changes in vascular resistances in the 
maternal uterine artery and the fetal umbilical artery to ketanserln. 
Thirty minutes after ketanserln infusion, MUABF was still decreased 
after DOM at 5, 10, 20, 40 pg/kg (P < 0.05) (Fig. 5). However, the 
reductions were significantly less (P < 0.01) than those in MUABF to DOM 
without ketanserln (Fig. 5), Indicating the reduction in MUABF to DOM 
was inhibited by ketanserln. In the presence of ketanserln, DOM, in 
doses of 10, 20 and 40 pg/kg, produced a linear reduction in MUABF (Fig. 
5). DOM (10, 20 and 40 /ig/kg) produced a significant reduction (P < 
0.05) in FUmABF after ketanserln administration but there was no 
significant difference between the doses of DOM., The decrease in FUmABF 
to DOM (2.5, 5, 10 and 20 /ig/kg) in the presence of ketanserln (1 mg/kg) 
was significantly less than that to the same doses of DOM in the absence 
of ketanserln (P < 0.05) (Fig. 5). 
Since both an increase in MBP and reduction in MUABF to DOM were 
blocked by ketanserln. Fig. 6 shows that the changes in vascular 
resistance in the maternal uterine artery to DOM in the presence of 
ketanserln was much less (P < 0.01) than that to the same dose of DOM in 
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the absence of ketanserin. There was a linear increase (P < 0.05) in 
vascular resistance in the maternal uterine artery at DOM doses of 10, 
20 and 40 pg/kg after ketanserin administration (Fig. 6). The changes 
in vascular resistances in the fetal umbilical artery to DOM with 
ketanserin was also less (P < 0.05) than that to DOM without ketanserin 
(Fig. 7). The increase in vascular resistance in the fetal umbilical 
artery reached its plateau at the DOM dose of 20 /ig/kg after ketanserin 
administration (Fig. 7). 
Effect of ketanserin on arterial blood gas and pH responses to DOM 
Maternal and fetal arterial blood gas values (Pog, Pcog, BE and pH) 
did not vary significantly from baseline values after ketanserin 
infusion. The reduction in fetal arterial blood pH to DOM 10 /ig/kg was 
blocked by ketanserin (Table 2). DOM (20 /ig/kg) still produced a 
reduction (P < 0.05) in fetal pH, but the change was less (P < 0.05) 
than that to the same dose of DOM without ketanserin. With a higher 
dose of DOM (40 /ig/kg), fetal pH was further decreased (Table 2). No 
significant changes in fetal arterial blood Pcog and Pog were observed 
to DOM in doses up to 20 /ig/kg after ketanserin administration. A 
higher dose of DOM (40 /ig/kg) produced an increase on fetal Pcog and 
decrease in Pog ( Table 2). No inhibitory effect of ketanserin on the 
reduction in BE to DOM (20 /ig/kg) was observed (Table 2). 
Discussion 
The results of this study indicate that maternally administrated 
DOM produces dose-dependent increases in ovine maternal and fetal blood 
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pressures accompanied by a fall in heart rate. Ketanserin, a selective 
5-HT2 receptor antagonist (Leysen et al., 1981; Leysen et al,, 1982; Van 
Nueten et al., 1981), inhibited the pressor response to DOM, indicating 
that 5-HT2 receptor stimulation was involved in the response to DOM. 
This observation is in accord with previous reports involving rats, dogs 
and cats which indicate that the DOM-induced increase in blood pressure 
was mediated via serotonin receptor stimulation (Huang and Ho, 1972; 
Cheng et al., 1973; Tadepalli et al., 1975). It has been demonstrated 
that DOM is a potent agonist at S-HTg receptors both in the central 
nervous system (Glennon et al., 1983, 1984) and in the periphery (Dyer, 
1983; Zhang and Dyer, 1989a, 1989b). S-HTg receptors mediate 
vasoconstriction (Bradley et al., 1986; Cohen et al., 1983, Humphrey, 
1984; Leysen et al., 1984; Maayani et al., 1984; Van Nueten et al., 
1981, 1984) and since DOM selectively activates S-HTg receptors, DOM 
always produces a pressor effect. In the present study, ketanserin 
produced a transitory decrease in maternal and fetal blood pressure 
without affecting the heart rate. The transitory decreases in the 
maternal uterine artery and fetal umbilical artery blood flow following 
ketanserin administration were probably reflected by the decrease in the 
blood pressure. Ketanserin has been shown to reduce blood pressure in 
both animals (Van Nueten et al., 1981) and hypertensive humans (DeCree 
et al., 1981) without causing a compensatory increase in heart rate. 
However, there is a controversy as to whether the hypotensive effect of 
ketanserin rests with the blockade of Oj- or 5-HT2-receptors or with 
both (Humphrey et al., 1982; Vanhoutte and Van Nueten, 1983; Fozard, 
1983; Janssen, 1983). Since ketanserin can block the pressor response 
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mediated by a-receptors (Fozard, 1982; Kalkman et al,, 1982; Nelson et 
al., 1984), alpha-receptor stimulation in the pressor response to DOM 
can not be ruled out in this study. However, Cheng et al. (1973) and 
Tadepalli et al. (1975) demonstrated that the pressor response to DOM 
was not mediated by a-receptor stimulation in dogs and cats since 
phentolamine did not block this response. The pressor response to DOM 
was not elicited by increasing myocardial activity (cardiac output) nor 
inhibition of the vagus (Tadepalli et al., 1975). It has been reported 
that DOM could release 5-HT from platelets in rabbits and dogs (Cheng et 
al., 1973). Therefore, some of the pressor effects produced by DOM 
could be contributed by 5-HT. 
The significance of dose-dependent decreases in uterine and 
umbilical blood flow was defined more clearly in terms of vascular 
resistance. Alterations in blood flow to a vascular bed may result from 
changes in perfusion pressure or changes in vascular resistance from 
vasoconstriction or vasodilatation. In response to maternally 
administrated DOM, there was a concurrent rise in maternal blood 
pressure and a decrease in uterine blood flow, reflecting a dramatic 
increase in vasoconstriction of the uterine artery. The vaso­
constriction effect of DOM was antagonized by ketanserin. This is in 
accord with our recent finding that DOM produced a potent 
vasoconstriction on the isolated uterine artery from late pregnant sheep 
with the dissociation constant being 1.8 x lO'^M (Zhang and Dyer, 
1989a). Ketanserin shifted the dose-response curves of DOM in a 
parallel manner to the right with the pAg value being 8.33, indicating 
uterine artery vasoconstriction produced by DOM was mediated by 5-HT2 
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receptors. The reduced vasoconstriction observed in the fetal umbilical 
artery as compared to the uterine artery is unexpected since DOM was a 
more potent agonist in isolated umbilical arteries than in isolated 
uterine arteries (Zhang and Dyer, 1989a, 1989b). One of possibilities 
is that DOM is not crossing the placenta in sufficient concentration to 
elicit umbilical artery vasoconstriction. This is supported by 
preliminary experiments which indicated that if DOM was directly given 
to the fetus through a femoral vein catheter, there was a dramatic 
increase in umbilical artery vascular resistance. In the absence of 
measured DOM concentrations in maternal or fetal blood in this study, 
the relative portion of the effect of DOM which is a direct action on 
the fetal circulation remains speculative. 
Tachyphylaxis to the effects of DOM was not observed in this study. 
This observation does not agree with those by Friedman and co-workers 
(1978) or of Tadepalli et al, (1975). They found that tachyphylaxis to 
the blood pressure response to the second dose of DOM developed rapidly 
and was present up to at least 2 hrs following the first DOM injection. 
The third response was less than 30% of the first response. Marked 
tachyphylaxis to DOM has also been reported to occur for its 
hallucinatory effect in man (Angrist et al. 1974) and to its behavioral 
and EEC effects in cats (Wallach et al. 1972). However, vascular 
reactivity following DOM remained the same and tachyphylaxis was not 
observed (Dyer et al., 1973; Dyer, 1983; Zhang and Dyer, 1989b). The 
mechanism of tachyphylaxis development is not clear. The difference 
between this study and those of Friedman et al. (1978) and Tadepalli et 
al. (1975) could result from the different route of administration 
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and/or the different dose used or the use of different species. The 
intraventricular administration of DOM was used by Friedman et al. 
(1978) and Tadepalli et al. (1975) while intravenous administration was 
used in this study. The higher dose of DOM (1-4 mg/kg) used by 
Tadepalli et al. ( 1975) may also have contributed to the development of 
tachyphylaxis. 
The bradycardia which occurred following DOM administration 
appeared to be mediated reflexively in response to the increased blood 
pressure. The finding that the decrease in fetal heart rate was more 
pronounced than that in the ewe is of interest. The existence of 
arterial baroreceptor reflexes in the fetus (0.6-1.0 gestation) is well 
established (Shinebourne et al., 1972; Maloney et al., 1977). The 
degree of slowing of the heart rate in response to a rise in arterial 
pressure varied between the results reported by these authors. 
Shinebourne et al. (1972) found no difference between the fetus and the 
neonate, whereas Maloney et al. (1977) found a reduced bradycardia to 
increase in blood pressure in the newborn as compared to the fetus. 
Using a balloon to alter arterial pressure, Dawes et al. (1980) found 
that there was a consistent increase of baroreflex sensitivity from the 
fetus to the adult. In our study, the decrease in fetal heart rate 
could be caused by the decreased blood flow in the maternal uterine 
artery as well as the increase in the fetal blood pressure. 
The physiological importance of the heart rate stems from the fact 
that it is one of the two components of the cardiac output, the other 
being the stroke volume. Since the two ventricles effectively function 
parallel with the fetus, the Frank-Starling mechanism would not be of 
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particular importance. Because of this limited ability for Increasing 
stroke volume, fetal cardiac output is regulated predominantly by 
changes in heart rate (Rudolph and Heymann, 1974). The fast heart rate 
is an important mechanism which provides the fetus with the high cardiac 
output necessary to meet its metabolic activities. In general, 
sustained bradycardia is thought to reflect fetal distress. It has been 
found that the unanesthetized fetal lamb consistently developed 
bradycardia coupled with an increase in the systematic arterial pressure 
when fetal arterial Pog was lowered (Cohn et al., 1972). In the present 
study, vasoconstriction by DOM of the maternal uterine artery reduced 
oxygen delivery to the fetus and impaired fetal oxygenation. It is well 
established that norepinephrine (NE) concentration increases in the 
fetal plasma during acutely induced fetal hypoxia (Cohen et al., 1982; 
Lewis et al., 1982, 1984). Under resting conditions, small variations 
in oxygen tension may be an important modulator of NE release. Cheung 
and Brace (1988) showed that NE increased 41 pg/ml for each 1-mmHg 
decrease in oxygen tension. The high NE concentration found during 
fetal hypoxia tends to produce a progressive increase in arterial 
pressure and a decrease in heart rate. Vasopressin may also be involved 
in the fetal bradycardia and hypertension since it has been shown that 
arginine vasopressin (AVP) is increased in the fetal plasma during 
hypoxia (Rurak, 1978; Stark et al., 1982; Stegner et al., 1984; Tomita 
et al., 1985). 
The direct pressor effect of DOM on umbilical vasculature may also 
contribute to an Increase in fetal blood pressure and the fall in the 
heart rate. The vunbilico-placental circulation of the fetus is the 
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major factor which contributes to the low fetal systemic vascular 
resistance. This part of the fetal vascular bed accounts for about two-
thirds of the fetal cardiac output and is regarded as a low resistance 
network grafted in parallel with the circulation of the body of the 
fetus (Assali et al., 1968). Therefore, a small increase in umbilical 
vasculature resistance would promptly increase the systemic vascular 
resistance and produce an increase in arterial blood pressure and a 
decrease in cardiac output. It has been demonstrated that compression 
of the whole umbilical cord of the fetal lamb produced a bradycardia 
along with hypertension (Assali et al., 1968). We have demonstrated 
that DOM is a potent vasoconstrictor on the Isolated umbilical 
vasculature of the fetal lamb and the vasoconstriction is mediated via 
5-HT2 receptors (Zhang and Dyer, 1989b). The dissociation constant of 
DOM in constriction of the umbilical artery of the fetal lamb was 36nM 
(Zhang and Dyer, submitted for publication). In the present study, DOM 
(10 /ig/kg) increased the umbilical artery resistance about 2.3 times, 
which was less than it did on the maternal uterine artery (about 17 
times). However, as discussed above, the reason for the increased 
response of the uterine vasculature over that of the umbilical 
vasculature is likely due to the fact that the drug was directly 
introduced to the systemic circulation of the mother. Therefore, the 
concentration of DOM was higher at the level of the uterine vasculature 
than that of the umbilical vasculature since it would need to diffuse 
across the placenta in order to produce vasoconstriction of the 
umbilical artery. 
Mild hypoxia per se may not depress myocardial function. However, 
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a combination of hypoxia and acidemia produced marked depression of 
myocardial performance (Rudolph and Heymann, 1974). The combined 
metabolic and respiratory acidosis which developed in the fetus after 
the maternal administration of DOM could impair fetal brain function as 
well as myocardial performance. Ketanserin inhibited the fall in Pog 
and pH in the fetus in response to the maternal administration of DOM 
and probably due to its inhibitory effect on maternal uterine 
vasoconstriction produced by DOM. 
In summary, DOM, administered to the pregnant ewe, produced a dose-
dependent increase in maternal and fetal arterial pressure accompanied 
by a decrease in heart rate. The maternal uterine blood flow 
dramatically decreased following DOM (5 to 20 /ig/kg), which indicated a 
significant increase in vasoconstriction of the uterine artery. The 
fetus was distressed after maternal administration of DOM. Hypoxia and 
combined metabolic and respiratory acidosis were developed in the fetus 
after maternal DOM injection. A significant proportion of the fetal 
cardiovascular responses were probably produced by an indirect effect of 
DOM on the maternal uterine artery which in turn impaired the 
oxygenation of the fetus. Ketanserin inhibited the effects of DOM on 
the cardiovascular system of the ewe and fetus and on changes in blood 
gas values in the fetus, indicating the involvement of S-HTg receptors 
in these responses. These observations suggest that the administration 
or consumption of S-HTj receptor agonists during pregnancy may be 
hazardous to the fetus. 
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SECTION II. CHARACTERIZATION OF S-HYDROXYTRYPTAMINE (5-HT) RECEPTORS ON 
ISOLATED OVINE UTERINE ARTERY IN LATE PREGNANCY^ 
Abstract 
5-Hydroxytryptamine (5-HT) and 2,5-dimethoxy-4-methyl-amphetamine 
(DOM) are potent agonists on isolated ovine uterine arteries in late 
pregnancy. Similar pA2 values (8.56 and 8.33, respectively) of 
ketanserin, tested against 5-HT and DOM, indicate that responses 
produced by both agonists are mediated by the 5-HT2 receptor. The 
contractions produced by 8-OH-DPAT (8-hydroxy-dipropylarainotetralin) and 
2-methyl-5-HT were also blocked by ketanserin (10"%) with the 
dissociation constants (Kg) being 2.49 nM and 2.88 nM, respectively. 
This provides evidence that these agonists are activating 5-HT2 
receptors in the ovine uterine artery. DOM was more potent than 5-HT, 
but had a similar efficacy to that of 5-HT. The greater affinity of DOM 
may explain its greater potency. The dissociation constants (Ky^) of 5-
HT and DOM acting on 5-HT receptors were determined by analysis of 
concentration-response data before and after fractional inactivation of 
receptors with dibenamine. The mean values for 5-HT and DOM were 3.7 
± 0.7 X lO'^M and 1.8 + 0.3 x lO'^M, respectively. Assessment of 
receptor occupancy vs. functional response demonstrated little or no 
receptor reserve in this tissue. Several other 5-HT receptor agonists 
caused contractions but were much less potent than 5-HT. The order of 
^Submitted to J. Pharmacol. Exp. Ther. as a research paper by Lubo 
Zhang and Donald C. Dyer. 
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potency of these agonists was determined to be DOM > 5-HT > a-methyl-5-
HT » 8-OH-DPAT > 2-methyl-5-HT > 1-(3-chlorophenyl) piperazine (mCPP) > 
m-trifluoromethyl-phenylpiperazine (TFMPP). The presence of S-HT^^ 
receptor in this tissue is unlikely since ketanserin antagonized the 
contractile response to 8-OH-DPAT, 1-(2-methoxyphenyl) piperazine (2-
MPP) lacked agonist activity and TFMPP and mCPP had very weak agonist 
activities. All three phenylpiperazine derivatives effectively blocked 
contractile responses to 5-HT. The dissociation constants (Kg) were 
determined to be: mCPP, 0.13 /iM; TFMPP, 0.22 jM-, 2-MPP, 1.43 iM. The 
potent and selective S-HTg receptor antagonist MDL 72222 was without 
effect against 5-HT, indicating that the uterine artery 5-HT receptor is 
not of the S-HTg subtype. Activation of a-adrenergic receptors was not 
involved in contractions to 5-HT. 
Introduction 
Various blood vessels contract upon exposure to 5-hydroxytryptamine 
(5-HT). One of the vascular beds which has received little study 
concerning 5-HT receptors is that of the uterus, especially in 
pregnancy. Dyer and Cough (1971) observed that 5-HT has primarily 
excitatory actions on isolated human uterine arteries. At lower 
concentrations, 5-HT and norepinephrine (NE) were equally active. Since 
uteroplacental exchange can be altered by drugs acting on either uterine 
or umbilical placental blood vessels as well as on uterine muscle 
(Meschia, 1983), it is important to have knowledge of drug responses and 
drug receptors on uterine blood vessels. 
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The pregnant ewe is widely used as an experimental animal in the 
study of fetal physiology/pharmacology and since we are currently 
investigating the effects of serotonergic agonists in the chronically 
instrumented ewe/fetus model, we found it desirable to study the effects 
of 5-HT agonists/antagonists on isolated uterine arteries. This 
approach permits a more detailed investigation of receptor mechanisms. 
In addition, our previous studies on isolated umbilical vasculature were 
carried out on tissues obtained at term or within two weeks of term 
(Dyer, 1970; Gant and Dyer, 1971). Therefore, the investigation of 5-
HT receptor mechanisms in uterine artery near term will permit us to 
correlate these data with our previous work on umbilical vasculature and 
our ongoing investigation of serotonergic receptor mechanisms in the 
near term chronically instrumented ewe/fetus model. 
The original classification of 5-HT receptors proposed by Gaddura 
and Picarelli (1957) and modified by Peroutka and Snyder (1979) 
continues to evolve (Bradley et al., 1986). The characterization of 5-
HT receptors with the corresponding pharmacological responses has been 
investigated in various tissues, including blood vessels. 
Vasoconstriction in many arteries has been found to be mediated by a 
receptor similar to the 5-HT2 binding site (Van Nueten et al., 1981, 
1984; Leysen et al., 1984; Maayani et al., 1984). The classification of 
S-HTj receptors in tissues is complicated since at least four subtypes 
have been proposed and because highly selective antagonists are not 
available (Pedigo et al., 1981; Pazos et al., 1984; Heuring and 
Peroutka, 1987). This is in contrast with that of 5-HT2 or S-HTg 
receptors for which selective antagonists exist. 
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Knowing the dissociation constants of 5-HT receptor agonists and 
competitive antagonists acting on uterine blood vessels would provide 
fundamental information necessary for the eventual subtyping of 5-HT 
receptors in this tissue and permit a comparison to other tissues. In 
the present study, the potency order of 5-HT, 2,5-dimethoxy-4-methyl-
amphetamine (DOM) and other serotonergic agonists acting on the ovine 
uterine artery obtained in late pregnancy has been determined. The 
apparent dissociation constants were obtained for 5-HT, DOM and several 
competitive 5-HT receptor antagonists in this tissue. 
Methods 
Adult pregnant mixed breed sheep near term were anesthetized with 
pentobarbital and then exsanguinated. The pentobarbital was 
administered via the external left jugular vein. An incision in the 
abdomen was made and the uterus exposed. The left main uterine artery 
was isolated and removed without stretching and placed in a modified 
Krebs-Henseleit (Krebs') solution of the following composition (mM): 
NaCl, 115.21; KCl, 4.70; CaClg, 1.80; MgSO^, 1.16; KHgPO^, 1.18; NaH CO3, 
22.14; dextrose, 7.88. Disodium ethylenediamine tetracetic acid (EDTA 
0.03 mM) was added to suppress oxidation of amines. The Krebs' solution 
was oxygenated with a mixture of oxygen-carbon dioxide (95:5). Tissues 
not used immediately were stored for up to 24 hours at 4°C in Krebs' 
solution continuously oxygenated with 95% Og - 5% 00%. No changes in 
tissue responsiveness have been observed during storage. Helically-cut 
strips were prepared according to methods previously described (Dyer, 
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1970). Histological examination of strips at the completion of an 
experiment indicated that greater than 80% of the endothelial cells 
remained intact. Furthermore, rubbing the strips did not change the 
responsiveness to 5-HT. The tissues were placed under 1 g of tension in 
10-ml isolated organ baths maintained at 37°C and contractions were 
recorded isotonically. The tissues were allowed to equilibrate for at 
least 90 minutes before beginning the experiment. Concentration-
response data were obtained by cumulative additions of the agonists in 
approximately one-half log increments (van Rossum, 1963). 
Determination of agonist potencies 
Concentration-response data to 5-HT and other serotonergic agonists 
were obtained after each tissue had been exposed to KCl (150 mM) and 
this response to KCl was set as the 100% response. EC50 values for 
agonists in the experiment were recorded at the molar concentration 
where the curves intersected the 50% level of the response axis to that 
agonist. Relative potencies were calculated by comparing the 
concentration of agonist required to produce a contraction equivalent to 
that of 5-HT at the 30% response. No calculations were possible for 
TFMPP and 2-MPP since their maximum response did not reach the 30% level 
in this study. 
Determination of agonist dissociation constants and relative 
efficacies (e^) 
Matched strips from an adjoining portion of the same uterine artery 
were used in all experiments to determine the and e,. values for 5-HT 
(the reference agonist) or DOM, A concentration-response relationship 
to each agonist was obtained in a separate tissue prior to exposing the 
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tissue to dibenamine in order to inactivate a fraction of the receptors. 
To avoid the possibility of desensitization, the highest concentration 
of agonist added was that which would produce about 90% of the maximal 
response to that agonist. After fractional inactivation of the 
receptors by dibenamine (2.5-7.5xlO"®M for 15 minutes), the bath fluid 
was changed 5 or 6 times over 30 minutes. The concentration-response 
relationship for that agonist was then repeated. The concentration of 
dibenamine used in the present study usually reduced the maximal 
response to an agonist by 20 to 40%, a reduction suitable for K* 
determinations. 
values were determined as described by Furchgott and Bursztyn 
(1967). The reciprocals of the concentrations of an agonist before 
dibenamine treatment (1/[A]) were plotted against the reciprocals of the 
corresponding equieffective concentrations after treatment (1/[A']). 
From the slope and intercept of the straight line fitting the points, 
the values for Ky^ and for the fraction of active receptors remaining (q) 
were calculated on the basis of the equation (Furchgott, 1966): 
1 1-q 1 
- + (1) 
[A] q Ka q[A'] 
according to which equals (slope-1)/intercept, and q equals 1/slope. 
In each experiment, the relative affinity for DOM as compared to 5-HT 
was obtained by dividing the value obtained for 5-HT by that obtained 
for DOM. 
The values for 5-HT and that for DOM determined in an experiment 
on paired strips were then used to calculate the respective fractional 
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occupation of receptors by each agonist for each concentration used in 
establishing the control concentration-response curves prior to 
dibenamine treatment. The fractional occupancy was calculated from the 
equation (Furchgott and Bursztyn, 1967): 
[RA] [A] 
-  (2)  
[Rt] [A] + KA 
Where [RA] is the concentration of the receptor-agonist complex and [Rj] 
is the total concentration of receptors. Control pre-dibenamine 
response data for 5-HT and DOM were then replotted to show response as a 
function of log [RA]/[Ri]. The relative efficacy (e^) of DOM compared 
to 5-HT was the antilogarithm of the mean distance between the two 
agonists' curves along the abscissa. 
In all experiments, cocaine (3xlO"®M) was added to block uptake 
mechanisms (Dyer, 1970), phentolamine (10"'M) to inhibit alpha 
adrenergic receptors and iproniazid (0.36 mM) to block monoamine oxidase 
(MAO). Iproniazid was added for 40 minutes and the tissues were then 
washed 4 times over 30 minutes with fresh Krebs' solution. Cocaine and 
phentolamine were added 15 minutes prior to adding the agonists. 
Determination of apparent dissociation constants for antagonists 
Methiothepin, ketanserin and MDL 72222 were used in a series of 
experiments to determine the subtype of 5-HT receptors involved in 
contraction of the ovine uterine artery. Initially a concentration 
response relationship was obtained to a specific agonist. Then 
antagonists were allowed to equilibrate for 1 hour with the tissue 
before repeating the concentration response relationship to the same 
100 
agonist. The displacement of the log concentration-response curve for 
the agonist in the presence of the antagonist from that of the control 
was determined. 
The time-related shift of the agonist's response curve was measured 
in matched preparation not treated with antagonist. The concentration 
ratio (CRj) (EC50 at time t/ECgQ at time 0) was determined from the two 
control agonists' concentration-response curves. The concentration 
ratio (CR) (EC50 in the presence of antagonists/ECjo in the absence of 
antagonists) obtained for the antagonist treated tissue was then 
adjusted according to the following formula : 
CR 
Adjusted CR -
CR? 
Cocaine, phentolamine and iproniazid were also used as described above. 
To quantify antagonism, the method described by Schild (1947) for 
the determination of pAg values was employed. The adjusted 
concentration ratio (see above) obtained from the shifts in the agonist 
concentration response curve by the different concentrations of the 
antagonist were utilized in the Schild equation (Arunlakshana and 
Schild, 1959) 
log (CR-1) - log [B] - log Kb (3) 
where [B] is the molar concentration of the antagonist and the CR is the 
adjusted concentration ratio. A linear regression performed on the line 
generated by plotting log (CR-1) vs. - log [B] will have a slope of -1 
if blockade is competitive. The intercept along the abscissa (i.e., 
when CR - 2) represents the negative log of the dissociation constant 
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(Kg) for a competitive antagonist (i.e., PA2) . The mathematical 
calculations involved in obtaining a pA2 value were performed using a 
computer program which is based on procedures outlined by Tallarida and 
Murray (1981). 
Apparent dissociation constants (Kg) for ketanserin against 2-
methyl-5-HT and 8-OH-DPAT and the phenylpiperazines against 5-HT were 
determined for each concentration of antagonist according to the 
following equation (Furchgott, 1972): 
[B]  
KB " (4) 
CR -1 
Where [B] is the concentration of the antagonist and CR is the adjusted 
concentration ratio as discussed above. 
Experiments to evaluate alpha-adrenergic receptor stimulation 
Experiments were performed to evaluate the possibility that alpha 
adrenergic receptor stimulation was involved in the response to 5-HT. 
Pairs of adjacent strips from a single uterine artery were studied to 
compare the antagonism of prazosin and yohimbine to 5-HT and 
norepinephrine (NE). The strips were first exposed to KCl (150 mM) and 
then washed to permit relaxation to the original resting level. 
Prazosin or yohimbine were added to the bath and allowed to equilibrate 
with the tissue for 20 minutes. The preparations were then tested with 
a series of cumulative additions of 5-HT or NE in the presence of the 
antagonists. The data were plotted to determine the displacement of the 
log concentration-response curve for the agonist in the presence of the 
antagonists. 
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Drugs 
The following drugs were used: cocaine HCl; serotonin creatinine 
sulfate (Sigma Chemical Co., St. Louis, MO); R(-)-2,5-diraethoxy-4-
methyl-amphetamine (National Institute of Drug Abuse, Rockville, MD); 8-
hydroxy-dipropylaminotetralin (8-OH-DPAT), a-methyl-5-hydroxytryptamine, 
2-methyl-5-hydroxytryptamine, m-trifluoromethyl-phenylpiperazine HCl 
(TFMPP), l-(3-chlorophenyl)pipera2ine HCl (m-CPP), 1-(2-methoxypheny1) 
piperazine HCl (2-MPP), 3-tropanyl-3,5-dichlorobenzoate (MDL 72222) 
(Res. Biochem. Inc., Natick, Massachusetts); Ketanserin tartrate 
(Janssen, Beerse, Belgium); iproniazid, methiothepin maleate (Hoffmann-
LaRoche, Nutley, NJ); prazosin HCl (Pfizer Inc., Brooklyn, NY); 
yohimbine HCl (Merck, Rahway, NJ); phentolamine methane sulfate (CIBA 
Pharmacentical Company, Summit, NJ); dibenamine HCl (Smith, Kline and 
French Lab., Philadelphia, PA); 1-norepinephrine bitartrate (Calbiochem 
Behring Corp., La Jolla, CA). Drugs were dissolved in saline, except 
for dibenamine and MDL 72222, which were dissolved in alcohol and 
diluted in saline just prior to use. 
Data were expressed as means ± S.E.; for each experiment, n refers 
to the number of sheep from which vessels were taken. The student's t-
test was used for statistical analysis of the difference of means. 
Results 
Contractions of ovine uterine artery by 5-HT. DOM and other serotonergic 
agonists 
Serotonin, a-methyl-5-HT and DOM were found to be potent agonists 
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of ovine uterine arteries from pregnancy. The contractions were smooth 
and readily reproducible. Typical concentrations required for threshold 
contractions were about 10"%. All other agonists required a higher 
concentration to produce a threshold response. Concentration-response 
curves to 5-HT, DOM and other agonists are illustrated in Figure 1. In 
Table 1 the EC50 values and potency ratios are presented. The potencies 
of the agonists were determined to be DOM > 5-HT > a-methyl-5-HT » 8-
OH-DPAT > 2-methyl-5-HT > mCPP > TFMPP. DOM and a-methyl-5-HT were full 
agonists relative to 5-HT, their Emax values being no different from 
100%. The maximal contractile effects elicited by the other agonists 
tested were significantly less than those obtained with 5-HT and DOM. 
2-MPP caused minimal contraction of the uterine artery with the maximal 
response being 2 percent of that to 5-HT. 
Agonist dissociation constants 
The response to 5-HT before and after exposing the tissue to 
dibenamine (7.5 x 10"®M for 15 min) is shown in Figure 2. Dibenamine 
reduced the maximal response to 5-HT about 40%. Figure 3 illustrates a 
double reciprocal plot of equieffective concentrations of 5-HT before 
(1/A) and after (1/A') dibenamine treatment in a single experiment. The 
mean dissociation constant (K^) for the seven tissues was 3.7 ± 0.7 x 
10"'M (Table 2). Results of experiments concurrently carried out with 
DOM are presented in Table 2. The mean value for DOM was 1.8 ± 0.3 x 
lO'^M. It should be noted that the estimated fraction of receptors 
remaining active (q value) after pretreatment with dibenamine was 
essentially the same for 5-HT (0.19 ± 0.09) and DOM (0.25 ± 0.04). The 
results of the experiments with DOM were also used to evaluate the 
Fig. 1. Concentration-contractile response relationships for 5-HT and other serotonergic agonists. 
Results are illustrated as the x ± S. E. of the tissues from 3 to 8 animals and is expressed 
as a percentage of the contraction obtained with 150mM KCl 
Ovine Uterine Artery 
Log [Agonist] (M) 
R(-) DOM 
5-KT 
a -Methyl-5-HT 
2-Methyl-5-HT 
8-OH-DPAT 
mCPP 
TFMPP 
2-MPP 
Table 1. Comparative properties of serotonergic agonists on the ovine uterine artery 
Agonists EC^g Relative Approximate Percentage of Maximum 
Potency^ EC^QQ^ Tissue Response 
Obtained at ECinn^ 
M M % 
5-HT 8 1.27 X 10-7 1, .000 1.0 X 10-5 100 
DOM 8 5.41 X 10-8 2. 000^ 1.0 X 10-5 98 
a-methyl-5-HT 6 1.34 X 10-7 0. 934 1.0 X 10-5 100 
2-methyl-5-HT 4 3.88 X 10-G 0, .014^ 1.0 X 10-5 66 
8-OH-DPAT 4 2.14 X 10-G 0, .025^ 3.0 X 10-5 65 
mCPP 3 3.21 X 10-5 0, OOlf 1.0 X 10-4 40 
TFMPP 3 5.35 X 10-5 1.0 X 10-4 20 
2-MPP 3 3.30 X 10-5 1.0 X 10-4 2 
is the number of animals. 
^EC^Q is the effective concentration to produce 50% of the maximal response to the respective 
agonist. 
^Relative Potency was calculated at the EC^q (See Methods), 5-HT arbitrarily set at 1. 
Values for TFMPP and 2-MPP were not calculated since contraction to these agonists did not reach the 
EC30. , 
100 the effective concentration to produce 100% of the maximal response to the 
respective agonist. 
®5-HT is arbitrarily set at 100%. 
^Significantly different from 1 (P<0.05). 
Fig. 2. Effect of treatment with dibenamine on 5-HT-elicited contractions of the isolated ovine 
uterine artery in late pregnancy. Contractions to 5-HT were obtained before and after 
exposure to 7.5 x 10"®M dibenamine for 15 min. Dibenamine was washed out of the tissue 
before obtaining the second concentration-response relationship to 5-HT. The left panel 
represents the response of the paired tissue (strip 1) to 5-HT over the course of the 
experiment (time control) 
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Fig. 3. Determination of the dissociation constant for 5-HT acting on serotonergic receptors using 
the tissue responses illustrated in Figure 2. A double reciprocal plot of equiactive 
concentrations before and after incubation with dibenamine were used to determine the 
dissociation constant (Ky^) of 5-HT and the fraction of receptors still active (q) after 
dibenamine (see "Methods") 
Ovine Uterine Artery 
5-HT Dissociation Constant (Ky^) 
DB 7.5x10"®M 
y = 7.72x+17.33 X 106 
r = 0.98 
Ky^=3.88x10-7 
q = 0.13 
5 10 
1/IA']x10® 
15 
Table 2. Comparison of dissociation constants (Ky^) , relative efficacy (e^), affinity and fraction of 
receptors remaining active after dibenamine (7.5 x 10"®M) treatment (q) for 5-HT and DOM 
acting on the serotonergic receptors of ovine uterine artery 
Agonists N= K. Relative 
Affinity^ 
5-HT 
DOM 
7 
7 
M 
3.7 ± 0.7x10 
1.8 + 0.3x10 
-7 
-7 
0.19 ± 0.09 
0.25 ± 0.04 
1.00 
1.18 ± 0.17 
1.00 
1.80 + 0.24^ 
is the number of animals. 
'^5-HT is arbitrarily set at 1. 
'^Significantly different from 1 (P<0.05). 
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relationship between the estimated for DOM and the q values after 
treatment with two different concentrations of dibenamine. The value 
for q declined from 0.45 to 0.25 as the concentration of dibenamine was 
increased from 2.5 x 10"®M to 7.5 x 10"®M. Despite this significant 
decline in q, the estimated mean values of DOM remained essentially 
the same. 
In each experiment with paired strips, the affinity of DOM relative 
to that of 5-HT was calculated by dividing the estimated of 5-HT by 
that of DON. The affinity of DOM was on the average about 80% greater 
than that of 5-HT (P < 0.05) (Table 2). 
Relative efficacy fe^) of DOM 
The individual concentration-response curves to DOM and 5-HT that 
were obtained in the above experiments were compared. The 
concentration-response curves before exposure to dibenamine were 
replotted as response against log RA/R^ which was determined from the 
relevant value (see "Methods"). The relative efficacy of DOM to 5-
HT was obtained from individual experiments as the distance along the 
log RA/Rt axis. The mean values (± S.E.) are presented in Table 2. The 
efficacy of DOM was not significantly different from that of 5-HT. 
Relation of response to the fraction of receptors occupied by 5-HT and 
DOM 
The average value for 5-HT (3.7 x lO'^M) was used in Equation 2 
to calculate the fraction of receptors occupied ([RAj/fR?]) at each 
concentration employed in obtaining the complete concentration-response 
curve shown in Figure 4 (left panel). The result of replotting relative 
response against the calculated values for fractional receptor 
Fig, 4. Relationship of the relative response to the log concentration and to the fraction of 5-HT 
receptors occupied. Left panel: Log concentration-response curve drawn through average data 
points obtained on the strips from 21 animals (control strips in experiments to determine the 
pAj of ketanserin and methiothepin as antagonists to 5-HT and control tissues in determining 
the for 5-HT). The contractile response at each concentration is shown relative to that 
obtained at 5-HT (3 x 10"%). Right panel: Replot of data from the left panel showing the 
relative response as a function of the fraction of receptors occupied by 5-HT. The fraction 
of receptors occupied at each concentration was calculated from equation 2, employing the 
average Ky^ value for 5-HT of 3.7 x lO'^M 
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occupation is shown in Figure 4 (right panel). The curves indicate that 
one-half the maximal response is obtained when only about 17% of 
receptors are occupied by 5-HT, and that 90% of the maximum is obtained 
when about 65% of receptors are occupied. Similar results were found 
with DOM in that 22% of the receptors are occupied at one-half the 
maximal response and about 54% of the receptors are occupied at 90% of 
the maximum response. 
Studies using competitive inhibitors 
Three antagonists of 5-HT receptors were used in this 
investigation. These included: methiothepin, ketanserin and MDL 72222. 
Ketanserin competitively inhibited responses to 5-HT as demonstrated by 
parallel shifts in the log concentration-response curves to the right 
(Figure 5). Maximal responses were not affected by ketanserin at the 
highest concentration used (10"'M) . The curves for DOM were shifted to 
the right by ketanserin about the same as those for 5-HT. Schild plots 
for ketanserin vs. 5-HT and DOM yield straight lines with the slopes not 
significantly different from unity. The pAg values for ketanserin vs. 
5-HT and DOM are shown in Figure 6. Ketanserin (10"®M) effectively 
blocked the contractions to 8-OH-DPAT and 2-methyl-5-HT and shifted 
their concentration-response curves in a parallel manner to the right 
without affecting the maximum response. The dissociation constants (Kg) 
of ketanserin vs. 8-OH-DPAT and 2-methyl-5-HT were 2.49 ± 0.71 nM (n-3) 
and 2.88 ± 0.59 nM (n-3), respectively. 
Four different concentrations ranging from 6.4 x 10""M to 2.1 x 10" 
®M of methiothepin were employed to test for antagonism of contractions 
to 5-HT, The concentration-response curves for 5-HT were shifted to the 
Fig. 5. Cumulative concentration-response curves for 5-HT obtained with isolated ovine uterine artery 
in late pregnancy in the presence of various concentrations of ketanserin after equilibration 
for 60 min. Each point represents the x ± S.E. of the tissues from 8 animals and is 
expressed as a percentage of the contraction obtained to 3 x 10"®M 5-HT in control 
experiments 
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Fig. 6. Schild plot for determination of the pAg for ketanserin when 
tested against 5-HT (bottom) and DOM (above) on isolated ovine 
uterine artery in late pregnancy. Each point represents the 
average of the experiments from 8 animals. The intercept on 
the abscissa gives the pAg value. The slopes of the fitted 
regression lines are shown in the figure 
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right by methiothepin with depression of the maximal response. At the 
highest concentration of methiothepin used (2.1 x 10"®M) , the maximal 
response for 5-HT was depressed to 68 ± 4.9% (Figure 7). The Schild 
plot for methiothepin vs 5-HT yields a straight line with the slope 
being -1.27 which was significantly different from unity. The pAg value 
determined by the Schild plot was 8.94. 
Figure 8 presents the results of the antagonism by MDL 72222 of 
responses to 5-HT. MDL 72222 (10"® to 10"®M) had little or no effect on 
contractions to 5-HT. MDL 72222 (10"®M) shifted the concentration-
response curve for 5-HT slightly to the left and decreased the EG50 1.7 
fold which was not significantly different from the control. MDL 72222 
(10"®M) had no effect on the contractile responses to 2-methyl-5-HT. 
Antagonist activities of the phenvlpiperazine derivatives on 5-HT-
induced contractions 
Figure 9 presents the results of the antagonism of responses to 5-
HT by 2-MPP, TFMPP and mCPP. No agonist activity of 2-MPP (up to lO'^M) 
occurred in this smooth muscle preparation. TFMPP (10"^) and mCPP (10" 
produced 5% and 11%, respectively, of the response to 5-HT (Fig. 9). 
All three phenylpiperazines effectively blocked the contractile 
responses to 5-HT and shifted the concentration-responses curves to the 
right in a parallel manner without changes in the maximum response (Fig. 
9). Among the three phenylpiperazines, mCPP was the most potent 
antagonist against 5-HT-induced contractions, followed by TFMPP and 2-
MPP. The dissociation constants (Kb) of these phenylpiperazines against 
5-HT-induced contraction were determined to be: mCPP, 0.13 ± 0.06 ^M 
(n-3); TFMPP, 0,22 ± 0.08 /iM (n-3); 2-MPP, 1.43 ± 0.54 ^ M (n-3). 
Fig. 7. Cumulative concentration-response curves for 5-HT obtained with isolated ovine uterine artery 
in late pregnancy after equilibration for 60 min. in the presence of various concentrations 
of methiothepin. Each point represents the x + S.E. of the tissues from 7 animals and is 
expressed as a percentage of the contraction obtained to 3 x 10"®M 5-HT in control 
experiments 
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Fig. 8. Cumulative concentration-response curves for 5-HT obtained with isolated ovine uterine artery 
in late pregnancy after equilibration for 40 min. in the presence of various concentrations 
of MDL 72222. Each point represents the average of the tissues from 4 animals and is 
expressed as a percentage of the contraction obtained to 150mM KCl. *, significantly 
different from the control (P<0.05) 
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Activation of a-adrenergic receptors bv 5-HT 
The ability of 5-HT to stimulate a-adrenergic receptors was 
evaluated in uterine artery strips pretreated with prazosin or 
yohimbine. Paired strips from the same artery were used to compare the 
antagonism of prazosin and yohimbine to NE. Figure 10 illustrates the 
results of this experiment. Both prazosin (10"^M) and yohimbine (10"^M) 
did not antagonize responses to 5-HT, but effectively antagonized those 
to NE. Yohimbine (lO'^M) increased the ECgg of NE 2.5 times (P<0.05), 
while prazosin (10"^M) increased it 356 fold. 
Discussion 
The pA2 values of ketanserin for 5-HT and DOM were not 
statistically different in this study (Figure 6). This finding provides 
strong evidence that both DOM and 5-HT evoke contractions of the late 
pregnant ovine uterine artery by acting on the same type of receptor. 
Additional evidence for this conclusion comes from the finding that when 
strips from the same artery were pretreated in an identical manner with 
dibenamine, the fraction of receptors remaining active (q) for DOM, was 
not significantly different from those remaining active for 5-HT (Table 
2 ) .  
Ketanserin has been documented to be a potent and selective S-HTg 
receptor antagonist (Leysen et al., 1981, Leysen et al., 1982; Van 
Nueten et al., 1981). In this study, ketanserin caused parallel shifts 
of the concentration-response curves for 5-HT and DOM to the right, 
consistent with competitive inhibition. This was supported by the 
Fig. 10. Cumulative concentration-response curves to 5-HT (left panel) and norephinephrine (right 
panel) obtained with isolated ovine uterine artery strips in late pregnancy following 
equilibration with prazosin (lO'^M) or yohimbine (lO'^M) for 40 min. Each point represents 
the average of the tissues from 4 animals and is expressed as a percentage of the 
contraction obtained to 150mM KCl. *, significantly different from the control (P<0.05) 
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Schild plots whose slopes were not significantly different from unity. 
The pAg values of ketanserin against 5-HT (8.56) and DOM (8.33) in the 
present study are comparable to its affinity (Ki-2.1nM) for S-HTg 
binding sites in brains (Leysen et al., 1981; Leysen et al., 1982) and 
its pAg values determined on peripheral blood vessels (8.1 to 9.7) by 
other authors (Cohen et al., 1983b; Cohen, 1986; Humphrey, 1984; Van 
Nueten et al., 1982, Van Nueten et al., 1981). This suggests that the 
contractile responses produced by 5-HT and DOM in the ovine uterine 
artery are mediated by 5-HT2 receptors. The contractions produced by 8-
OH-DPAT and 2-methyl-5-HT were also blocked by ketanserin with 
dissociation constants (2.49 nM and 2.88 nM, respectively) which were 
similar to those for 5-HT and DOM. This provides further evidence that 
5-HT2 receptors are present in the ovine uterine artery. The finding 
that DOM acts on 5-HT2 receptors is in accord with our previous studies 
of ovine umbilical arteries (Dyer, 1983) and those reported by Glennon 
and co-workers in the central nervous system (1983, 1984). 
The values obtained for DOM after different degrees of receptor 
inactivation by dibenamine were not signficantly different. This 
suggests that 5-HT receptors remaining active after dibenamine treatment 
have the same characteristic (i.e., affinity) as the total population of 
original receptors prior to treatment. The determined for DOM in the 
present study was about two times less than that for 5-HT (Table 2). 
The affinity of DOM was about 80% greater than that of 5-HT. Despite 
the difference in values for DOM and 5-HT, they have essentially the 
same e,. (Table 2). If 5-HT is designated as a "full agonist" for the 5-
HT receptor, then on the basis of its similar relative efficacy, DOM is 
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also a full agonist. This classification of DOM as a full agonist does 
not agree with those by Sanders-Bush and co-workers (1988) or of Dyer et 
al. (1973). Sanders-Bush et al. found DOM to be a partial agonist on 
the S-HTg receptor which stimulates phosphoinositide hydrolysis in rat 
cerebral cortex. DOM stimulated phosphoinositide hydrolysis in the 
cerebral cortex with a maximum effect that was 76% of that produced by 
5-HT. Dyer and co-workers found that DOM contracted the ovine umbilical 
artery 82% of that to 5-HT. The difference between this study and that 
of Sanders-Bush et al. or Dyer et al. could be from the different 
methodologies and/or tissues used to study DOM's action on the 5-HT 
receptor. 
Phentolamine was used in the present studies to block activation of 
adrenergic receptors by 5-HT as reported by Innes (1962), In 
preliminary experiments we established that the Kg of phentolamine was 
1.08 X 10'®M when 5-HT was the agonist (data not presented). This is 
about 100-fold higher than the Kg value for phentolamine when 
phenylephrine was the agonist on strips of rabbit aorta (Furchgott, 
1972) . Since a concentration of phentolamine (lO'^M) was used to block 
adrenergic receptors in this study and this concentration is about ten­
fold lower than the Kg when 5-HT is the agonist it is doubtful that 
phentolamine contributed to the antagonism of 5-HT or DOM by ketanserin 
or methiothepin. 
Additional experiments were carried out to help ascertain whether 
or not 5-HT might be acting in part via alpha adrenergic receptors in 
the ovine uterine artery. Prazosin in a concentration (100 nM) which is 
approximately 30 times its reported Kg value of 3.5 nM in the rabbit 
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aorta (Furchgott, 1980) did not antagonize contractions to 5-HT but did 
increase the norepinephrine EC50 356 fold (Figure 9). Similarly, 
yohimbine (lO'^M) had no effect on the response to 5-HT but increased 
the EC50 for norepinephrine 2.5 fold which was significantly from the 
control. The results clearly indicate that contractions to 5-HT in the 
ovine uterine artery are not mediated by adrenergic receptors, This 
conclusion is in agreement with those of Stollak and Furchgott (1984) 
and Apperley et al. (1976) based on their determination of the pAg 
values for a series of competitive antagonists in the rabbit aorta. 
Theoretically, the same fractional occupation of receptors by 
either 5-HT or DOM in an individual artery strip would give the same 
degree of contraction of the strip. The relation between occupation of 
receptors and response in percentage of maximum for 5-HT and DOM were 
very similar in the present studies. Both agonists gave half of the 
maximum response with about 20% occupation, and 90% of the maximum with 
about 60% occupation. As predicted from inactivation studies with 
dibenamine, there is very little, if any, receptor reserve, since almost 
all the receptors need to be occupied to produce a maximal response. 
Evidence suggesting a lack of spare receptors for 5-HT2 receptors in 
other tissues was also obtained by Cohen et al. (1986a) in the rat 
jugular vein and uterus. 
The relative potencies of various agonists acting on serotonergic 
receptors were determined by comparing the concentrations of each 
required to produce the 30 percent of maximum response. Differences in 
relative potencies among the agonists may result from differences in 
their affinities and/or their relative efficacies. In the case of DOM 
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and 5-HT which have equal relative efficacy, the difference in the 
relative potency can be attributed to the difference in their affinity 
for the 5-HT2 receptor in the ovine uterine artery. 
5-HTiy^ receptor has been reported to be linked to contractions in 
the canine basilar artery (Peroutka et al., 1986; Taylor et al., 1986). 
However, in this study contractions to 8-OH-DPAT were effectively 
blocked by ketanserin, suggesting that S-HT^^ subtype of receptors are 
not present in this tissue. The three phenylpiperazine derivatives used 
in this study, TFMPP, mCPP and 2-MPP, have been identified as relatively 
selective ligands for the S-HT^g binding sites in the rat brain (Sills 
et al., 1984; Fuller et al., 1980). However, these compounds can bind 
to 5-HT2 binding sites as well. TFMPP and mCPP have only 3- to 18-fold 
selectivity for S-HT^ vs. S-HTg sites (Glennon, 1987; Martin and 
Sanders-Bush, 1982). 2-MPP possesses a 100-fold selectivity for S-HT^ 
vs. 5-HT2 sites and its affinity for S-HT^ sites is comparable to that 
of TFMPP (Glennon, 1987). These compounds are generally thought to be 
agonists at central 5-HT receptors with which they interact and which 
activate presynaptic autoreceptors on serotonin neurons that modulate 
the neurogenic release of serotonin (Markin and Sanders-Bush, 1982). 
However, in the present study, these compounds lacked agonist activity 
or had very weak agonist activity but instead antagonized the 
contractile responses produced by serotonin. As discussed above, the 5-
HT-induced contraction was mediated by S-HTg receptors in this tissue. 
It is apparent that these phenylpiperazine derivatives are better 
antagonists than agonists at S-HTj receptors in the ovine uterine 
artery. Our results are totally consistent with those reported by Cohen 
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et al. (1983a, 1983b, 1986b). These authors demonstrated that mCPP and 
TFMPP were potent competitive antagonists at S-HTj receptors in the rat 
jugular vein and aorta. The dissociation constants (Kg) of mCPP (0.13 
/iM) and TFMPP (0.22 /zM) vs. 5-HT in this study were comparable to those 
(0.04 fiM. and 0.06 fM, respectively) reported by Cohen and Fuller (1983). 
The higher dissociation constant of 2-MPP (1.43 /iM) than that of mCPP or 
TFMPP may be due to its lesser affinity at 5-HT2 binding site than the 
other two phenylpiporazines, as discussed above. More recently, 
Sanders-Bush and Conn (1986) found that TFMPP and mCPP acted as pure 
antagonists of the central S-HTg receptors. It has been demonstrated 
that TFMPP and mCPP failed to stimulate phosphoinositide hydrolysis at 
concentrations which completely inhibited the response to 5-HT in the 
rat cerebral cortical slices (Sanders-Bush and Conn, 1986). Therefore, 
the central agonists' activities of these phenylpiperazines may be 
mediated by different subtypes of 5-HT receptors. 
Methiothepin is a nonselective antagonist with affinity for both 5-
HT^ and 5-HT2 binding sites in the brain (Martin and Sanders-Bush, 1982; 
Engel et al., 1983). It has been demonstrated that methiothepin 
competitively antagonized the 5-HT-induced contraction in canine 
coronary and femoral arteries (Cohen, 1986; Houston and Vanhoutte, 
1988). In the present study, methiothepin produced a potent 
concentration-dependent inhibition of 5-HT-induced contractions and 
shifted the concentration-response curves to the right in a parallel 
manner. However, the maximum response was depressed as well. The slope 
of the Schild plot was greater than one. This might be due to its 
noncompetitive nature of antagonism as reported in the canine saphenous 
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vein (Apperley and Humphrey, 1986) and in the endothelial responses of 
the canine coronary artery to 5-HT (Houston and Vanhoutte, 1988). The 
pA2 value (8.94) determined in this study was similar to those reported 
in the canine femoral artery (8.8) by Cohen (1986) and in the canine 
coronary artery (8.78) by Houston and Vanhoutte (1988). 
MDL 72222, a selective and potent 5-HT3 antagonist (Fozard, 1984), 
did not antagonize responses to 5-HT, providing strong evidence that 5-
HT3 receptors were not present in this tissue. Furthermore, the 
contractions to 2-methyl-5-HT, a selective 5-HT3 receptor agonist 
(Bradley et al. 1986), were not blocked by MDL 72222 (10"®M) but were 
effectively blocked by ketanserin (10"®M). The dissociation constant of 
ketanserin vs. 2-methyl-5-HT (2.88nM) was similar to that of ketanserin 
vs. 5-HT (2nM), suggesting that the 2-methyl- 5-HT- induced contraction in 
the uterine artery was mediated by S-HTg receptors. 
In summary, 5-HT and DOM are potent agonists in producing 
contraction via 5-HT2 receptors in the late pregnant ovine uterine 
artery. Activation of alpha adrenergic receptors are not involved in 
the response to 5-HT. The presence of 5-HTia receptors in this tissue 
was unlikely since ketanserin antagonized contractions to 8-OH-DPAT. In 
contrast to their agonist properties at central 5-HT receptors, the 
phenylpiperazine derivatives, TFMPP, mCPP and 2-MPP acted as antagonists 
at 5-HT2 receptors in the uterine artery. S-HTg receptors are not 
present in this tissue. 
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SECTION III. 5-HT2 RECEPTOR-STIMUIATED CALCIUM INFLUX IN THE OVINE 
UTERINE ARTERY IN LATE PREGNANCY^ 
Abstract 
The effects of 5-hydroxytryptamine (5-HT) and 2,5-dimethoxy-4-
methyl-amphetamine (DOM) on the Ca^"*" influx in the ovine uterine artery 
in late pregnancy have been studied by measuring the ^^Ca^^ uptake. Both 
5-HT and DOM induced concentration-dependent (2.5 x 10"® - 2.5 x 10"%) 
rises in ^^Ca^"*" uptake in the uterine artery, from a basal level of 30.5 
±3.5 pMoles/kg wet tissue to peak levels of 91.1 ± 9.2 and 84.2 ± 8.1 
/iMoles/kg wet tissue, respectively. Ketanserin inhibited the Ca^^ 
influx evoked by 5-HT and DOM. The dissociation constants (kg) of 
ketanserin, tested against 5-HT and DOM, were not significantly 
different, indicating that the Ca^"*" influx produced by both agonists are 
mediated by the same 5-HT receptor, i.e., 5-HT2 receptor. Methiothepin 
(2.5 X 10"^M) also inhibited 5-HT (2.5 x 10"®M) induced Ca2+ influx by 
86%. No antagonism has been found with 2.5 x 10"% of 3-tropanyl-3,5-
dichlorobenzoate (MDL 72222). The contraction elicited by 5-HT (10"®M) 
and DOM (10"®M) was blocked by D600 (10"%) which also blocked the 
contraction produced by KCl (90mM). Amrinone (10"%) showed no 
inhibitory effect of these contractions. In accord with the results of 
the contraction study, D600 (2.5 x 10"%) blocked the Ca^"*" influx 
stimulated by 5-HT (2.5 x 10"%) and amrinone (2.5 x 10"%) failed 
^Submitted to Eur. J. Pharmacol, as a research paper by Lubo Zhang 
and Donald C. Dyer. 
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to inhibit 5-HT-induced Ca^"*" influx. These data clearly showed that 5-
HT induced Ca^"*" in this preparation was mediated by voltage-dependent 
channels. The further evidence came from the inhibition of 
nifedipine (2.5 x 10"%) on the 5-HT-induced Ca^"*" influx. Sodium 
nitroprusside was also shown to inhibit the 5-HT-induced influx, 
which indicated that at least part of its inhibitory effect on the 
vasoconstriction evoked by 5-HT was due to the inhibition of the 5-HT-
induced Ca^"*" influx. 
Introduction 
The calcium ions that initiate a mechanical response in smooth 
muscle cells may be mobilized from calcium reservoirs within the cell 
and/or from the calcium pool (both free and loosely bound calcium) in 
the external environment (VanBreeman et al., 1982). The relative 
dependence of the contraction on these two calcium sources has been 
shown to vary with agonist, concentration of agonist, blood vessels and 
species studied (Fleckenstein, 1977; Kalsner et al., 1970; Weiss, 1977). 
A series of calcium channel blockers have helped to unravel the possible 
role of the extracellular calcium in the agonist-induced 
vasoconstrictions. It has been proposed that 5-hydroxytryptamine (5-
HT) could stimulate depolarization of the smooth muscle membranes 
(Fujiwara et al., 1982) and induce contractions mediated by influx of 
the extracellular calcium (Berta et al., 1986; Capponi; et al., 1987; 
Nakaki et al., 1985; Ratz and Flaim, 1984), 
It has been well demonstrated that 5-HT produced a vasoconstriction 
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in many blood vessels (Van Nueten et al., 1981, 1984; Leysen et al., 
1984; Maayani et al., 1984; Zhang and Dyer, 1989a, 1989b). Major 
advances in 5-HT receptor classification have undoubtedly arisen as a 
result of new drug tools recently identified such as the potent 
pharmacologically selective antagonists ketanserin and MDL 72222 (3-
tropanyl-3,5-dichlorobenzoate). In our previous study, we demonstrated 
that 5-HT and 2,5-dimethoxy-4-methyl-amphetamine (DOM) were potent 
agonists mediating vasoconstriction in ovine uterine artery by acting on 
5-HT2 receptors (Zhang and Dyer, 1989a). We have now demonstrated that 
5-HT and DOM stimulated voltage-dependent calcium channel mediated Ca^"*" 
influx in ovine uterine artery by measuring the smooth muscle 
uptake. Additionally, several serotonergic antagonists have been used 
to determine the subtype of 5-HT receptors linked to 5-HT-induced Ca?* 
influx. 
Methods 
Uterine arteries from pregnant mixed breed sheep were helically cut 
and prepared as previously described (Zhang and Dyer, 1989a). The 
arterial strips were suspended in 10-ml isolated organ baths, maintained 
at 37°C and bathed with a modified Krebs-Henseleit (Krebs) solution of 
the following composition (mM): NaCl, 115.21; KCl, 4.70; CaClg, 1.80; 
MgSO*, 1.16; KHgPO^ 1.18; NaHCOg, 22.14; dextrose, 7.88. Disodium 
ethylenediamine tetracetic acid (EDTA 0.03 mM) was added to suppress 
oxidation of amines. The Krebs' solution was oxygenated with a mixture 
of oxygen-carbon dioxide (95:5). The tissues were equilibrated under Ig 
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of tension for 90 min before initiating the experiment, and contractions 
were recorded isotonically. 
Effects of Ca^"*" channel blockers on KCl and agonist-induced contractions 
After the 90 min equilibration period a concentration-response 
relationship was developed by adding a single concentration of an 
agonist to a series of isolated muscle baths containing arterial strips 
prepared from the same uterine artery. Initially all tissues were 
exposed to KCl 90mM, a concentration which produced approximately 80% of 
the maximum response, and the responses to all agonists were compared to 
the KCl (90mM) response. This was followed by adding a single 
concentration of the agonist under study to establish a control 
response. The tissues were then repeatedly washed and the tissues 
allowed to relax to the original baseline. Tissues were then exposed to 
D600 (10"®M) or amrinone (10"®M) for 30 min. A second exposure to the 
same concentration of the agonist was obtained and the contraction 
produced compared to the control. In another set of experiments the 
effect of D600 on contractions developed to agonists was determined by 
adding the D-600 at the peak of the contraction. 
Ca^'*" uptake studies 
Calcium influx was measured by using a technique previously 
reported by Stice et al. (1987). In brief, the segment of the uterine 
artery of the same positional location from different animals was 
utilized for Ca^^ influx determinations. The uterine artery was 
helically cut into strips 10mm long and 2 mm wide. A 1 g weight was 
used to apply a constant tension to the arterial smooth muscle. After 
equilibration, each strip was exposed to a different concentration of 
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agonist, i.e., 5-HT (10 min) or DOM (15 min), in a buffer (0.5 
)tiCi/ml) . Where appropriate, inhibitors were added 30 min prior to the 
agonist challenge. Thereafter, the strips were emersed in cold (4°C) 
lanthanum chloride (10"®M) solution for 60 min. The tissues were then 
blotted dry on filter paper, weighed and placed in a separate 
scintillation vial containing 0.5 ml of protosol (NEN Research Products, 
Boston, MA) and heated at 60°C for 2 hrs to dissolve the tissues. Ten 
milliliters of Scinti Verse (Fisher Scientific, Fair Lawn, New Jersey) 
was added to each vial. Radioactivity in the tissue was detected by 
scintillation counting. Ca^^ uptake was determined by the apparent 
tissue content of ^^Ca^^ with adjustment for its original specific 
activity and normalized for the weight of each tissue. Nonspecific 
binding of ^ ^Ca to the tissue was determined for each uterine artery by 
incubating the uterine artery strip with 4 ml of aerated Ca^^-free 
buffer containing lO'^M LaClg for 30 min before exposure to 0.5 /xCi/ml 
of *^Ca. Nonspecific binding, which averaged 20.3 ± 4.7% of specific 
uptake, was subtracted from total ^®Ca uptake for each artery to obtain 
specific uptake. The influx is referred to as the difference between 
the uptake measured in the presence of stimulant and the corresponding 
control. Inhibitory activity of a drug is expressed as a percent of 
maximal influx induced by the stimulant in question. 
Data analysis 
Estimates of ECgg for 5-HT and DOM in Ca^"*" uptake studies were 
obtained by fitting Equation 1: R - RmaxD/(D + EC50) to the observed 
response R as a function of drug concentration [D] using a computer 
program which is based on procedures outlined by Tallarida and Murray 
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(1981) . To obtain estimates of ICggS for the experiments in which the 
5-HT and DOM responses were inhibited by ketanserin, Equation 1 was 
fitted so that the Rmax was a constant equal to 100% of the uninhibited 
responses to 5-HT or DOM, the ECgq being equivalent to ICgQ. 
For inhibition experiments, ketanserin ICggS were converted to 
dissociation constant (kg) values using the Cheng-Prussof Equation 2 
(Cory et al., 1986): kg - IC5o/(l + [Agonist]/EC50) in which [Agonist] 
is the concentration (2.5 x 10"®M) of 5-HT and/or DOM used in the 
inhibition experiments and EC50 is the mean value of those determined 
for 5-HT and/or DOM in this study. This equation is based on a model of 
competitive antagonism which is obtained by using ketanserin in the 
present study. 
Data were expressed as means ± SE. For each experiment, n refers 
to the number of sheep from which the uterine artery was taken. The 
Student's t-test was used for statistical analysis of the difference of 
means. 
Drugs and chemicals 
The following drugs and chemicals were used; serotonin creatinine 
sulfate, sodium nitroprusside (Sigma Chemical Co., St. Louis, MO); R(-) 
-2,5-dimethoxy-4-methyl-amphetamine (DOM) (National Institute of Drug 
Abuse, Rockville, MD); 1-epinephrine bitartrate, 1-norepinephrine 
bitartrate (Calbiochem Behring Corp., La Jolla, CA); methiothepin 
maleate (Hoffmann-LaRoche, Nutley, NJ); ketanserin tartrate (Janssen, 
Beerse, Belgium); 3-tropanyl-3,5-dichlorobenzoate (MDL 72222) (Res. 
Biochem. Inc., Natick, Massachusetts); Nifedipine (Pfizer, Brooklyn, 
NY); D600 (A. G. Knoll Pharmaceutical Laboratories, Ludwigshafen, W. 
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Germany); amrinone (Sterling Winthrop, Rensselaer, NY); and (31.18 
mCi/mg; New England Nuclear, Boston, MA). 
Results 
Effects of D600 and amrinone on KCl and the agonist-induced contractions 
Single concentration (10"®M) of 5-HT and DOM elicited contractions 
that were 112 and 114 percent, respectively, of that produced by KCl 90 
mM. Following exposure of the tissues to D600 (lO'^M) for 15 min, 
responses to KCl, 5-HT and DOM were blocked (Fig. 1), No antagonism by 
amrinone (10"®M) was observed (Fig. 1). 
D600 (10"®M) totally blocked the 5-HT and DOM-induced contractions 
when added after the contractions have reached their plateaus, but 
incompletely blocked those to KCl, norepinephrine and epinephrine when 
added at the same manner (Fig. 2). 
Effects of 5-HT and DOM on Ca^"*" uptake 
5-HT (2.5 X 10'® to 2,5 x 10"%) induced concentration-dependent 
increases of Ca^^ uptake in uterine artery from resting values of 30.5 ± 
3.5 pMoles/kg wet tissue to a peak of 91.1 ± 9.7 pMoles/kg wet tissue. 
The concentration-response curve of 5-HT was showed in Fig. 3. ECjo of 
5-HT in stimulating Ca^^ uptake was determined to be 4.57 ± 1.33 x 10" 
'M. Similar results were obtained to DOM (Fig. 3). DOM (2.5 x 10"®M to 
2.5 x 10"%) increased Ca^^ uptake dose-dependently from the resting 
level of 30.5 ± 3.5 ^Moles/kg wet tissue to the peak level of 84.4 ± 7.9 
^Moles/kg wet tissue, which was not significantly different from that of 
5-HT. The ECgg of DOM was determined to be 2.75 ± 1.15 x lO'^M and was 
Fig. 1. Effects of D600 and amrinone on the vasoconstriction responses to KCl, 5-HT and DOM in ovine 
pregnant uterine artery. Both the D600 and amrinone were equilibriated with the tissue for 
30 min prior to challenge to the agonists. The results are presented as x ± S.E. (N - 3). 
The treatment groups are compared to their control groups. ** P < 0.01 
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not significantly different from that of 5-HT. 
Effects of serotonergic antagonists on 5-HT and DOM induced influx 
The ability of three serotonergic antagonists to inhibit the 5-HT 
elicited increase in Ca^"*" uptake was investigated. Two of these 
compounds, the 5-HT2 selective antagonist ketanserin and S-HT^ and 5-
HT2 antagonist methiothepin, were potent inhibitors of Ca^^ influx 
induced by 2.5 x 10"®M 5-HT (Fig. 4). Exposure of the tissues to 
ketanserin (2.5 x lO'^M) and methiothepin (2.5 x 10"^M) for 30 min, 
significantly (P < 0.01) decreased Ca^"*" uptake by 5-HT (2.5 x 10"%) from 
79 ± 9.1 ^ Moles/kg wet tissue to 39 ± 5.1 /iMoles/kg wet tissue and 39 ± 
4.2 /iMoles/kg wet tissue, respectively. Ketanserin produced a 
concentration-dependent inhibition on Ca^"*" influx elicited by 5-HT 
and/or DOM (Fig. 5). The two ketanserin inhibition curves were 
essentially superimposed. The ICggS of ketanserin vs. 5-HT and DOM were 
determined to be 2.60 ± 0.98 x 10"®M and 3.00 ± 1.28 x 10"%, 
respectively. Ketanserin is a competitive 5-HT2 antagonist. In the 
previous study, we showed that ketanserin competitively antagonized the 
contractions produced by 5-HT and DOM in the ovine uterine artery (Zhang 
and Dyer, 1989a). The Kg values for ketanserin in inhibiting Ca^^ 
influx induced by 5-HT and DOM were calculated using Equation 2 and were 
found to be 4.02 ± 1.42 x 10"®M and 2.97 ± 1.25 x 10"%, respectively. 
The selective 5-HT3 antagonist MDL 72222 (2.5 x 10"%) produced no 
antagonism on the Ca^"*" influx Induced by 5-HT (2.5 x 10"%) (Fig. 4). 
Effects of Ca^^ channel blockers on 5-HT induced Ca^^ influx 
The resting Ca^"*" uptake measured with *^Ca^+ was 30.5 ± 3.5 /«Moles 
Ca^^/kg wet tissue per 10 min. 5-HT (2.5 x 10"%) increased the Ca^"*" 
Fig. 4. Effects of serotonergic antagonists on the 5-HT-induced Ca^"*" uptake in ovine pregnant uterine 
artery. Met., methiothepin; ket., ketanserin; MDL., MDL 72222 were equilibriated with the 
tissue for 30 min prior to adding 5-HT. The results are presented as x ± S.E. (N - 6). The 
serotonergic antagonist treatment groups are compared to the 5-HT alone treatment group. ** 
P < 0.01 
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uptake to 79.6 ± 9.2 pMoles Ca^^/kg wet tissue per 10 min. The Ga^"*" 
influx induced by 5-HT was referred to as the difference between the 
uptake measured in the presence of 5-HT and the corresponding resting 
level. In this case 5-HT (2.5 x 10"®M) stimulated Ca^^ influx was 49.1 ± 
6.1 /iMoles Ca^^/kg wet tissue per 10 min. Fig. 6 showed the effects of 
Ca^"*" channel blockers on the influx induced by 5-HT (2.5 x 10"%) . 
D600 (2.5 X 10"%) decreased the 5-HT-stimulated Ca^^ influx to 7.4 ± 2.1 
pMoles Ca^^/kg (P<0.01). The same concentration of nifedipine showed no 
inhibitory effect on the 5-HT-induced Ca^* influx. However, increasing 
the concentration of nifedipine (2.5 x 10"%) 10 times produced a 
similar inhibition as that to D600 (Fig. 6). Sodium nitroprusside (2.5 
X 10"%) also decreased the 5-HT-stimulated Ca^"*" influx with its 
inhibitory effect being slightly less than that produced by the same 
concentration of nifedipine (Fig. 6). No antagonism of the 5-HT-
induced Ca^^ influx was observed with 2,5 x 10"% amrinone (Fig.6). 
Discussion 
Extracellular Ca^"*" has been proposed to play a role in the vascular 
contractions produced by 5-HT receptor activation (Berta et al., 1986; 
Capponi et al., 1987; Nakaki et al., 1985; Ratz and Flaim, 1984). 
Experiments in the present study clearly demonstrate that extracellular 
Ca^"*" was involved in 5-HT mediated responses in the ovine uterine 
artery. 5-HT produced a concentration-dependent increase in Ca^+ uptake 
in the uterine artery. The EC50 (0.46pM) of 5-HT in mediating Ca^ "^  
influx in this preparation was comparable to its EC50 (0.13 /iM) for 
Fig. 6. Effect of channel blockers on the 5-HT-induced Ca^"*" influx in ovine pregnant uterine 
artery. Amr., amrinone; Nif., nifedipine; S.P., sodium nitroprusside were equilibriated with 
the tissue for 30 min prior to challenge with the 5-HT. The results are presented as x ± 
S.E. (Control, D600 and amrinone treatment groups, N — 6, nifedipine and sodium nitroprusside 
treatment groups, N - 3). The Ca^"*" channel blocker treatment groups are compared to 5-HT 
control group. ** P < 0.01 
q> 
D 
m 
m 
Q) 
o> 
CO 
Q> 
X 
3 
+ 
CM 
O 
O 
60 
5 50 
40 
-S 30 
20 
10 
5-HT 2.5X10 
+D600 2.5X10 
4-Amr. 2.5X10 
É 
+Nif. 2.5X10 
+S.P. 2.5X10~®M 
H» 
a\ 
** 
** 
162 
producing contractions (Zhang and Dyer, submitted for publication). 
These results suggest that the 5-HT-induced Ca^"*" influx and contractions 
are causally related. 
5-HT has been found to stimulate phosphatidylinositol metabolism in 
the cerebral cortex (Berridge et al., 1982; Brown et al., 1984; Conn and 
Sanders-Bush, 1984, 1987; Pierce and Peroutka, 1988) and in vascular 
smooth muscle (Doyle et al., 1986; Roth et al., 1984). The 
phosphatidylinositol turnover stimulated by 5-HT was via S-HTg-
receptors. One can therefore assume that in vascular smooth muscle 
cells as in the cerebral cortex serotonin acts through activation of a 
membranous phospholipase C. The breakdown of phosphoinositides 
generates inositol 1,4,5-triphosphate (IP3), which is known to mobilize 
calcium from intra-cellular stores and 1,2-diacylglycerol, which 
activates the Ca^^-sensitive, phospholipid-dependent protein kinase C 
(Rasmussen et al., 1987). It has been shown that 5-HT stimulated 
phosphatidylinositol turnover in rat aorta and that in this tissue the 
mechanism of the 5-HT-induced contraction required the participation of 
the opening of a voltage-gated calcium channel and the stimulation of a 
phosphatidylinositol-specific phospholipase C (Nakaki et al., 1985; Roth 
et al., 1986). Recent evidence indicates that a rise in cytosolic 
can also activate phospholipase C (Eberhard and Holz, 1987; Fisher and 
Agranoff, 1981; Kendall and Nahorski, 1984, 1985). Ca^*-activated 
phospholipase C may represent a positive feedback system for Ca^^; that 
is, small increases in cytosolic Ca^"*" induced by Ca^"*" influx across the 
plasma membrane may result in higher cytosolic Ca^^ concentrates due to 
IP3-induced release of Ca^"*" from intracellular stores. The IP3 produced 
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in this way could also act on the plasma membrane to increase Ca^"*" 
influx as it does on the membrane of the responsive fraction of 
endoplasmic reticulum (Kuno and Gardner, 1987; Slack et al., 1986). The 
activation of phospholipase C by Ca^"*" may also provide a mechanism for 
diacylglycerol generation and protein kinase C activation following Ca^^ 
influx. Thus, a rise in cytosolic Ca^"*" initially induced by 5-HT in 
this study may contribute to the activation of phospholipase C which in 
turn will stimulate phosphatidylinositol turnover as demonstrated by 
others. 
There are two major routes by which calcium ions from the 
extracellular pool may traverse the cell membrane and thereby gain 
access to the contractile apparatus. One pathway is the receptor-
operated calcium channel system; the other is the voltage-dependent 
calcium channel system (Bolton, 1979; Meisheri et al., 1981; VanBreemen 
et al., 1982). D600, an inhibitor of the voltage-dependent channel 
(Bolton, 1979; Meisheri et al., 1981), potently inhibited Ga^"*" influx 
mediated by 5-HT. Amrinone has been demonstrated as an inhibitor on 
norepinephrine- or phenylephrine-induced Ca^"*" influx in the rabbit aorta 
and the pig uterine artery (Meisheri et al., 1981; Stice et al., 1987). 
The k"*"-induced Ca^^ influx was not affected by amrinone. These authors 
suggested that amrinone may act on the receptor-operated calcium 
channel. In the present study, amrinone (2.5 x 10"%) showed no 
inhibition on 5-HT-induced Ca^^ influx. These results indicate that 5-
HT-induced Ca^^ influx in this tissue is mediated by the voltage-
dependent calcium channels. Further evidence comes from the contraction 
studies in the uterine artery in which D600 (lO'^M) blocked contractions 
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evoked by KCl, 5-HT and DOM but amrinone (lO'^M) had no effect. It has 
been demonstrated that the vascular contraction elicited by 5-HT 
involves depolarization of the smooth muscle membranes (Fujiwara et al., 
1982) which could open the voltage-dependent calcium channel (Brown et 
al., 1981; Hille, 1984). 
One of the interesting findings was that when added after the 
agonist-induced contractions had reached plateaus, D600 (lO'^M) totally 
blocked the contractions elicited by 5-HT and DOM but only partially 
blocked those by NE and EPI. It has been demonstrated that NE-induced 
Ca^^ influx could include both receptor-operated and voltage-dependent 
Ca^^ channel mechanisms (Hester, 1988; Nelson et al., 1988). On the 
other hand, D600 has been demonstrated as an apparent competitive 
antagonist of 5-HT receptors in rabbit isolated aortas (Auguet et al., 
1986). It has been proposed that D600 could be termed a 'Ca^V^-HT-
antagonist' (DeFeudis, 1984). 
Nifedipine is also an inhibitor of the voltage-dependent Ca^* 
channel (Kanmura et al., 1983). In the present study, nifedipine (2.5 x 
lO'^M) inhibited 86% of 5-HT-induced Ca^^ influx. The concentration of 
nifedipine used seems very critical since 2.5 x 10"®M nifedipine showed 
no inhibition on 5-HT-mediated Ca^"*" influx. This is in accord with the 
finding by Capponi et al. (1987) in which they found that 10"®M 
nifedipine was unable to prevent the intracellular free Ca^^ rise 
triggered by 5-HT challenge. The finding that nifedipine at higher 
concentrations can inhibit 5-HT-induced Ca^^ influx further confirms 
that voltage-dependent Ca^  ^channel mechanisms are involved in Ca^ "*" 
influx evoked by 5-HT in the ovine uterine artery from pregnancy. 
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The mechanisms of action of sodium nitroprusside may include 
membrane hyperpolarization, inhibition of Ca^  ^uptake, increase in Ca^ * 
extrusion or sequestration, inhibition of contractile elements, or 
inhibition of receptor-linked phosphoinositide breakdown (Karaki et al., 
1984, 1988; Popescu et al., 1985; Rapoport, 1986). Sodium nitroprusside 
potently inhibited the contractile response to NE in human pregnant 
uterine arteries (Nelson and Suresh, 1988) and the contractions to 5-HT 
in ovine pregnant uterine arteries (Isla and Dyer, submitted for 
publication). In the present study sodium nitroprusside inhibited the 
5-HT-induced Ca^"*" influx. This finding indicates that the inhibitory 
effect of sodium nitroprusside on 5-HT-evoked contraction in the 
pregnant uterine artery may be at least partly due to inhibition of the 
5-HT-induced Ca^"*" influx in this preparation. 
Ketanserin, a selective S-HTg receptor antagonist (Leysen et al., 
1981; Van Nueten et al., 1981; Leysen et al., 1982) potently inhibited 
the influx evoked by 5-HT and DOM. This result is in accord with 
the finding by Capponi et al. (1987) in which ketanserin (10"®M) has 
been shown to completely block the free Ca^"*" rise induced by 5-HT. Our 
recent studies have demonstrated that ketanserin competitively 
antagonized the contraction produced by 5-HT and DOM in the ovine 
uterine artery from pregnancy (Zhang and Dyer, 1989a). The dissociation 
constants for ketanserin vs. 5-HT (4.02 nM) and DOM (2.97 nM) determined 
in this study were in accord with those of ketanserin against 5-HT (2 
nM) and DOM (4 nM) in our recent contraction studies in the ovine 
uterine artery (Zhang and Dyer, 1989a) and were comparable to its 
affinity (k^ - 2.1 nM) for 5-HT2 binding sites (Leysen et al., 1981; 
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Leysen et al., 1982) and its dissociation constants (7 nM to 0.2 nM) 
reported in other vessels by other authors (Cohen et al., 1983; Cohen, 
1986; Humphrey, 1984; Van Nueten et al., 1982; Van Nueten et al., 1981). 
This indicates that both 5-HT and DOM induced Ca^"*" influx in the uterine 
artery and contractions to these agonists are related to activation of 
the same receptor, i.e., the S-HTg receptor. 
Methiothepin is a nonselective antagonist with affinity for both 5-
HTi and S-HTg binding sites (Martin and Sanders-Bush, 1982; Engel et 
al., 1983). It produced a potent inhibition on 5-HT-induced Ca^"*" influx 
in this study. It was also a strong antagonist of 5-HT-induced 
contraction in the ovine uterine artery (Zhang and Dyer, submitted for 
publication). The presence of 'S-HT^-like' subtype receptors in this 
tissue is unlikely since we have demonstrated that 5-HT-induced 
contractions in the ovine uterine artery was mediated by 5-HT2 receptors 
(Zhang and Dyer, 1989a). The 5-HT3 receptor antagonist MDL 72222 
(Fozard, 1984) did not antagonize 5-HT-induced Ca^^ influx, indicating 
that 5-HT3 receptor is not present in this tissue. This supports our 
previous finding in which MDL 72222 was found not to antagonize 
contractions to 5-HT (Zhang and Dyer, 1989a). 
In summary, 5-HT and DOM stimulated concentration-dependent Ca^^ 
influx in ovine pregnant uterine artery, implying that the extracellular 
Ca^"*" played an important role in the responses mediated by 5-HT 
receptors. It was demonstrated that 5-HT2 receptors were involved in 
the 5-HT-induced Ca^+ influx. The presence of 5-HTi receptors in this 
tissue is unlikely. 5-HT3 receptors were not involved in the 5-HT-
induced Ca^"*" influx. D600 and nifedipine blocked the 5-HT-induced Ca^+ 
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influx in the ovine uterine artery from pregnancy and amrinone had no 
effect. These results suggest that 5-HT-induced influx in this 
tissue was mediated by voltage-dependent Ca^^ channel. The inhibitory 
effect by sodium nitroprusside of the 5-HT-induced Ca^'*' influx could 
explain in part its inhibition on the contraction evoked by 5-HT. 
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SECTION IV. CHARACTERIZATION OF SEROTONERGIC RECEPTORS MEDIATING 
CONTRACTION OF THE OVINE UMBILICAL ARTERY^ 
Abstract 
Responses to serotonergic agonists were studied in isolated 
umbilical arteries obtained from fetuses within 2 weeks of term. The 
order of potency of the agonists was determined to be 2,5-dimethoxy-4-
methyl-amphetamine (DOM) > 5-HT > a-methyl-5-HT > 1-(3-chlorophenyl) 
piperazine (mCPP) - m-trifluoromethyl-phenylpiperazine (TFMPP) > 8-
hydroxy-dipropylaminotetralin (8-OH-DPAT) > 2-methyl-5-HT > l-(2-
methoxyphenyl) piperazine (2-MPP). Variations in the sensitivity and 
potency of the agonists results primarily from the variation in the 
affinity for the 5-HT2 receptor and less so in the efficacy. Alpha-
methyl-5-HT was a full agonist compared to 5-HT. The others were 
partial agonists. The mean values for 5-HT and DOM were 4.71 ± 0.62 
X 10"^M and 0.36 ± 0.04 x 10"^M, respectively. Contractions to 5-HT and 
DOM were antagonized by ketanserin with pA2 values being 9.4 and 9.1, 
respectively, suggesting that they act on the same receptor and that 
their responses are mediated by 5-HT2 receptors. Contractile responses 
to 8-OH-DPAT, 2-methyl-5-HT and the phenylpiperazines (TFMPP and mCPP) 
were blocked by ketanserin (10"®M) , indicating that contractions 
produced by these agonists were mediated by S-HTg receptors. There is a 
significant correlation between the dissociation constants of the 
^Submitted to J. Pharmacol. Exp. Ther. as a research paper by Lubo 
Zhang and Donald C. Dyer. 
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serotonergic agonists in producing vasoconstriction in the ovine 
umbilical artery and their affinity at S-HTg binding sites in brain 
tissues while there is a negative correlation with the 5-HTi binding 
sites in brain tissues. No antagonism by 3-tropanyl-3,5-
dichlorobenzoate (MDL 72222) of responses to 5-HT indicates that S-HTg 
receptors are not present in this tissue. 
Introduction 
The first classification of 5-HT receptors comes from the work of 
Gaddum and Picarelli (1957) who demonstrated the existence of two 
pharmacologically distinct 5-HT receptors (D and M receptors) in the 
guinea-pig ileum. The D receptor is sensitive to dibenzyline 
(phenoxybenzamine) and mediates constriction of the smooth muscle. The 
M receptor is sensitive to morphine and mediates depolarization of the 
cholinergic nerves. Since phenoxybenzamine (dibenzyline) and morphine 
are not specific 5-HT receptor blocking drugs, they have no value as 
tools for the classification of 5-HT receptors. Recently, two 
classification schemes of 5-HT receptors have been proposed (Bradley et 
al., 1986; Peroutka and Snyder, 1979). Major advances in our knowledge 
have undoubtedly arisen as a result of new drug tools recently 
identified as 5-HT2 receptor antagonist ketanserin (Leysen et al., 1981; 
Leysen et al., 1982; Van Nueten et al., 1981) and the 5-HT3 receptor 
antagonist MDL 72222 (3-tropanyl-3, 5-dichlorobenzoate) (Fozard, 1984). 
The characterization of 5-HT receptors with the corresponding 
pharmacological responses has been investigated in various tissues. 
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including blood vessels. Vasoconstriction in many arteries has been 
found to be mediated by a receptor similar to the S-HTg binding site 
(Van Nueten et al., 1981, 1984; Leysen et al., 1984; Maayani et al., 
1984). The classification of S-HT^ receptors is somewhat less clear 
since selective antagonists have yet to be described. 
We have shown that the hallucinogen 2,5-dimethoxy-4-methyl-
amphetamine (DOM) is potentially harmful to the fetus in that it 
strongly activates uterine and umbilical vascular 5-HT receptors which 
produce vasoconstriction (Dyer et al., 1973; Dyer, 1983; Zhang and Dyer, 
1988), The purpose of this study was to define the activity of 5-HT and 
DOM in terms of dissociation constants and to ascertain if 5-HT and DOM 
activate 5-HT2 receptors in the ovine umbilical artery. By using 
specific competitive antagonists we were able to classify, in part, the 
subtype(s) of 5-HT receptors in the ovine umbilical artery. 
Methods 
Umbilical cords were obtained from mixed breed sheep within two 
weeks of term (145 days). The umbilical cord was sectioned at least 3 
inches from the fetus. Helically cut umbilical arteries were prepared 
as previously described (Dyer, 1970). The arterial strips were 
suspended in lO-ml isolated organ baths, maintained at 37°C and bathed 
with a modified Krebs-Henseleit (Krebs') solution of the following 
composition (mM): NaCl, 115.21; KCl, 4.70; CaClg, 1.80; MgSO*, 1.16; 
KH2P0,^, 1.18; NaHCOg, 22.14; dextrose, 7.88. Disodium ethylenediamine 
tetracetic acid (EDTA. 0.03 mM) was added to suppress the oxidation of 
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amines. The Krebs' solution was oxygenated with a mixture of oxygen-
carbon dioxide (95:5). The tissues were allowed to relax under Ig of 
tension for 90 min before initiating the experiment. Contractions were 
recorded isotonically. Concentration-response data were obtained by the 
cumulative additions of agonists in approximately one-half log 
increments (van Rossum, 1963). 
Determination of agonist potency 
Concentration-response data to serotonergic agonists were obtained 
after each tissue had been exposed to KCl (150mM) and this response to 
KCl was set as the 100% response. ECgg value for each agonist was 
recorded at the molar concentration where the curve intersected the 50% 
level of the response axis to that agonist. Relative potencies were 
calculated by comparing the molar concentration of agonists required to 
produce an equivalent percent contraction as that of KCl (150mM) at the 
40% response. 
Determination of agonist dissociation constants (K^ or K^.) and relative 
efficacy fe^) 
Because of the different characteristics of the various agonists, 
two procedures were used to ascertain their dissociation constants. For 
5-HT, the Ky^ value was determined as described by Furchgott and Bursztyn 
(1967). Dibenamine was used to inactivate a fraction of the receptors. 
After fractional inactivation of the receptors by dibenamine (7.5 x 10" 
®M, for 15 minutes), the bath fluid was changed 5 or 6 times over 30 
minutes. The reciprocals of the concentrations of 5-HT before 
dibenamine treatment (1/[A]) were plotted against the reciprocals of the 
corresponding equieffective concentrations after treatment (1/[A']). 
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From the slope and intercept of the straight line fitting the points, 
the value for and for the fraction of active receptors remaining (q) 
were calculated on the basis of the equation (Furchgott, 1966); 
1 1-q 1 
- + (1) 
[A] qKA q[A'] 
according to which equals (slope -1)/intercept, and q equals 1/slope. 
For determining the dissociation constant (Kp) of a partial agonist 
the technique of Waud (1969) was inapplicable in the present study since 
the umbilical artery was found not to have a large spare receptor 
capacity for the full agonist, 5-HT [see Kenakin (1984) for a discussion 
of this requirement]. The procedure developed by Gero and Tallarida 
(1977) was, therefore, applied to DOM, phenylpiperazine derivatives 
(TFMPP, mCPP and 2-MPP), 2-methyl-5-HT and 8-OH-DPAT, which were partial 
agonists on the umbilical artery. Contractile responses produced by the 
partial agonist (P), DOM, phenylpiperazines, 2-methyl-5-HT and 8-OH-
DPAT, were matched with those of the full agonist (A), 5-HT. The 
dissociation constants (Kp) for these partial agonists were obtained 
from the equation (Gero and Tallarida, 1977): 
Ka (Ap-Ai) - Pi 
Kp - (2) 
(Ap + Ka) • Ai 
where K^ was the dissociation constant obtained for 5-HT [using the 
procedure of Furchgott and Bursztyn (1967) as described above], Ap was 
the concentration of the full agonist A (i.e., 5-HT) producing a 
response equal to the maximum of the partial agonist P (DOM, 
phenylpiperazines, 2-methyl-5-HT and 8-OH-DPAT) and and P^ were any 
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other pair of concentrations giving a matching contractile response. 
The relative affinities for the serotonergic agonists as compared 
to 5-HT were obtained by dividing the value obtained for 5-HT by 
those (Kp) obtained for the other agonists. 
To obtain the relative efficacies (e^) for the serotonergic 
agonists as compared to 5-HT, the respective fractional occupation of 
receptors by each agonist for each concentration used in establishing 
the control concentration-response curves was calculated from the 
equation (Furchgott and Bursztyn, 1967). 
[RA] [A] 
- (3) 
[Rt] [A] + Ka 
Where [RA] is the concentration of the receptor-agonist complex, [Rj] is 
the total concentration of receptors, [A] is any given concentration of 
agonist and (or Kp) is the agonist dissociation constant. The 
contractile response data for each agonist were then replotted to show 
response as a function of log [RA]/[Ri]. The antilog of the distance 
between the two curves along the abscissa was taken as the ratio of the 
intrinsic efficacy of the second agonist to that of 5-HT (Furchgott and 
Bursztyn, 1967), and thus was a measure of e^, the relative efficacy of 
the second agonist as compared to 5-HT. 
In all experiments, cocaine (3 x 10"%) was added to block uptake 
mechanisms (Dyer, 1970) and iproniazid was used (0.36 mM) to block 
monoamine oxidase (MAO), Iproniazid was added for 40 minutes and then 
tissues were washed four times over 30 minutes with fresh Krebs' 
solution. Cocaine was added 15 minutes prior to adding the agonists. 
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Determination of apparent dissociation constants for antagonists 
Ketanserin and MDL 72222 were used in a series of experiments to 
determine the subtypes of 5-HT receptors involved in contraction of the 
ovine umbilical artery. Initially a concentration-response curve was 
obtained to a specific agonist. The antagonists were then allowed to 
equilibrate for 1 hour with the tissue before repeating the 
concentration-response curve to the same agonist. The concentration 
ratio (CR) of the agonist (EC50 in the presence of antagonists/ECso in 
the absence of antagonists) was determined. The time related shift of 
the agonist response curve was measured in a matched preparation not 
treated with antagonist. The concentration ratio (Rj) (EC50 at time 
t/ECjo at time 0) was determined from the two control agonist 
concentration response curves. The concentration ratio (CR) obtained 
from the antagonist treated tissue was then adjusted according to the 
following formula; 
CR 
Adjusted CR -
CRj 
Cocaine and iproniazid were also used as described above. 
Schild plots were employed to determine the pAg values for the 
antagonists. The adjusted CR (see above) obtained from the shifts in 
the agonist concentration-response curve by the different concentrations 
of the antagonist were utilized in the Schild equation (Arunlakshana and 
Schild, 1959): 
log (CR -1) - log [B] - log Kb (4) 
where [B] is the molar concentration of the antagonist and Kg is the 
dissociation constant of the antagonist. A linear regression performed 
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on the line generated by plotting log (CR -1) vs. -log [B] will have a 
slope of -1 if the antagonism is competitive. The intercept along the 
abscissa (i.e., when CR - 2) represents the negative log of the Kg for a 
competitive antagonist (i.e., pAg). The mathematical calculations 
involved in determining a pA2 value were performed using a computer 
program based on procedures outlined by Tallarida and Murray (1981). 
Apparent dissociation constants (Kg) of ketanserin agonist 8-OH-
DPAT, 2-methyl-5-HT, TFMPP and mCPP were determined for each tissue and 
at each concentration of antagonist, using the equation (Furchgott, 
1972) 
[ B ] 
Kg - (5) 
CR - 1 
where [B] is the concentration of antagonist and CR is the adjusted 
concentration ratio as discussed above. 
Drugs 
The following drugs were used: cocaine HCl; serotonin creatinine 
sulfate (Sigma Chemical Co., St. Louis, MO); R(-)-2,5-dimethoxy-4-
methyl-amphetamine (National Institute of Drug Abuse, Rockville, MD); 8-
hydroxy-dipropylaminotetralin (8-OH-DPAT), o-methyl-5-hydroxytryptamine 
(o-methyl-5-HT), 2-methyl-5-hydroxytryptamine (2-methyl-5-HT), m-
trifluoromethyl-phenylpiperazine HCl (TFMPP), 1-(3-chlorophenyl) 
piperazine HCl (mCPP), l-(2-methoxyphenyl) piperazine HCl (2-MPP), 3-
tropanyl-3, 5-dichlorobenzoate (MDL 72222) (Res. Biochem. Inc., Natick, 
Massachusetts); Ketanserin tartrate (Janssen, Beerse, Belgium); 
iproniazid phosphate, (Hoffmann-LaRoche, Nutley, NJ); dibenamine HCl 
(Smith, Kline and French Lab., Philadelphia, PA); 1-norepinephrine 
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bitartrate (Calbiochem Behring Corp., La Jolla, CA). Drugs were 
dissolved in saline, except for dibenamine and MDL 72222, which were 
dissolved in alcohol and diluted in saline just prior to use. 
Data are expressed as mean ± SE; for each experiment, n refers to 
the number of fetal lambs from which vessels were taken. The Student's 
t-test was used for statistical analysis of the differences of means. 
Results 
Contractions of ovine umbilical artery by serotonergic agonists 
Concentration-response curves to serotonergic agonists in the cord 
umbilical artery are illustrated in Fig. 1. The contractions were 
smooth and readily reproducible. In Table 1 the EC50 values and potency 
ratios are presented. The order of potencies of the agonists was 
determined to be D0M>5-HT>a-methyl-5-HT>mCPP - TFMPP>8-OH-DPAT>2-
methyl-5-HT>2-MPP. DOM was 5 times more potent than 5-HT but only 
produced 78% of the maximal response to that of 5-HT. a-methyl-5-HT was 
slightly less potent than 5-HT with its maximal response being similar 
to that of 5-HT. 8-OH-DPAT, 2-methyl-5-HT and the phenylpiperazines, 
TFMPP, mCPP and 2-MPP only produced 32 to 61% of the maximum responses 
to that of 5-HT. TFMPP and mCPP were about 3.5 times less potent than 
5-HT. 8-OH-DPAT was about 67 times less potent than 5-HT. 2-methyl-5-
HT and 2-MPP were 250 and 500 times, respectively, less potent than 5-
HT. 
Agonist dissociation constants or 
The response to 5-HT before and after exposing the tissues to 
Fig. 1. Concentration-contractile response relationship for serotonergic agonists. Results are 
illustrated as the x ± SE. of tissues from 3 to 8 animals and are expressed as percentage of 
the contraction obtained to 150mM KCl 
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Table 1. Comparative properties of serotonergic agonists on the ovine umbilical artery 
Agonist ECgQ Relative Approximate Maximum Response 
Potency^ ^*^100^ ^ Percentage 
of the Response 
to 150mM KCl 
M (x 10-7) M % 
5-HT 8 1.04 ± 0.27 1.000 3.0 X lO'S 161 
DOM 8 0.10 ± 0.02 5.000® 1.0 X 10-5 126 
a-Methyl-5-HT 7 1.25 ± 0.27 0.714® 3.0 X 10-5 157 
TFMPP 3 1.58 ± 0.25 0.280® 1.0 X 10-4 96 
mCPP 3 1.54 ± 0.19 0.280® 1.0 
O
 
1—1 X 93 
8-OH-DPAT 4 19.95 ± 2.40 0.015® 1.0 X 10-4 98 
2-Methyl-5-HT 3 70.79 ± 9.10 0.004® 1.0 X 10-4 74 
2-MPP 3 79.43 ± 9.89 0.002® 1.0 X 10-4 52 
is the number of animals. 
is the effective concentration to produce 50% of the maximal response to the respective 
agonist. 
^Relative potency was calculated at the EC^q (see Methods), 5-HT arbitrarily set at 1. 
'^ECj^qq is the effective concentration to produce the maximal response to the respective 
agonist. 
^Significantly different from 1 (P<0'. 05). 
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dibenamine (7.5 x 10"®M for 15 min) is shown in Fig. 2. Dibenamine 
reduced the maximal response to 5-HT about 45%. The inset (Fig. 2) 
illustrates a double reciprocal plot of equieffective concentrations of 
5-HT before (1/[A]) and after (1/[A']) dibenamine treatment. The mean 
5-HT dissociation constant (K^) for the individual tissues was 4.71 ± 
0.62 X 10"'M (Table 2). The dissociation constants (Kp) for the partial 
agonists DOM, 8-OH-DPAT, 2-methyl-5-HT, TFMPP, mCPP and 2-MPP are 
presented in Table 2. The relative affinities of the agonists studied 
as compared to 5-HT were calculated by dividing the estimated of 5-
HT by Kp values of the other agonists (Table 2). The affinity of DOM 
was, on the average, 13 times that of 5-HT (P<0.05). TFMPP and mCPP 
possessed similar affinities to that of 5-HT. The relative affinities 
of the other three agonists were lower, ranging from 9% in the case of 
8-OH-DPAT to 4% in the case of 2-methyl-5-HT and 2-MPP when compared to 
5-HT (Table 2). 
Relative efficacy of agonists 
The average dissociation constants (Ky^ or Kp) values of 5-HT and 
other agonists were used in Equation 3 (see "Methods") to calculate the 
fraction of receptors occupied ([RAj/fR?]) at each concentration 
employed in order to obtain the complete concentration-response curves 
for the agonists. The results of replotting relative response against 
log [RA]/[Ri] are shown in Fig. 3. The curve for 5-HT indicates that 
one-half the maximal response is obtained when about 18% of receptors 
are occupied by 5-HT, and that 90% of the maximum is obtained when about 
69% of receptors are occupied. The relative efficacies of DOM, 8-OH-
DPAT, 2-methyl-5-HT and the phenylpiperazines to 5-HT were obtained as 
Fig. 2. Effect of dibenamine on 5-HT-elicited contractions of ovine umbilical artery. Contractions 
were obtained before (open circles) and after (closed circles) exposure to 7.5 x 10"®M 
dibenamine for 15 min. Dibenamine was washed out of the tissue before obtaining the second 
concentration-response to 5-HT. Each point represents the x ± SE. of tissues from 8 animals. 
Inset: Plot of the reciprocals of equieffective concentrations of 5-HT before (1/[A]) and 
after (1/[A']) dibenamine treatment (See Methods) 
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Table 2. Comparison of dissociation constant or Kp), relative efficacy (ej.) and relative 
affinity for the agonists acting on the serotonergic receptors in the ovine fetal 
umbilical artery 
Agonist Dissociation 
Constant 
Relative 
Efficacy 
Relative 
Affinity^ 
M (x icr?) 
5-HT 8 4.71 + 0.62 1.00 1.00 
DOM 8 0.36 + 0.04 0.64^ 13.08^ 
TFMPP 3 4.34 + 1.14 0.41^ 1.08 
mCPP 3 3.15 + 0.97 0.32^ 1.49 
8-OH-DPAT 4 49.81 + 12.11 0.41^ 0.09* 
2-Methyl-5-HT 3 113.16 + 37.27 0.25^ 0.04^ 
2-MPP 3 107.14 + 23.48 0.15^ 0.04^ 
% is the number of animals. 
'^S-HT is arbitrarily set at 1. 
^Significantly different from 1 (P<0.05). 
Fig. 3. Contractions to serotonergic agonists plotted as a function of log [RA]/[Rj] in the ovine 
umbilical artery. Receptor occupancy ([RA]/[Rj]) at a given concentration of agonist was 
calculated as described under "Methods" using the mean dissociation constant obtained for 
each agonist, as given in Table 2. Contractile responses were taken from the results 
illustrated in Figure 1 
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the antilog of the distance between the respective agonist and 5-HT 
along the log [RA]/[Ri] axis. The mean values were presented in Table 
2 .  
Correlations between sensitivity and relative potency of agonists and 
their affinity and efficacy 
There is a significant linear correlation between pDg (-log ECgo) of 
the individual agonists and their pKj^ (-log Ky^) where r - 0.993, P < 
0.001 (Fig. 4). The slope of the regression line was 0.86, which was 
not significantly different from unity. Fig. 5 (left panel) shows that 
there is a significant correlation between relative potency (RP) and the 
relative affinity (RA) of the agonists where r - 0.974 (P < 0.001). The 
slope of the regression line was 0.72 which was significantly different 
from unity. The correlation between relative potency and the relative 
efficacy (RE) of the agonists was also significant with r - 0.829 (P < 
0.05) (Fig. 5, right panel). The slope of the regression line was 0.21 
which was significantly different from unity. 
Competitive antagonists 
Ketanserin competitively inhibited responses to DOM as demonstrated 
by producing parallel shifts in the log concentration-response curves to 
the right (Fig. 6). The maximal response was not affected by ketanserin 
at the highest concentration used (lO'^M). Schild plot for ketanserin 
vs. DOM yields a straight line with the slope being -0.91, which was not 
significantly different from unity. The concentration-response curves 
for 5-HT were shifted to the right by ketanserin similarly as those for 
DOM. The pA2 values for ketanserin vs. DOM and 5-HT were 9.1 and 9.4, 
respectively. Contractile responses to 8-OH-DPAT, 2-methyl-5-HT, TFMPP 
Fig. 4. Relationship between pKy^ (-log K^) and pD2 (-log ECgg) of serotonergic agonists in the ovine 
umbilical artery. EC50 value for each agonist was recorded at the molar concentration where 
the curve intersected the 50% level of the response axis to that agonist. Correlation 
coefficient r — 0.993, P < 0.001. Slope is 0.86 which is not significantly different from 
unity 
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Fig. 5. Relationship between the relative potency (RP) and the relative affinity (RA) (left panel) 
and the relative efficacy (RE) (right panel) of the sertonergic agonists in the ovine 
umbilical artery. The relative potency, relative affinity and relative efficacy were 
determined as described in Methods. For the relationship between RP and RA, r - 0.974, P < 
0.001; slope - 0.72. For the relationship between RP and RE, r = 0.829, P < 0.05; 
slope - 0.21 
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closed circle: time control; open triangle, 10"®M; closed triangle, 3 x lO'^M; open square, 
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± S.E. of tissues from 8 animals and is expressed as a percentage of the contraction obtained 
to 10"®M DOM in control experiments. Inset: Schild plot for determination of the pAg for 
ketanserin vs. DOM. The intercept on the abscissa gives the pAg value (9.10). The slope (-
0.91) of the fitted regression line was not significantly different from unity 
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and mCPP were also effectively blocked by ketanserin (10"®M) and the 
concentration-responses curves for these agonists were shifted in a 
parallel manner to the right without affecting the maximum response. 
The dissociation constants (Kg) of ketanserin vs. 8-OH-DPAT, 2-methyl-
5-HT, TFMPP and mCPP are presented in Table 3. No antagonism by MDL 
72222 (10"®M to 10"®M) of contractions to 5-HT was observed (Fig. 7). 
Discussion 
The validity of the determination of value carried out for 5-HT 
depends on the acceptance of the theoretical assumptions of receptor-
agonist interactions following fractional irreversible receptor 
inactivation as outlined by Furchgott (1966). The value for 5-HT 
(0.47pM) is not significantly different from that (0.37/iM) determined in 
the ovine uterine artery (Zhang and Dyer, 1989), implying that the same 
type of 5-HT receptors are involved in the contraction to 5-HT in these 
two vessels. The difference in dissociation constants determined for 5-
HT and DOM in this study indicates there are differences in the affinity 
of these two agonists for 5-HT receptors. By comparing the two 
dissociation constants, the affinity of DOM was found to be 13 times 
that of 5-HT. Our results are comparable to those previously reported 
in binding studies in brain tissue (Glennon, 1987). It has been shown 
that 5-HT displayed a high affinity (K^ - 1-lOnM) for 5-HTi binding 
sites but a relatively low affinity (K^ - 0.4 - 1 /iM) for S-HTg binding 
sites. DOM was identified as a 5-HT2 agonist with a relatively high 
affinity (K^ - 0.1 /«M) for 5-HT2 binding sites (Glennon, 1987). 
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Table 3. Dissociation constants (Kg) for ketanserin against the 
agonists acting on the serotonergic receptors in ovine fetal 
umbilical artery 
Agonist Kg 
nM 
5-HT 8 0, 
+
1 o
 0, .05^ 
DOM 8 0, VO
 
1+
 
0, 10^ 
TFMPP 4 1. ,01 ± 0, .31= 
mCPP 4 0, 38 ± 0. .12= 
8-OH-DPAT 4 0, ,29 ± 0, .09= 
2-Methyl-5HT 3 0.49 ± 0, ,17= 
is the number of animals. 
Kg values are obtained from the pAg values according to the 
relationship pAg—logKg. 
®Kg values are calculated for each tissue at ketanserin 3 X 
10"®M according to the equation Kg-[antagonist]/CR-1. 
Fig. 7. Cumulative concentration-response curves for 5-HT obtained on ovine umbilici artery in teh 
absence and presence of various concentrations of MDL 72222. Each point represents the 
average of tissues from 4 animals and is expressed as a percentage of the contraction 
obtained to 150mM KCl 
o 5-HT 
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Differences in agonists' potencies in a biologic system could 
result from differences in their affinities for the receptors and/or 
their relative efficacies (see discussion by Kenakin, 1984). In the 
present study, there was a significant linear correlation between 
agonist potency and affinity (r = 0.974, P < 0.001) and relative 
efficacy (r = 0.829, P < 0.05). The slopes of the regression lines for 
the potency vs. the affinity and the potency vs. efficacy were 0.72 and 
0.21, respectively. This implies that about 70% of the variation in the 
potency of the serotonergic agonists in producing vasoconstriction in 
the ovine umbilical artery is due to variation in the affinity of the 
agonists for the S-HTg receptors. The variation in the efficacy of the 
agonists in this study contributes about 20% of the variation in the 
potency of the agonists. There is an excellent linear correlation (r -= 
0.993, P < 0.01) between sensitivity and the affinity (pD2 versus pK^) 
of serotonergic agonists. The slope of the regression line relating 
affinity to sensitivity was 0.86, which was not significantly different 
from unity. This suggests that the differences in the agonist's 
sensitivity in this study could be explained by the variation in the 
affinity alone. In the recent review article, Sevan et al. (1989) 
discussed the relationship between the receptor affinity and the agonist 
sensitivity in different vessels. In rabbit arteries, the slope of the 
regression line relating norepinephrine (NE) affinity for adrenergic 
receptors to its sensitivity was 0.90 (Oriowo et al., 1989). They 
suggested that differences in sensitivity of the rabbit arteries to NE 
was caused by variation in the receptor affinity. However, in rat 
arteries, variation in receptor affinity for NE only counted for 60% of 
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the variation in its sensitivity. The other 40% variation in NE 
sensitivity came from the variation in its receptor reserve (Oriowo et 
al., 1989). 
In comparison to 5-HT, o-methyl-5-HT behaved as a full agonist 
while DOM and the other five agonists were partial agonists. The lower 
efficacies (e^) of DOM and the other agonists when compared to 5-HT 
supports their classification as partial agonists in this tissue. It is 
interesting to note that the affinity of DOM did not correspond with its 
efficacy. This observation provides a striking example of the 
pharmacological principle that affinity and efficacy are separate and 
distinct properties possessed by agonists. The classification of DOM as 
a partial agonist is in an agreement with the findings by Dyer et al. 
(1973) and Sanders-Bush et al. (1988), but not with our recent finding 
in the uterine artery in which DOM was a full agonist (Zhang and Dyer, 
1989). The reason for these differences of DOM is not quite clear. 
There is little, if any, receptor reserve in this tissue, since 
nearly all the receptors need to be occupied by 5-HT to produce a 
maximal response. This is in accord with our recent findings in the 
ovine uterine artery (Zhang and Dyer, 1989). Evidence supporting a lack 
of spare receptors for 5-HT in other tissues was also obtained in canine 
basilar artery (Taylor et al., 1985) rat fundic strips (Clineschmidt, 
1985) and rat jugular vein and uterus (Cohen et al., 1986). 
In a previous study, cinanserin competitively blocked contractile 
responses to 5-HT and DOM in the ovine umbilical artery and produced 
similar pAg values for 5-HT (8.7) and DOM (8.5) (Dyer, 1983). 
Ketanserin has been documented to be a potent and selective 5-HT2 
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receptor antagonist (Leysen et al., 1981; Leysen et al., 1982; Van 
Nueten et al., 1981). It possesses a high affinity (K^ < InM) for 5-
HTg binding sites in the brain tissue (Glennon, 1987). In this study, a 
series of concentrations (10"® to lO'^M) of ketanserin effectively 
inhibited contractile responses to 5-HT and DOM and shifted the 
concentration-response curves to the right in a parallel manner without 
affecting the maximum response, consistent with competitive inhibition. 
This was supported by Schild plots whose slopes were not significantly 
different from unity. The pAg values of ketanserin against 5-HT (9.4) 
and DOM (9.1) in the present study are somewhat higher than those (8.56 
and 8.33, respectively) determined previously in the ovine uterine 
artery (Zhang and Dyer, 1989) but are comparable to those determined on 
other blood vessels (8.1 to 9.7) (Cohen et al., 1983; Cohen, 1986; 
Humphrey, 1984; Van Nueten et al., 1982; Van Nueten et al., 1981). This 
suggests that the contractile responses produced by 5-HT and DOM.in the 
ovine umbilical artery are mediated by S-HTg receptors. The 
contractions produced by 8-OH-DPAT, 2-methyl-5-HT, TFMPP and mCPP were 
also blocked by ketanserin with the dissociation constants (Table 3) 
similar to those for 5-HT and DOM. This provides further evidence that 
these agonists are producing contractions via 5-HT2 receptors in the 
ovine umbilical artery. The finding that DOM acts on S-HTg receptors is 
in accord with the previous findings by us (Dyer, 1983; Zhang and Dyer, 
1989) and those reported by Glennon and co-workers in the central 
nervous system (1983, 1984). 
The finding of great interest is that the dissociation constants of 
the serotonergic agonists in producing vasoconstriction of the umbilical 
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artery is significantly correlated to their affinities at the S-HTg 
binding sites in the CNS obtained by other workers (Fig. 8, left panel) 
but fails to correlate with those at the 5-HTi binding sites (Fig. 8, 
right panel). This provides good evidence that these serotonergic 
agonists produce vasoconstriction in the ovine umbilical artery by 
acting on 5-HT2 reception and that these receptors are the same as those 
in the CNS. 
8-OH-DPAT strongly binds to the binding site (K^ - 2nM) and 
weakly at the S-HTg binding sites (K^ = 5500 to 7100 nM) in brain tissue 
(Glennon, 1987). It has been shown that 5-HTi^ receptors were linked to 
contraction in the canine basilar artery (Peroutka et al., 1986; Taylor 
et al., 1987). However, contractile responses to 8-OH-DPAT in the 
present study were unlikely mediated by S-HT^^ receptors because 
ketanserin effectively blocked the contraction produced by 8-OH-DPAT. 
The dissociation constant of ketanserin vs. 8-OH-DPAT (0.29 nM) was not 
significantly different from that of ketanserin vs. 5-HT (0.40nM) in 
this study. This suggests that the contraction produced by 8-OH-DPAT in 
the ovine umbilical artery was mediated by 5-HT2 receptors. This is in 
agreement with our recent finding in the ovine uterine artery (Zhang and 
Dyer, submitted for publication). The dissociation constant (4981 nM) 
of 8-OH-DPAT in this study was comparable to that at S-HTg binding sites 
in brain tissue (5500 to 7100 nM) (Glennon, 1987) but was much higher 
than that at S-HT^* binding sites in brain tissue (2nM) Glennon, 1987). 
Three phenylpiperazines used in this study, TFMPP, mCPP and 2-MPP, 
have been identified as ligands for 5-HTib binding sites in the rat 
brain (Sills et al., 1984; Fuller et al., 1980). The values of TFMPP 
Fig. 8. Correlation between the dissociation constant of the agonists (pK^ - - log K^) to produce the 
vasoconstriction in the ovine umbilical artery and their binding affinities (pK^ - - log K^) 
for 5-HT2 binding sites in brain tissue (labelled with [®H] ketanserin; 5-HT and DOM, 
Glennon, 1987; TFMPP and 8-OH-DPAT, Taylor et al., 1985; mCPP, Martin and Sanders-Bush, 1982; 
2-methyl-5-HT, Engel et al., 1986) or S-HT^ binding sites (5-HT and DOM, labelled with [^H]-
5-HT, Glennon, 1987; TFMPP and mCPP labelled with [^HJ-ICYP, Glennon, 1987; 8-OH-DPAT, 
labelled with [^H]-8-OH-DPAT, Glennon, 1987; 2-methyl-5-HT, labelled with [^H]-8-OH-DPAT, 
Engel et al., 1986). The correlation coefficient of pKy^ in this study and pK^ for 5-HT2 and 
5-HTi binding sites in the CNS are 0.983 (P < 0.001) and -0.187, respectively 
pKî (5—HT2 binding sites) 
pKj (5-HTi binding sites) 
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and mCPP at S-HT^g sites were 30nM and 75nM, respectively (Glennon, 
1987). However, the selectivity for 5-HTi vs S-HTg binding sites was 
not high. TFMPP and mCPP possess only 3- to 18- fold selectivity for 5-
HTi vs. S-HTg sites (Glennon, 1987; Martin and Sanders-bush, 1982). 2-
MPP possesses a 100-fold selectivity for 5-HTi vs. S-HTg sites with an 
affinity for 5-HTi sites comparable to that of TFMPP (Glennon, 1987). 
TFMPP and mCPP are generally thought to be agonists at central 5-HT 
receptors which activate pre-synaptic autoreceptors on serotonin 
neurons, thereby modulating the neurogenic release of serotonin (Martin 
and Sanders-Bush, 1982). In the present study, these phenylpiperazines 
were demonstrated to be partial agonists on the ovine umbilical artery. 
Contractile responses to these phenylpiperazines were effectively 
blocked by ketanserin with the dissociation constants (Table 3) which 
were similar to that for ketanserin vs. 5-HT. This suggests that 
contractile responses to these phenylpiperazines on the ovine umbilical 
artery are mediated by S-HTg receptors. In our recent study in ovine 
uterine artery, we demonstrated that TFMPP and mCPP were weak partial 
agonists and 2-MPP lacked agonist activity (Zhang and Dyer, submitted 
for publication). Instead, these three phenylpiperazines blocked 
contractions produced by 5-HT in the ovine uterine artery. The 
dissociation constants (Kg) of TFMPP (0.22 ^ M) and mCPP (0.13 /iM) vs. 5-
HT in the ovine uterine artery were comparable to those (Kp) of TFMPP 
(0.43 fM) and mCPP (0.31 ^ M) as partial agonists in the ovine umbilical 
artery. This suggests that the same type of 5-HT receptors was 
interacted by the phenylpiperazines in both vessels. Cohen et al. 
(1983) also showed that TFMPP and mCPP had a very weak agonist activity 
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in the rat Jugular vein and could competitively antagonize 5-HT-induced 
contractions. The much lower agonist activity of the phenylpiperazines 
in the ovine uterine artery and in the rat jugular vein than in the 
ovine umbilical artery may be due to the differences in their relative 
efficacies and/or to differences in the efficiency of stimulus-response 
coupling in the different vessels (see discussion by Kenakin, 1984). 
MDL 72222 is a selective and potent antagonist of S-HTg receptors 
such as those mediating excitation of postganglionic sympathetic neurons 
(Fozard, 1984). MDL 72222 (10"® to 10"%) did not inhibit contractions 
of the umbilical artery to 5-HT, providing a strong evidence that S-HTg 
receptors are not present in the ovine umbilical artery. This is 
similar to our previous observation in the ovine uterine artery (Zhang 
and Dyer, 1989). Contractions to 2-methyl-5-HT, a selective S-HTg 
receptor agonist (Bradley et al., 1986), were not blocked by MDL 72222 
(10"®M) but were effectively blocked by ketanserin (10"®M) . The 
dissociation constant (Kg) of ketanserin vs. 2-methyl-5-HT (0.49 nM) was 
similar to that of ketanserin vs. 5-HT (0.40nM), indicating that 
contractions produced to 2-methyl-5-HT were mediated by 5-HT2 receptors 
in the ovine umbilical artery. 
In summary, 5-HT and DOM are potent agonists and produce 
contractions via S-HTg receptors in the ovine umbilical artery. DOM is 
5 times more potent than 5-HT but only produces 78% of the 5-HT maximum 
contraction. Variations in the sensitivity and potency of the 
serotonergic agonists in this study result primarily from the variation 
in the affinity for the 5-HT2 receptor. Vasoconstrictions produced by 
8-OH-DPAT, 2-methyl-5-HT, TFMPP and mCPP were effectively antagonized by 
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ketanserin, suggesting that the constrictions were mediated by 5-HT2 
receptors. The highly significant correlation between the affinity of 
the agonists in producing vasoconstriction in the ovine umbilical artery 
with their affinities at S-HTg binding sites in brain tissue supports 
the conclusion that S-HTg receptors mediate the vasoconstriction in the 
ovine umbilical artery and they are similar to those S-HTj receptors in 
the CNS. 5-HT3 receptors were not present in the ovine umbilical artery. 
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SECTION V. RECEPTOR MECHANISMS FOR 5-HYDROXYTRYPTAMINE (5-HT) IN THE 
ISOLATED OVINE UMBILICAL VEIN^ 
Abstract 
5-hydroxytryptamine (5-HT) and 2,5-dimethoxy-4-methyl-amphetaniine 
(DOM) produced a concentration-dependant contraction in isolated 
umbilical veins obtained from fetal lambs within 2 weeks of term. 
Contractions to 5-HT were antagonized by ketanserin, mianserin and 
methiothepin with the dissociation constants (Kg) being 2.17 ± 0.36 nM, 
1.37 ± 0.55 nM and 1.98 ± 0.48 nM, respectively. The order of potency 
of serotonergic agonists in this tissue was: DOM > 5-HT > o-methyl-5-
HT > 1-(3-chloropheny1) piperazine (mCPP) > m-trifluoromethyl-
phenylpiperazine (TFMPP) > 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) •= 
2-methyl-5-HT. a-Methyl-5-HT was a full agonist compared to 5-HT. DOM 
possessed greater affinity but less efficacy than that of 5-HT. The 
affinities and efficacies of the other agonists studied were lower than 
those of 5-HT. Variation in the sensitivity and potency of agonists is 
primarily due to variations in their affinity for 5-HT receptors. 
Assessment of receptor occupancy vs. functional response demonstrated 
very little, if any, receptor reserve for 5-HT receptors in this tissue. 
Contractile responses to DOM, 8-OH-DPAT, mCPP and 2-methyl-5-HT were 
effectively blocked by ketanserin. The dissociation constants (Kg) of 
ketanserin against these agonists were as follows : DOM, 2.78 ± 0.85 nM; 
^Submitted to Eur. J. Pharmacol, as a research paper by Lubo Zhang 
and Donald C. Dyer. 
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8-OH-DPAT, 3.47 ± 1.12 nM; mCPP, 1.45 ± 0.51 nM; 2-methyl-5-HT, 1.99 ± 
0.74 nM. The dissociation constant of MDL 72222 (3-tropanyl-3,5-
dichlorobenzoate) vs. 5-HT was 13833 nM. No antagonism by prazosin (10' 
'M) or yohimbine (10"'M) of the responses to 5-HT was observed. These 
results indicate that 5-HT2 receptors are present in the ovine umbilical 
vein. 5-HT3 receptors were not present in this tissue. Activation of 
a-adrenergic receptors was not involved in the contractions to 5-HT. 
Introduction 
5-Hydroxytryptamine (5-HT) has been demonstrated to be a potent 
vasoconstrictor of ovine (Dyer, 1970) and human umbilical blood vessels 
(Gant and Dyer, 1971; Altura et al., 1972; Nair and Dyer, 1973). 
However, the receptor mechanisms involved in 5-HT induced 
vasoconstriction in the umbilical vein remain to be elucidated. Major 
advances in 5-HT receptor classification have become possible as a 
result of the availability of new drug antagonists such as ketanserin 
for the S-HTg receptor and MDL 72222 (3 -tropanyl-3,5-dichlorobenzoate) 
for the 5-HT3 receptor. The classification of 5-HTi receptors in 
tissues is somewhat complicated since at least four subtypes have been 
proposed and highly selective antagonists are not available (Heuring and 
Feroutka, 1987; Fazos et al., 1984; Fedigo et al., 1981). Functional 
correlates of the various 5-HTi binding sites have been proposed 
(Feroutka, 1984) but are more speculative. 
We demonstrated that 5-HT is a potent agonist mediating 
vasoconstriction in ovine uterine and umbilical arteries by acting on 
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5HT2 receptors (Zhang and Dyer, 1989a, 1989b). The present study was 
conducted to characterize 5-HT receptor subtypes in ovine umbilical 
vein. The potency order of a series of serotonergic agonists was 
determined. The apparent dissociation constants were obtained for 5-HT 
and several competitive antagonists of 5-HT receptors. The 
characteristics of the serotonergic receptors in the umbilical vein are 
compared and related to the current receptor classification schemes. 
Methods 
Adult pregnant mixed breed sheep within two weeks of term (145 
days) were anesthetized with pentobarbital and then exsanguinated. The 
pentobarbital was administered via the external jugular vein. An 
incision in the abdomen was made and the uterus exposed. Another 
incision was made in the uterus and the fetus delivered. The umbilical 
cord was sectioned at least 3 inches from the fetus. Helically cut 
umbilical veins were prepared as previously described (Dyer, 1970). The 
helical strips were approximately 2 cm long and 2-3 mm wide and were 
suspended in a series of 10 ml isolated organ baths. Tissues were 
equilibrated under 1 gram tension in a modified Krebs-Henseleit (Krebs') 
solution at 37°C for at least 90 min before initiating the experiment. 
The composition of Krebs' solution was as follows (mM) : NaCl, 115.21; 
KCl, 4.70; CaClg, 1.80; MgSO^, 1.16; KHgPO^, 1,18; NaKCGg, 22.14; 
dextrose, 7.88. Disodium ethylenediamine tetracetic acid (EDTA, 0.03 
mM) was added to suppress oxidation of amines. The Krebs' solution was 
constantly oxygenated with a mixture of oxygen-carbon dioxide (95:5). 
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Contractions were recorded isotonically. Concentration-response data 
were obtained by cumulative additions of the agonists in approximately 
one-half log increments (van Rossum, 1963). 
Determination of agonist potencies 
Concentration-response data to serotonergic agonists were obtained 
after each tissue had been exposed to a series of concentrations of KCl 
and the maximum response to KCl (150mM) was set as the 100% response. 
EC50 values for agonists in the experiment were recorded at the molar 
concentration where the curves intersected the 50% level of the response 
axis to that agonist. Relative potencies were calculated by comparing 
the concentration of agonist required to produce an equivalent 
contraction as that to 5-HT at the 20% response. No calculations were 
possible for 2-MPP since its maximum response did not reach the 20% 
level in this study. 
Determination of agonist dissociation constant or Kp) and relative 
efficacy Ce,.') 
value for 5-HT was determined as described by Furchgott and 
Bursztyn (1967). Dibenamine was used to inactivate a fraction of the 
receptors. After fractional inactivation of the receptors by dibenamine 
(7.5 X 10"®M, for 15 min) , the bath fluid was changed 5 or 6 times over 
30 minutes. The reciprocals of the concentration of 5-HT before 
dibenamine treatment (1/[A]) were plotted against the reciprocals of the 
corresponding equieffective concentrations after the treatment (1/[A']). 
From the slope and intercept of the straight line fitting the points, 
the value for K* and for the fraction of active receptors remaining (q) 
was calculated on the basis of the equation (Furchgott, 1966): 
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1 1-q 1 
+ (1) 
[A] QKa q[A'] 
according to which equals (slope - 1)/intercept, and q equals 
1/slope. 
DOM, 2-methyl-5-HT, 8-OH-DPAT and the phenylpiperazines (TFMPP and 
mCPP) were partial agonists on the umbilical vein. The technique of 
Waud (1969) was initially used to determine the dissociation constant 
(Kp) for partial agonists. However, it was not applicable in the 
present study since the umbilical vein was found not to have a large 
spare receptor capacity for the full agonist, 5-HT [see Kenakin (1984) 
for a discussion of this requirement]. Therefore, the procedure 
developed by Gero and Tallarida (1977) was used to determine the Kp of 
partial agonists by using the following equation; 
where Ky^ was the dissociation constant obtained for 5-HT (see above), Ap 
was the concentration of the full agonist A (i.e., 5-HT) producing a 
response equal to the maximum of the respective partial agonist p and Ai 
and Pi were any other pair of concentrations giving a matching 
contractile response. 
The relative affinities of the agonists for serotonergic receptors 
as compared to 5-HT were obtained by dividing the dissociation constant 
(Ky^) obtained for 5-HT by those Kp constants obtained for the other 
agonists. 
The dissociation constants (K^ or Kp) determined were then used to 
Ka • (Ap - Ai) • Pi 
Kp ( 2 )  
(Ap + Ka) • Ai 
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calculate the respective fractional occupation of receptors by each 
agonist for each concentration used in establishing the control 
concentration-response curves. The fractional occupancy was calculated 
from the equation (Furchgott and Bursztyn, 1967); 
[RA] [A] 
- (3) 
[Rj] [A] + kA 
where [RA] is the concentration of the receptor-agonist complex, [Rj] is 
the total concentration of receptors, and (or Kp) is the agonist 
dissociation constant. 
The contractile response data for each agonist were then replotted 
to show response as a function of log [RA]/[Rj] . The antilog of the 
distance between two curves along the abscissa was taken as the ratio of 
the intrinsic efficacy of the second agonist to that of 5-HT (Furchgott 
and Bursztyn, 1967), and thus was a measure of e,., the relative efficacy 
of the second agonist as compared to 5-HT. 
In all experiments, cocaine (3 x 10"%) was added to block uptake 
mechanisms (Dyer, 1970), phentolamine (lO'^M) to inhibit a-adrenergic 
receptors and iproniazid (0.36 mM) to block monoamine oxidase (MAO). 
Iproniazid was added to the bath for 40 min. and then the tissues were 
washed 4 times over 30 min with fresh Krebs' solution. Cocaine and 
phentolamine were added 15 min prior to adding 5-HT. 
Determination of the apparent dissociation constant (Kg) of antagonist 
Methiothepin, ketanserin, mianserin and MDL 72222 were used in a 
series of experiments to determine the subtypes of 5-HT receptors 
involved in contractions of the ovine umbilical vein. Initially a 
221 
concentration response relationship was obtained to an agonist. Then 
antagonists were equilibrated for 1 hour with the tissue before 
repeating the concentration response relationship to that agonist. The 
concentration ratio (CR) of the agonist (EC50 in the presence of 
antagonists/ECjo in the absence of antagonists) was determined. The 
time related shift of the agonist response curve was measured in a 
matched preparation not treated with antagonist. The concentration 
ratio (CRj) (EC50 at time t/ECgq at time 0) was determined from the two 
control agonist concentration-response curves. The concentration ratio 
(CR) of the agonist obtained from the antagonist treated tissue was then 
adjusted according to the following formula: adjusted CR - CR/CRj. Kg 
was calculated from the relationship (Furchgott, 1972): 
(B] 
KB - (4) 
CR - 1 
where [B] is the molar concentration of the antagonist and CR is the 
adjusted concentration ratio for the agonist as described above. 
Cocaine, phentolamine and iproniazid were also used as described above. 
Evaluation of q-adrenergic receptor stimulation 
Experiments were performed to evaluate the possibility that a-
adrenergic receptor stimulation was involved in the response to 5-HT. 
Pairs of adjacent strips from a single umbilical vein were studied to 
compare the antagonism of prazosin and yohimbine to 5-HT and 
norepinephrine (NE). The strips were first exposed to KCl (150mM) and 
then washed to permit relaxation to the original resting level. 
Prazosin or yohimbine were added to the bath and allowed to equilibrate 
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with the tissue for 20 minutes. The preparations were then challenged 
with a series of cumulative additions of 5-HT or NE in the presence of 
the antagonists. The data were plotted to determine the displacement of 
the log concentration-response curve for the agonists in the presence of 
the antagonists. 
Drups 
The following drugs were used: cocaine HCl, serotonin creatinine 
sulfate (Sigma Chemical Co., St. Louis, MO); R(-)-2,5-dimethoxy-4-
methyl-amphetamine (National Institute of Drug Abuse, Rockville, MD); 8-
hydroxy-dipropylaminotetralin (8-OH-DPAT), a-methyl-5-hydroxytryptamine 
(a-methyl-5-HT), 2-methyl-5-hydroxytryptamine (2-methyl-5-HT), m-
trifluoromethy1-phenyIpiperazine HCl (TFMPP), 1-(3-chlorophenyl) 
piperazine HCl (mCPP), 1-(2-methoxyphenyl) piperazine HCl (2-MPP), 3-
tropanyl-3,5-dichlorobenzoate (MDL 72222), mianserin HCl (Res. Biochem. 
Inc., Natick, Massachusetts). Ketanserin tartrate (Jansson, Beerse, 
Belgium); iproniazid phosphate, methiothepin maleate (Hoffmann-LaRoche, 
Nutley, NJ): prazosin HCl (Pfizer Inc., Brooklyn, NY); yohimbine HCl 
(Merck, Rahway, NJ); phentolamine methane sulfate (CIBA Pharmaceutical 
Company, Summit, NJ); dibenamine HCl (Smith, Kline and French Lab., 
Philadelphia, PA); 1-norepinephrine bitartrate (Calbiochem Behring 
Corp., La Jolla, CA). Drugs were dissolved in saline, except for 
dibenamine and MDL 72222, which were dissolved in alcohol and diluted in 
saline just prior to use. 
Data were expressed as means ± S.E.; for each experiment, n refers 
to the number of sheep from which vessels were taken. The student's t-
test was used for statistical analysis of the difference of means. 
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Results 
Contractions of ovine umbilical vein to serotonergic aponists 
Contractions produced by serotonergic agonists were compared to 
those by potassium chloride (150 mM). The concentration-response curves 
to serotonergic agonists are illustrated in Fig. 1. The threshold 
concentration of DOM was lower than that of 5-HT. Other agonists 
required a higher concentration to produce a threshold response. In 
Table 1, the EC50 values and potency ratios were presented. The potency 
order of the agonists was determined to be DOM > 5-HT > a-methyl-5-HT > 
mCPP > TFMPP > 8-OH-DPAT - 2-methyl-5-HT. DOM was 3.4 times more potent 
than 5-HT but only produced 84% of the maximum response to that of 5-
HT. The maximum contractile response elicited by the other agonists was 
significantly less than that obtained to 5-HT. 2-MPP caused only a 
minimal response, about 5 percent of that to 5-HT. 
Agonist dissociation constant or Kp) 
The response to 5-HT before and after exposing the tissues to 
dibenamine (7.5 x 10"®M for 15 min) is presented in Fig. 2. Dibenamine 
reduced the maximal response to 5-HT about 40%. The inset (Fig. 2) 
illustrates a double reciprocal plot of equieffective concentrations of 
5-HT before (1/[A]) and after (1/[A']) dibenamine treatment. The mean 
for the individual tissues was 4.25 ± 1.17 x lO'^M (n-7) . The 
fraction of receptors still active after dibenamine (i.e., the q value) 
was determined as described in 'Methods', The mean q value for 5-HT was 
0.26 ± 0,09 (n-7). 
The dissociation constants (Kp) for the partial agonists DOM, 8-
Fig. 1. Concentration response relationship for serotonergic agonists. Results are illustrated as 
the X ± SE. of the tissues from 3 to 7 animals and are expressed as a percentage of the 
contraction obtained to 150mM KCL 
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Table 1. Comparative properties of serotonergic agonists on the ovine umbilical vein 
Agonist ECgQ Relative Approximate Maximum Response 
Potency^ as a Percentage 
of the Response 
to 150mM KCl 
M (x 10'^) M % 
5-HT 7 0.95 ± 0.09 1. 000 1.0 X 10"^ 116 
DOM 7 0.22 ± 0.03 3, .400® 1.0 X 10"^ 97 
a-Methyl-5-HT 6 1.65 ± 0.11 0. 548® 1.0 X 10'^ 117 
mCPP 4 2.23 + 0.43 0, .096® 3.0 X 10*5 45 
TFMPP 4 5.62 ± 1.42 0. ,021® 1.0 X 10"^ 32 
8-OH-DPAT 4 63.09 ± 15.14 0, .003® 1.0 X 10"^ 42 
2-Methyl-5-HT 3 67.81 ± 18.90 0, 003® 1.0 X 10'^ 42 
2-MPP 3 121.13 ± 40.14 1.0 X 10'^ 5 
is the number of animals, 
ECgQ is the effective concentration to produce 50% of the maximal response to the respective 
agonist. 
^Relative potency was calculated at the EC20 (see Methods). 5-HT is arbitrarily set at 1. 
^^ECioo is the effective concentration to produce the maximal response to the respective 
agonist. 
^Significantly different from 1 (P<0.05). 
Fig. 2. Effect of treatment with dibenamine on 5-HT-elicited contractions of ovine umbilical vein. 
Contractions were obtained before (open circles) and after (closed circles) exposure to 7.5 x 
10~°M dibenamine for 15 min. Dibenamine was washed out of the tissues before obtaining the 
second concentration-responsive relationship to 5-HT. Each point represents the x ± SE. of 
tissues from 7 animals. Inset: plot of the reciprocals of equieffective concentrations of 
5-HT before (1/[A]) and after (1/[A']) dibenamine treatment 
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OH-DPAT, 2-methyl-5-HT and the phenylpiperazines (TFMPP and mCPP) are 
presented in Table 2. The relative affinity of partial agonists were 
calculated by dividing the estimated of 5-HT by the Kp of the partial 
agonist (Table 2). Of the five agonists studied, DOM and mCPP had an 
affinity for the serotonergic receptor site which was greater than that 
of 5-HT (Table 2). The affinities of the other three agonists were 
lower than that of 5-HT (Table 2). 
Agonist relative efficacy (e,.)  
Fig. 3 presents the results of replotting agonist relative response 
against log [RA]/[Rt]. The fraction of receptors occupied ([RA]/[Rj]) 
for each agonist at each concentration employed in obtaining the 
complete concentration-response curves was calculated as described in 
Methods. The curve for 5-HT indicated that 50% of the maximum response 
was obtained when about 17% of the receptors were occupied by 5-HT. 
However, about 90% of the receptors had to be occupied to obtain 90% of 
the maximum response. The relative efficacies of DOM, 2-methyl-5-HT, 8-
OH-DPAT, mCPP and TFMPP to 5-HT were obtained as the antilog of the 
distance between the respective agonist and 5-HT along the log [RA]/[Rj] 
axis. The mean values are presented in Table 2. 
Correlation between agonist sensitivity and potency and aponist affinity 
and efficacy 
There is an excellent correlation between the sensitivity (pDg - -
log EC50) and the affinity (pK* - - log K^) of the serotonergic agonists 
in the ovine umbilical vein (pDj vs. pK^) (Fig. 4). The correlation 
coefficient is 0.966 (P < 0.001). The slope of the regression line 
relating the sensitivity to affinity is 0.84, which is not significantly 
Table 2. Comparison of dissociation constant (Kj^ or Kp) , relative efficacy (e,.) and relative 
affinity for the agonists acting on the serotonergic receptors in the ovine fetal 
umbilical vein 
Agonist Dissociation Relative Relative 
Constant Efficacy Affinity^ 
M (x 10-7) 
5-HT 7 4.25 + 1.17 1, .00 1.00 
DOM 7 0.85 ± 0.24 0, .63^ 5.00^ 
mCPP 4 2.64 ± 0.73 0, .lid 1.61 
TFMPP 4 5.40 ± 1.62 0, .07*^ 0.79 
8-OH-DPAT 4 113.89 ± 29.74 0, .12^ 0.04^ 
2-Methyl-5-HT 3 89.44 ± 21.80 0, .lid 0.05^ 
is the number of animals. 
^'^5-HT is arbitrarily set at 1. 
'^Significantly different from 1 (P<0.05). 
Fig. 3. Contractions to serotonergic agonists plotted as a function of log [RA]/[Rt] in the ovine 
umbilical vein. Receptor occupancy [M]/[Rj] at a given concentration of agonist was 
calculated as described under "Methods" using the mean dissociation constant obtained for 
each agonist, as given in Table 2. Contractile responses were taken from the results 
illustrated in Figure 1 
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different from unity. Fig. 5 (left panel) shows that there is a good 
correlation between the relative potency (RP) and relative affinity (RA) 
of the serotonergic agonists where r - 0.896 (P < 0.01). The slope of 
the regression line relating RP to RA is 0.6, which is significantly 
different from unity. The correlation between RP and relative efficacy 
(RE) of the agonists is also significant with r - 0.824 (P < 0.05) (Fig. 
5, right panel). The slope of the regression line is 0.32, which is 
significantly different from unity. 
Competitive antagonists 
Four antagonists of 5-HT receptors were used in this investigation. 
These included: methiothepin, ketanserin, mianserin and MDL 72222. 
Figure 6 presents the results of the inhibitory effects of these 
antagonists on the 5-HT-induced contractions on the ovine umbilical 
vein. Apparent dissociation constants, Kg values, are presented in 
Table 3. The potencies for inhibition of 5-HT-induced contractions were 
very similar among these antagonists except for MDL 72222, which was 
much less potent. 
Contractile responses to DOM, mCPP, 8-OH-DPAT and 2-methyl-5-HT 
were effectively blocked by ketanserin (10"®M) , The dissociation 
constants (Kg) of ketanserin against these agonists were determined to 
be: DOM, 2.78 ± 0.85 nM (n-3); mCPP, 1.45 ± 0.51 nM (n-3); 8-OH-DPAT, 
3.47 ± 1.12 nM (n-3); 2-methyl-5-HT, 1.99 ± 0.74 nM (n-3). 
Effect of blockade of a-adrenereic receptors 
The ability of 5-HT to stimulate a-adrenergic receptors was 
evaluated in umbilical vein strips pretreated with prazosin or 
yohimbine. Paired tissues from the same vein were used to compare the 
Fig. 5. Correlation between the relative potency (RP) and relative affinity (RA) (left panel) and 
relative efficacy (RE) (right panel) of the serotonergic agonist in the ovine umbilical vein. 
Correlation coefficients for relating RP to RA and RE are 0.896 (P < 0.01) and 0.824 (P < 
0.05), respectively. Slopes for the regression lines relating RP to RA and RE are 0.60 and 
0.32, respectively 
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Fig. 6. Cumulative concentration-response curves for 5-HT obtained with ovine umbilical vein in the 
absence and presence of various serotonergic antagonists. Each point represents the x ± SE. 
of the tissues from 3 to 4 animals 
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Table 3. Effect of antagonists on responses to 5-HT on the isolated ovine umbilical vein 
Antagonist Cone. Emax^ KgC 
M % nM 
Ketanserin 3 X 10'8 4 98 ± 2.13 2.17 ± 0.36 
Methiothepin 3 X 10-9 4 83 ± 3.47 1.98 ± 0.48 
Mianserin 3 X 10-8 4 99 ± 3.26 1.37 ± 0.55 
MDL 72222 1 X 10-5 3 124 ± 4.4 13833 ± 5674 
is the number of animals. 
^Maximum contraction to 5-HT in the presence of antagonist as a percentage of the maximum 
obtained before exposing tissues to the antagonist. 
^Calculated for each tissue at each concentration of antagonist according to the equation Kg 
= [antagonist]/concentration ratio-1. 
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antagonism of prazosin and yohimbine to NE or 5-HT. Fig. 7 illustrates 
the results of this experiment. Neither prazosin (lO'^M) nor yohimbine 
(10"'M) antagonized responses to 5-HT. In contrast, NE-induced 
contractions were effectively antagonized by the same concentration of 
yohimbine and prazosin. Yohimbine (lO'^M) increased the EC50 of NE 2-
fold, while prazosin (10"'M) increased it 112-fold. 
Discussion 
Norepinephrine produced a concentration-dependent contraction of 
the isolated ovine umbilical vein which was antagonized effectively by 
prazosin and less so by yohimbine. This result indicates that a-
adrenergic receptors are present in this tissue. It has been 
demonstrated that in the cat spleen (Innes, 1962) and rabbit central ear 
artery (Apperley et al., 1976; Purdy et al., 1980) that a-adrenergic 
receptors can mediate a 5-HT response. In the present study, prazosin, 
with a reported Kg of 3.51nM for a-receptors in the rabbit aorta 
(Furchgott, 1980), was not effective at lOOnM in antagonizing the 5-HT 
response. Similarly, yohimbine (10~'M) was without inhibitory effects 
on the 5-HT-induced contractions. We conclude that contractions to 5-
HT in the ovine umbilical vein do not involve activation of a-adrenergic 
receptors. This conclusion is in accord with that found in the ovine 
uterine artery (Zhang and Dyer, 1989a) and in the rabbit aorta (Stollak 
and Furchgott (1984). That a-adrenergic receptors can mediate a 5-HT 
response in some blood vessels but not in others indicates that there 
could be differences in the properties and/or relative numbers of a-
Fig. 7. Cumulative concentration-response curves to 5-HT (left panel) and norepinephrine (right 
panel) on the ovine umbilical vein in the absence and presence of prazosin (pra) and/or 
yohimbine (yoh). Each point represents the x ± SE. of the tissues from 4 animais 
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receptors from one tissue to another. It is possible that 5-HT could be 
a very weak partial agonist at a-receptors but in tissues like the ovine 
umbilical vein there may not be a large enough a-receptor reserve to 
permit generation of a response with a low-efficacy partial agonist. In 
fact, we have demonstrated that there is no receptor reserve for a-
receptors in the ovine umbilical artery since to obtain a 50% response 
to NE required about 50% of the a-receptors to be occupied (Zhang and 
Dyer, unpublished data). 
The value for 5-HT determined in this study was not 
significantly different from our previous finding in ovine uterine 
artery and umbilical artery (Zhang and Dyer, 1989a, 1989b) and is 
comparable to its binding affinity at S-HTg binding sites in brain 
tissue (k^ — 400-1000nM) (Glennon, 1987). Based on the determined of 
425nM, 5-HT would occupy 17% of the total functional receptor pool to 
produce one-half of the maximum response. However, about 90% of the 
receptors would need to be occupied by 5-HT when 90% of the maximum 
response is produced, suggesting a lack of any appreciable effective 
receptor reserve. The lack of an effective receptor reserve in the 
ovine umbilical vein agrees with our recent finding in the ovine uterine 
and umbilical artery (Zhang and Dyer, 1989a, 1989b). Evidence 
suggesting a lack of spare receptors for S-HTg receptors has been 
obtained by Cohen et al, (1986) in the rat jugular vein and uterus. 
Differences in the agonist sensitivity in producing the biological 
response of a tissue may result from the variation in the agonist 
affinity for the receptor as well as the number of the receptors 
involved and the vents that follow receptor occupation (see discussion 
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by Bevan et al., 1989). It has been shown that the sensitivity of 
rabbit arteries to NE was totally dependent on the affinity of NE for a-
adrenergic receptors, while in rat arteries only 60% of NE sensitivity 
was due to the variation in the receptor affinity and with 40% coming 
from the variation in the receptor density (Oriowo et al., 1989). In 
the present study, an excellent correlation between the sensitivity and 
the affinity of serotonergic agonists (pD2 vs. pK^) was observed. The 
slope of the regression line relating the sensitivity to the affinity is 
not significantly different from unity. This suggests that the 
variation in the sensitivity of the serotonergic agonists in the ovine 
umbilical vein is primarily due to the variation in their affinities for 
5-HT2 receptors. As discussed by Kenakin (1984), variation in the 
relative potencies among agonists may result from the difference in 
their affinities and/or their relative efficacies. This is supported by 
the observation in this study that there are good correlations between 
the relative potency of the serotonergic agonists and their relative 
affinity and efficacy. The slopes of the regression lines relating the 
relative potency to the relative affinity and the relative efficacy are 
0.6 and 0.32, respectively. This suggests that about a 60% variation in 
the serotonergic agonist potency is due to the variation in their 
relative affinity for S-HTg receptors and about 30% the variation in the 
relative potency comes from the variation in their relative efficacy. 
In comparison to 5-HT, a-methyl-5-HT behaved as a full agonist and 
all others as partial agonists. The relative efficacy of DOM, mCPP, 
TFMPP, 8-OH-DPAT and 2-methyl-5-HT was lower than that of 5-HT in the 
umbilical vein. The classification of DOM as a partial agonist in the 
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present study is in accord with that found in the ovine umbilical artery 
(Zhang and Dyer, 1989b) and in brain tissue (Sanders-Bush et al., 1988), 
but differs from that found in the ovine uterine artery (Zhang and Dyer, 
1989a). The reason why DOM is a full agonist in some tissues and a 
partial agonist in others is not clear at this point. Since DOM had a 
lower efficacy than that of 5-HT in the ovine umbilical vein, its 
greater potency when compared to 5-HT is probably linked to its greater 
affinity for 5-HT receptors. 
Ketanserin, a selective S-HTg receptor antagonist (Leysen et al., 
1981, Van Neuten et al., 1981; Leysen et al., 1982) caused a parallel 
shift of the concentration-effect curve for 5-HT to the right. The 
apparent Kg value (2.17 nM) for ketanserin obtained in this study was 
comparable to our recent finding in the ovine uterine artery (2 nM) and 
umbilical artery (0.4 nM) (Zhang and Dyer, 1989a, 1989b) and those (0.2 
to 7 nM) reported for other blood vessels (Cohen et al., 1983; Cohen, 
1986; Humphrey, 1984; Van Nueten et al., 1982; Van Nueten et al., 1981). 
This indicates that 5-HT evoked contractions of the umbilical vein are 
via the S-HTg receptor. Mianserin is generally regarded as selective 
for S-HTg as opposed to 5-HTi receptors, and [^H] mianserin has been 
used as a ligand for S-HTg sites (Peroutka and Snyder, 1981). Cohen 
(1984) demonstrated that mianserin acted as a typical competitive 
antagonist of 5-HT2 receptors in the rat jugular vein. The present 
finding that mianserin potently antagonized 5-HT-induced contractions in 
the umbilical vein further supports the contention that S-HTg receptors 
are involved in 5-HT-induced contractions in this tissue. The 
contractile response to DOM was effectively blocked by ketanserin. The 
247 
dissociation constant (Kg) of ketanserin vs. DOM (2.78 nM) was not 
significantly different from that (2.17 nM) of ketanserin vs. 5-HT, 
indicating that DOM acts on the same 5-HT receptors as 5-HT does, i.e., 
S-HTg receptors. That both 5-HT and DOM activate S-HT^ receptor is in 
accord with our findings in the ovine uterine and umbilical artery 
(Zhang and Dyer, 1989a, 1989b) and those by Glennon and co-workers 
(1983, 1984) in brain tissues. 
There is an excellent correlation (r - 0.964, P < 0.001) between 
the pK^ of the serotonergic agonists in this study and their affinities 
(pKi) at S-HTg binding sites in the CNS reported by other authors (Fig. 
8, left panel). In contract, there is a negative correlation (r - -
0.205) between the pKy^ of the agonists and their pK^ at S-HT^ binding 
sites in the CNS (Fig. 8, right panel). These results suggest that the 
5-HT receptors mediating the contractions produced by the agonists in 
this study are the same type of 5-HT2 binding sites in the CNS. 
It is unlikely that contractions produced by 8-OH-DPAT in the 
present study are mediated by 5-HTia receptors, since ketanserin 
effectively blocked contraction produced by 8-OH-DPAT. The dissociation 
constant (Kg) of ketanserin against 8-OH-DPAT (3.47 nM) was not 
significantly different from that of ketanserin vs. 5-HT (2.17 nM) , 
suggesting that contractions produced by 8-OH-DPAT in the ovine 
umbilical vein were mediated by S-HTg receptors. This is consistent 
with our finding in the ovine uterine artery (Zhang and Dyer, submitted 
for publication). 
In the present study, 2-MPP lacked agonistic activity up to 10"%. 
The other two phenylpiperazines, mCPP and TFMPP acted as partial 
Fig. 8. Correlation between the of the serotonergic agonists in this study and their pK^ at 5-
HT2 binding sites in brain tissue (labelled by ketanserin, 5-HT and DOM, Glennon, 1987; 
TFMPP and 8-OH-DPAT, Taylor et al., 1986; mCPP, Martin and Sanders-Bush, 1982; 2-methyl-5-
HT, Engel et al., 1986) or at S-HTj binding sites in brain tissue (5-HT and DOM, labelled by 
[^H] 5-HT, Glennon, 1987; TFMPP and mCPP, labelled by icyp, Glennon, 1987; 8-OH-DPAT, 
labelled by [^H] 8-OH-DPAT, Glennon, 1987; 2-methyl-5-HT, labelled by [^H] 8-OH-DPAT, Engel, 
et al., 1986). The correlation coefficient for relating the pK^^ to the pK^ at 5-HT2 binding 
sites and the pK^ at S-HT^ binding sites are 0.964 (P < 0.001) and -0.205, respectively 
pKi (5-HT2 binding sites) 
0> 
pKj (5-HTi binding sites) 
6V3 
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agonists at 5-HT receptors in the ovine umbilical vein. The 
dissociation constants (Kp) of mCPP (0.22 /iM) and TFMPP (0.56 /<M) in the 
present study were not significantly different from those of mCPP (0.32 
fiH) and TFMPP (0.43 /iM) found in the ovine umbilical artery (Zhang and 
Dyer, manuscript in preparation). This suggests that they act on the 
same 5-HT receptors in the two vessels. We have shown that mCPP and 
TFMPP acts on S-HTg receptors in the ovine umbilical artery (Zhang and 
Dyer, manuscript in preparation). In this study, ketanserin effectively 
blocked contractile responses to mCPP. The dissociation constant (Kg) 
of ketanserin against mCPP (1.45 nM) was not significantly different 
from that of ketanserin vs. 5-HT (2.17 nM) in the present study, 
suggesting that contraction produced by mCPP were mediated by S-HTg 
receptors in the ovine umbilical vein. The very weak agonist activities 
of mCPP and TFMPP were also found in the ovine uterine artery (Zhang and 
Dyer, submitted for publication) and the rat jugular vein and aorta 
(Cohen and Fuller, 1983), in which they antagonized the contractile 
responses to 5-HT at 5-HT2 receptors. The dissociation constants (Kp) 
of mCPP (0.22 |iM) and TFMPP (0.56 /iM) as partial agonists in the present 
study are comparable to the dissociation constants (Kg) of mCPP and 
TFMPP as antagonists against 5-HT in the ovine uterine artery (0.13 /iM 
and 0.22 /iM, respectively) (Zhang and Dyer, submitted for publication) 
and in the rat jugular vein and aorta (0.04 /iM and 0.06 /iM, 
respectively) (Cohen and Fuller, 1983). The much lower agonist activity 
of these phenylpiperazines in the ovine uterine artery and in the rat 
jugular vein than in the ovine umbilical vessels may be due to 
differences in their relative efficacies and/or to differences in the 
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efficiency of stimulus-response coupling in different vessels (see 
discussion by Kenakin, 1984). 
MDL 72222 was demonstrated by Fozard (1984) to be a potent and 
selective S-HTg receptor antagonist. In the present study, MDL 72222 
(10"®M) produced a slight rightward shift in the concentration-response 
relationship for 5-HT. The dissociation constant (Kg) of MDL 72222 vs. 
5-HT in this study was determined to be 13833 nM, which was about 450 to 
45000 times higher than that of MDL 72222 acting on S-HTg receptors (31 
to 0.31 nM) (Bradley et al. 1986). It is unlikely that 5-HT3 receptors 
are present in the ovine umbilical vein. This is in agreement with that 
found in the ovine uterine and umbilical artery (Zhang and Dyer, 1989a, 
1989b). Contractile responses to 2-methyl-5-HT, a selective 5-HT3 
agonist (Bradley et al., 1986), were effectively blocked by ketanserin. 
The dissociation constant (Kg) of ketanserin vs. 2-methyl-5-HT (1.99 nM) 
was not significantly different from that of ketanserin vs. 5-HT (2.17 
nM), suggesting that contractions produced by 2-methyl-5-HT are mediated 
by 5-HT2 receptors in the ovine umbilical vein. 
In summary, 5-HT and DOM were potent agonists and produced 
contraction of the ovine umbilical vein via 5-HT2 receptors. Activation 
of «-adrenergic receptors were not involved in the response to 5-HT. 
DOM was more potent than 5-HT but only produced 84% of the maximum 
response to that of 5-HT. Variation in the agonist sensitivity and 
potency is primarily due to the variation in their affinity for 5-HT 
receptors. There was no 5-HT receptor reserve in the ovine umbilical 
vein. 8-OH-DPAT, mCPP and 2-methyl-5-HT were partial agonists and 
produced contractions by acting on S-HTg receptors. S-HTg receptors 
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were not present in the ovine umbilical vein. 
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DISCUSSION 
The classification of 5-HT receptors in this study is based on the 
receptor occupation theory where it is assumed that the occupation of a 
receptor by a drug leads to a stimulus and a subsequent response. In 
the present study, the order of the relative potency of 5-HT and the 
other serotonergic agonists in the uterine artery and the umbilical 
artery and vein are similar except for the three phenylpiperazine 
derivatives which are more potent in the umbilical vessels than they are 
in the uterine artery (Table 1). In all three vessels, DOM is more 
potent than 5-HT, which is due to its greater affinity for the 5-HT2 
receptor. Differences in relative potency among agonists may result 
from differences in their relative affinity for receptors and/or their 
relative efficacy. In this study, the variation in the sensitivity and 
the potency of the serotonergic agonists on the uterine artery and the 
umbilical vessels is primarily due to the variation in their relative 
affinity for the S-HTg receptor and less so to the variation in their 
relative efficacy. 
In many isolated tissues, the relationship between receptor 
occupancy and tissue response is nonlinear (Furchgott, 1966). Receptor 
reserve may be different among different agonists and/or different 
tissues. In the present study, no 5-HT receptor reserve was found in 
the uterine and umbilical vessels even though the half maximum response 
was reached when only about 20% of the receptors were occupied by 5-HT. 
It should not be assumed that for drugs that have no receptor reserve 
the relationship between receptor occupancy and tissue response is 
Table 1. Comparative properties of serotonergic agonists in the ovine uterine artery (UA), umbilical 
artery (UmA) and umbilical vein (UmV) 
ECgQ^ Relative Potency^ Percentage of 
Response to 150mM 
Agonist 
KCl at EC^QQ 
UA UmA UmV UA UmA UmV UA UmA UmV 
M % 
(X 10 -7) 
5-HT 1.27 1, .04 0, 95 1, .000 1.000 1 .000 106 161 116 
DOM 0.54 0, .10 0. ,22 2, .000 5.000 3 .400 103 126 97 
a-Methyl-5-HT 1.34 1. ,25 1. 65 0. 934 0.714 0 .548 106 157 117 
8-OH-DPAT 21.40 19, ,95 63. 09 0, 025 0.015 0 .003 68 98 42 
2-Methyl-5-HT 38.80 70, ,79 67. 81 0, 014 0.004 0 .003 69 74 42 
mCPP 321.00 1, 54 2. 23 0. ,001 0.280 0. 096 42 93 45 
TFMPP 535.00 1, 58 5. 62 0.280 0, .021 21 96 32 
2-MPP 330.00 79. ,43 121. 13 0.002 2 52 5 
^ECjq is the effective concentration to produce 50% of the maximal response to the 
respective agonist. 
Relative potency is calculated at the concentration of agonists which produce the same 
effect. Potency of 5-HT is arbitrarily set at 1. 
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linear (Besse and Furchgott, 1976). The efficiency of the stimulus 
response mechanisms in different tissues could be different. The 
following two factors can affect the efficiency of the stimulus response 
mechanism in a tissue: 1) the number of receptors in the tissue, 2) the 
second messenger system which translates receptor stimulus into a tissue 
response. The second messenger system often performs as an amplifier in 
biological praparations (Ariens and Simonis, 1976; Goldberg, 1975). The 
formation of glucose by ^ -adrenergic drugs provides a very good example 
(Goldberg, 1975). On the other hand, a positive correlation between 
receptor density and agonist response has also been observed (Bevan et 
al., 1989; Oriowo et al., 1989). 
Selective agonism can provide useful information about the presence 
or absence of a certain receptor in an unclassified tissue. However, 
one should be very careful if a judgement is based only on the 
observation of the presence or absence of a response to a selective 
agonist. If a tissue does not respond to a selective agonist, it could 
mean either that the receptor is not present or that the stimulus-
response mechanism of the tissue produces insufficient amplification of 
the receptor stimulus to generate a response. The observation with 
prenalterol, a agonist, in the canine coronary artery provides a good 
example that an inadequately efficient stimulus-response mechanism in a 
tissue could lead to a wrong conclusion about the presence or absence of 
a certain receptor by using a selective agonist (Baron et al., 1972; 
Kenakin and Beek, 1980, 1982). In this study, the lack of or weak 
agonist activity of the phenylpiperazines in the uterine artery could be 
due to an inadequately efficient stimulus-response mechanism in this 
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tissue. On the other hand, if a selective agonist produces a response 
in a tissue, a distinction should be made between selectivity and 
specificity. In the present study, a 5-HT3 receptor agonist (2-methyl-
5-HT), a S-HTja receptor agonist (8-OH-DPAT) and several S-HT^g receptor 
agonists (2-MPP, TFMPP and mCPP) all produced contraction of the uterine 
artery and the umbilical vessels. However, the contraction produced by 
these agonists was effectively antagonized by the 5-HT2 receptor 
antagonist ketanserin, indicating that the contraction was mediated by 
the 5-HT2 receptor. 
In order to define the relationship between the agonist-induced 
response and the agonist-receptor interaction, it is extremely important 
to determine the dissociation constant (K^ value) of the agonist-
receptor complex. The reciprocal of is a quantitative measure of the 
affinity of the agonist for the receptor. As discussed by Furchgott 
(1966) , the same value for a given agonist in different tissue 
preparations provides strong evidence that the agonist acts on the same 
type of receptor. In this study, the dissociation constants determined 
for 5-HT (K^) and the partial agonists (Kp) are similar among the 
uterine artery and the umbilical vessels (Table 2), indicating that the 
agonists are activating the same 5-HT receptors in these tissues. K* 
values would also provide very useful information when the relationship 
between chemical structure and pharmacological activity of a series of 
agonists acting on a common receptor is being investigated. Once is 
known, the fraction of receptors ([RA]/[Rt]) which must be occupied by 
the agonist under equilibrium condition to elicit a response of a fixed 
magnitude can be determined (Furchgott, 1966). The relative efficacy in 
Table 2. Dissociation constants (Kj^ or Kp) of serotonergic agonists and dissociation constants (Kg) 
of ketanserin vs. the serotonergic agonists in the ovine uterine artery (UA), umbilical 
artery (UmA) and umbilical vein (UmV) 
Agonist UA 
Ka or Kp ( X 10-7% ) 
UmA UmV 
Kb ( X 10'\ ) 
UA UmA UmV 
5-HT 
DOM 
8-OH-DPAT 
2-Methyl-5-HT 
TFMPP 
mCPP 
3.70 
1.80 
4.71 
0.36 
49.81 
113.16 
4.34 
3.15 
4.25 
0.85 
113.89 
89.44 
5.40 
2.64 
2 .00  
4.00 
2.49 
2 . 8 8  
0.40 
0.79 
0.29 
0.49 
1.01 
0.38 
2.17 
2.78 
3.47 
1.99 
1.45 
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a series of agonists acting on a common receptor in a given tissue 
preparation can be obtained by a comparison of the fraction of receptor 
occupation required to give the same response. In this study, the 
intrinsic efficacy of DOM is the same as that of 5-HT in the uterine 
artery, but lower than that of 5-HT in the umbilical vessels. This 
suggests that DOM is a full agonist in the uterine artery, but is a 
partial agonist in the umbilical vessels. 
In general, antagonists are more selective for receptor subtypes 
than are agonists. As discussed by Ariens and co-workers (1979), a 
"complimentarily principle" dictates a sharper differentiation of 
receptor subtypes by antagonists rather than agonists. Molecules of 
antagonists usually bear the chemical structure of agonists but are 
generally larger and more flexible (Ariens et al., 1979). In general, 
they possess certain lipophilic structural groups and these groups can 
bind to accessory sites around the agonist binding site of the receptor 
(Ariens et al., 1979). This may be particularly important in the 
differentiation of receptor subtypes with variations in accessory sites. 
For the most part, the definitive classification of the major drug 
receptor types and subtypes has been accomplished with selective 
competitive antagonists. 
Since competitive antagonists possess no intrinsic efficacy, the 
potency of a competitive antagonist depends upon its equilibrium 
dissociation constant (Kg) for the drug receptor. The interaction of a 
competitive antagonist with a drug receptor is a pure chemical process. 
The rate of onset and offset of the antagonist with the drug receptor is 
governed only by molecular forces (Kenakin, 1984). Therefore, the Kg 
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should be independent of receptor function, location and animal species. 
No doubt, reliable estimates of Kg values for competitive antagonists 
are very important in drug receptor classification. 
If an antagonist is competitive and the experimental conditions are 
satisfied, the Schild plot should yield a straight line with the slope 
being unity. Obviously, if a antagonist is not competitive there will 
not be a straight line or the slope will be significantly different from 
unity. On the other hand, the experimental conditions can also affect 
the Schild plot. Failure to inhibit agonist uptake or metabolism 
processes in isolated tissues is one of the most common causes of slopes 
being less than unity (Furchgott, 1972; Furchgott at al., 1973). In 
order to determine properly the dissociation constant of a competitive 
antagonist, the sites of loss of the agonist should be blocked. In this 
study, cocaine was used to block the uptake of 5-HT and iproniazid to 
block monoamine oxidase (MAO). If a competitive antagonist is not 
allowed to fully equilibrate with the tissues, the slope of the Schild 
regression line will be greater than unity. This is more pronounced if 
drug-receptor interaction and not diffusion is the rate limiting step 
(Kenakin, 1980). If a given competitive antagonist has a low rate of 
offset from the receptor, it could behave as an essentially irreversible 
blocker and produce insurmountable antagonism. This phenomenon has been 
discussed by Paton and Waud based on the receptor rate theory (Paton and 
Waud, 1967). The degree of depression of the maximal response is 
dependent upon the intrinsic efficacy of the agonist (Kenakin, 1984) and 
the time of incubating the antagonist with the tissue. The interaction 
of agonist, antagonist and receptor could be in a "hemi-equilibrium" 
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state as described by Paton and Waud (1967). Under this condition, the 
equilibrium of the antagonist with the receptor is not changed by the 
presence of the agonist. The agonist only interacts with a portion of 
the total receptor population. The depression of the maximum response 
to 5-HT by methiothepin in this study could be due to the "hemi-
equilibrium" state as described by Paton and Waud (1967). 
It is apparent that the classification of drug and drug receptor 
depends on the measurement and comparison of parameters which depend 
only upon drug and receptor interaction. Obviously, an accurately 
determined pAg or Kg value for a competitive antagonist is extremely 
important in drug and drug receptor classification. A similar pAg or Kg 
value for a specific competitive antagonist against different agonists 
provides strong evidence that these agonists act on the same type of 
receptor. In this study, the dissociation constants of ketanserin vs. 
5-HT and the other serotonergic agonists studied are not significantly 
different in each tissue (Table 2), indicating that they act on the same 
type of 5-HT receptor, i.e., 5-HT2 receptor. Since the competitive 
antagonist possesses no intrinsic efficacy, its dissociation constant 
should be independent of receptor function, location, and animal 
species. In the present study, the dissociation constants of ketanserin 
vs. 5-HT and the other serotonergic agonists determined in the uterine 
artery and the umbilical vessels are comparable to each other and to 
those reported in other blood vessels (Cohen et al., 1983; Cohen, 1986; 
Humphrey, 1984; Van Nueten et al., 1981; Van Nueten et al., 1982). On 
the other hand, if an agonist-induced response is not antagonized by a 
specific competitive antagonist, it can be concluded that the respective 
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receptor is not presented. In this study, the potent and selective 5-
HT3 receptor antagonist MDL 72222 did not antagonize 5-HT-induced 
vasoconstriction in the uterine artery or in the umbilical vessels, 
indicating that the 5-HT3 receptor is not present in these tissues. 
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SUMMARY 
The effects of DOM on ovine maternal and fetal cardiovascular 
functions were investigated in the chronically instrumented 
ewe/fetus preparation. DOM was administrated intravenously to 
the ewe. Maternal and fetal heart rates and arterial blood 
pressures, maternal uterine artery blood flow and fetal 
umbilical artery blood flow were monitored. 
DOM produced dose-dependent increases in maternal and fetal 
blood pressure and a fall in heart rate. There was a linear 
relationship between the fall in the heart rate and the 
increase in the mean arterial blood pressure. When the 
arterial blood pressure increased 1 mmHg, maternal and fetal 
heart rates decreased 1.4 and 3.4 beats/min, respectively. 
Maternal uterine artery blood flow was dramatically decreased 
following DOM administration. A maximum reduction of 92% in 
the uterine artery blood flow was observed within 5 minutes 
after DOM injection at 20 /ig/kg. The uterine artery blood flow 
then went into a spasmodic pattern which lasted for more than 
an hour. The vascular resistance of the uterine artery 
increased by 6.8, 16.7 and 19.6 fold after DOM injection at 5, 
10 and 20 /ig/kg, respectively. 
Fetal intra-abdominal umbilical artery blood flow was also 
decreased following DOM administration. The maximal reduction 
in fetal intra-abdominal umbilical artery blood flow was 40% 
and the spasmodic pattern of blood flow after the 
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administration of DOM to the ewe was not observed. The maximum 
rise in the vascular resistance in the fetal umbilical artery 
was 260%. 
Maternal arterial blood P02, PCO2 and pH were not affected by 
DOM in the doses used in this study. Fetal arterial blood pH 
and Poj were decreased 20 minutes after maternal of DOM 
administration at 10 and 20 pg/kg. Pcog increased following 
DOM administration at 5, 10 and 20 pg/kg, while a reduction in 
BE was observed at the 20/ig/kg dose. 
Maternal administration of ketanserin (1 mg/kg) produced a fall 
in maternal arterial blood pressure from 99.7 mmHg to 69.4 
mmHg. The blood pressure returned to baseline within 25 
minutes. Fetal arterial blood pressure was decreased from 50.9 
mmHg to 43.8 mmHg. No significant decrease was observed in 
maternal and fetal heart rates to ketanserin. 
Maternal uterine artery blood flow and fetal umbilical artery 
blood flow decreased after maternal administration of 
ketanserin, which corresponded to the decrease in the maternal 
and fetal arterial blood pressures. Vascular resistances of 
the uterine artery and umbilical artery were not changed by 
ketanserin. 
Thirty minutes after ketanserin infusion, maternal and fetal 
arterial blood pressure responses to DOM were significantly 
inhibited. Significant increases in maternal and fetal 
arterial blood pressure were only observed at the higher dose 
of DOM (40 yug/kg). Maternal and fetal heart rates did not vary 
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significantly from the baseline at any dose of DOM after 
ketanserin infusion. 
9. The effects of DOM in reducing maternal uterine artery blood 
flow and fetal umbilical artery blood flow were significantly 
inhibited by ketanserin. Increases of vascular resistance in 
the uterine artery and umbilical artery to DOM were 
significantly inhibited by ketanserin. 
10. After ketanserin administration, changes in fetal arterial 
blood Pog, PCO2 and pH became more resistant to DOM. 
11. Isolated uterine and umbilical vessels from the ewe and fetus 
were used to explore in more detail agonist-antagonist receptor 
mechanisms. 
12. 5-HT and DOM potently constricted the maternal uterine artery 
and fetal umbilical artery and vein and these contractions were 
effectively antagonized by the selective 5-HT2 receptor . 
antagonist ketanserin. The dissociation constants (Kg) of 
ketanserin against 5-HT and DOM were not significantly 
different in each blood vessel and were comparable among the 
three different vessels. This indicates that constrictions 
produced by 5-HT and DOM are mediated by S-HTg receptors in 
these vessels. 
13. DOM was more potent than 5-HT in the uterine and umbilical 
vessels and possessed a greater affinity for S-HTg receptors in 
these vessels. In comparison to 5-HT, DOM was a full agonist 
in the uterine artery but was a partial agonist in the 
umbilical vasculature. 
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14. The dissociation constants of 5-HT, DOM and the other 
serotonergic agonists studied were not significantly different 
among the three different blood vessels examined, 
15. There was little or no 5-HT receptor reserve in the uterine and 
umbilical vessels. 
16. 8-OH-DPAT was a partial agonist in the uterine and umbilical 
vessels. It is unlikely that contractions produced by 8-OH-
DPAT were mediated by S-HT^a receptor, since the contractions 
were effectively blocked by ketanserin. The dissociation 
constant of ketanserin vs. 8-OH-DPAT was similar to that of 
ketanserin vs. 5-HT in each tissue and was comparable among the 
three different vessels. This indicates that the contractions 
produced by 8-OH-DPAT is mediated by S-HTg receptors. 
17. 2-MPP, TFMPP and mCPP were partial agonists in the umbilical 
vessels. However, they lacked (2-MPP), or had weak (TFMPP and 
mCPP) agonist activities on the uterine artery. These three 
compounds effectively blocked 5-HT-induced vasoconstriction in 
the ovine uterine artery. The dissociation constants (Kg) of 
these compounds as antagonists against 5-HT in the uterine 
artery were comparable to those Kp values of them as partial 
agonists in the umbilical vessels. 
18. 2-Methyl-5-HT was a partial agonist in the uterine and 
umbilical vessels. It was unlikely that the constriction 
produced by 2-methyl-5-HT was mediated by 5-HT3 receptors. The 
potent and selective 5-HT3 receptor antagonist MDL 72222 
(10"®M) did not antagonize the vasoconstriction produced by 
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2-methyl-5-HT. However, the selective S-HTg receptor 
antagonist ketanserin (10"®M) effectively antagonized the 
vasoconstriction produced by 2-methyl-5-HT. The dissociation 
constant of ketanserin vs. 2-methyl-5-HT was similar to that of 
ketanserin vs. 5-HT in each tissue and was comparable among the 
different vessels. This indicates that the vasoconstriction 
produced by 2-methyl-5-HT was mediated by 5-HT2 receptors. 
19. 5-HT-induced vasoconstriction was not antagonized by MDL 72222 
(10"®M to 10"®M) in the uterine and umbilical vessels, 
suggesting that S-HTg receptors were not present in these 
tissues. 
20. Activation of «-adrenergic receptors was not involved in the 
contraction produced by 5-HT in the uterine and umbilical 
vessels. 
21. The technique of uptake in the smooth muscle cells was 
employed to explore signal transduction coupling to the 5-HT 
receptors in the ovine uterine artery. 5-HT and DOM induced 
concentration-dependent rises in ^^Ca^^ uptake in the uterine 
artery. The EC50 of 5-HT in mediating Ca^^ influx was 
comparable to that which produced vasoconstriction in the same 
vessel. 
22. The Ca^^ influx evoked by 5-HT and DOM was antagonized by 
ketanserin and methiothepin. The dissociation constants (Kg) 
of ketanserin against 5-HT and DOM regarding their inducing a 
Ca^^ influx were not significantly different from those Kg 
values in the contraction studies. This indicates that the 
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influx induced by 5-HT and DOM was mediated by 5-HT2 
receptors in the uterine artery. 
23. MDL 72222 (2.5x10"%) did not antagonize 5-HT-induced Ca^"*" 
influx. This supports the assertion that S-HTg receptors are 
not present in this tissue. 
24. 5-HT-induced Ca^* influx was antagonized by D600 (2.5xlO"®M) and 
nifedipine (2.5x10"%) but not by amrinone (2.5x10"%). This 
suggests that the 5-HT-induced Ca^^ influx was mediated by 
voltage dependent calcium channels. 
271 
REFERENCES 
Altura, B. M., D. Malavlya, C. F. Reich and L. R. Orkin. 1972. Effects 
of vasoactive agents on isolated human umbilical arteries and 
veins. Am. J. Physiol. 222:345-355. 
Anderson, S. G., J. G. Still and F. C. Greiss. 1977. Differential 
reactivity of the gravid uterine vasculature: Effects of 
norepinephrine. Am. J. Obstet. Gynecol. 129:293-298. 
Andrade, R., R. C. Malenka and R. A. Nicoll. 1987. A G protein couples 
serotonin and GABAg receptors to the same channels in hippocampus. 
Science 234:1261-1265. 
Apperley, E. and P. P. A. Humphrey. 1986. The interaction of 5-
hydroxytryptamine and methysergide with methiothepin at " S-HT^ 
like" receptors in dog saphenous vein. Br. J. Pharmacol. 87:131. 
Apperley, E., P. P. A. Humphrey and G. P. Levy. 1976. Receptors for 5-
hydroxytryptamine and noradrenaline in rabbit isolated ear artery 
and aorta. Br. J. Pharmacol. 58:212-221. 
Ariens, E. J. and A. M. Simonis. 1976. Receptors and receptor 
mechanisms. Pages 3-27 in R. Saxena and R. P. Forsyth, eds. 
Beta-Adrenoceptor Blocking Agents. North-Holland Publishing 
Company, Amsterdam. 
Ariens, E. J., A. J. Beld, J. F. R. De Miranda, and A. M. Simonis. 
1979. The pharmacon-receptor-effector concept. A basis for 
understanding the transmission of information in biological 
systems. Pages 33-91 in R. D. O'Brien, ed. The Receptors, a 
Comprehensive treatise. Plenum Press, New York. 
Arvidsson, L. E., U. Hacksell, J. L. G. Nilsson, S. Hjorth, A. Carlsson, 
P. Lindberg, D. Sanchez and H. Wikstrom. 1981. 8-Hydroxy-l-(di-
n-propylamino)-tetralin, a new centrally acting 5-
hydroxytryptamine receptor agonist. J. Med. Chem. 24:921-923. 
Asarch, K. B., R. W. Ransom and J. C. Shin. 1985. [^H]-1-(2-(4-
aminophenyl) ethyl)-4-(3-trifluoromethylphenyl)piperzine: A 
selective radioligand for 5-HTu receptors in rat brain. Soc. 
Neurosci. Abstr. 11:1257. 
Assali, N. S. and C. R. Brinkman. 1972. The uterine circulation and 
its control. Pages 121-141 in L. D. Longo and H. Bartels, eds. 
Respiratory gas exchange and blood flow in the placenta. The 
National Institute of Child Health and Human Development, U. S. 
Department of Health, Education, and Welfare, Public Health 
Service, National Institute of Health, Bethesda, Maryland. 
272 
Assail, N. S., G, A, Bekey and L. W. Morrison. 1968. Fetal and 
neonatal circulation. Pages 52-143 in N, S. Assail, ed. Biology 
of Gestation. Vol. 2. Academic Press, New York. 
Baron, G. D., R. N. Speden and D. F. Bohr. 1972. Beta-adrenergic 
receptors in coronary and skeletal muscle arteries. Am. J. 
Physiol. 223:878-881. 
Bell, C. 1972. Autonomic nervous control of reproduction; Circulatory 
and other factors. Pharmacol. Rev. 24:657-736. 
Berrldge, M. J., C. P. Downes and M. P. Hanley. 1982. Lithium 
amplifies agonist dependent phosphatidyllnosltol responses in 
brain and salivary glands. Biochem. J. 206:589-595. 
Berta, P., J. Seguin, N. Vidal, J. Haiech, M. W. Mathieu and C. 
Chevlliard. 1986. Influence of Ca^^ on S-HTg- and Oi-Induced 
arterial contraction and phosphoinositlde metabolism. Eur. J. 
Pharmacol. 132:253-257. 
Besse, J. C. and R. F. Furchgott. 1976. Dissociation constants and 
relative efficacies of agonists acting on alpha adrenergic 
receptors in rabbit aorta. J. Pharmacol. Exp. Ther. 197:66-78. 
Bevan, J. A., R. D. Beven and S. M. Shreeve. 1989. Variable receptor 
affinity hypothesis. FASEB J. 3:1696-1704. 
Bjoro, K. and S. Stray-Pedersen. 1986. Characterization of the 
responses to serotonin and prostanoids in human umbilical arteries 
perfused in vitro. Scand. J. Clin. Lab. Invest. 184:85-90. 
Bolton, T. B. 1979. Mechanisms of action of transmitter and other 
substances on smooth muscle. Physiol. Rev. 59:606-718. 
Bouhelal, R., L. Smounya and J. Bockaert. 1988. S-HTm receptors are 
negatively coupled with adenylate cyclase in rat substantia nigra. 
Eur. J. Pharmacol. 151:189-196. 
Boura, A. L. A., B. Lyndall, T. A. Slnnathuray and W. A. W. Walters. 
1979. Release of prostaglandins during contraction of the human 
umbilical vein on reduction of temperature. Br. J. Pharmacol. 
65:360-362. 
Bradley, P. B., P. P. A. Humphrey and R. H. Williams. 1986a. Evidence 
for the existence of 5-hydroxytryptamlne receptors, which are not 
the S-HTg type, mediating contraction of isolated rabbit basilar 
artery. Br. J. Pharmacol. 87:3-4. 
Bradley, P. B., G. Engel, W. Feniuk, J. R. Fozard, P. P. A. Humphrey, D. 
W. Middlemlss, E. J. Mylecharane, B. P. Richardson and P. R. 
Saxena. 1986b. Proposals for the classification and nomenclature 
273 
of functional receptors for 5-hydroxytryptamine. 
Neuropharmacology 25:563-576. 
Brown, A. M., K. Morimoto, Y. Tsuda and D. L. Wilson. 1981. Calcium 
current-dependent and voltage-dependent inactivation of calcium 
channels in Helix asperse. J. Physiol. 320:193-218. 
Brown, E., D. A. Kendall and S. R. Nahorski. 1984. Inositol 
phospholipid hydrolysis in rat cerebral cortical slices: I. 
Receptor characterization. J. Neurochem. 42:1379-1387. 
Buccino, R. A., J. W. Covell, E. H. Sonnenblick and E. Braunwald. 1967. 
Effects of serotonin on the contractile state of the myocardium. 
Am. J. Physiol. 213:483-486. 
Capponi, A. M., P. D. Lew and M. B. Vallotton. 1987, Effect of 
serotonin on cytosolic free calcium in adrenal glomerulose and 
vascular smooth muscle cells. Eur. J. Pharmacol. 144:53-60. 
Carl, P. W. 1985. Serotonin and the preeclampsia eclampsia syndrome. 
Pages 147-154 in P. M. Vanhoutte, ed. Serotonin and the 
Cardiovascular System. Raven Press, New York. 
Carter, F. B., W. B. Cherny and C. Crenshaw. 1962. Serotonin studies 
in abnormal pregnancies-A preliminary report. Am. J. Obstet. 
Gynecol. 84:913. 
Chaichareon, D. P., J. H. Rankin and 0. J. Ginther. 1976. Factors 
which affect the relative contributions of ovaries and uterine 
arteries to the blood supply of reproductive organs in guinea 
pigs. Biol. Reprod. 15:281-290. 
Cheng, H. C., J. P. Long, C. F. Barfknecht and D. E. Nichols. 1973. 
Cardiovascular effects of 2,5-dimethoxy-4-methylamphetamine (DOM, 
STP). J. Pharmacol. Exp. Ther. 186:345-354. 
Cheung, C. Y. and R, A. Brace. 1987. Norepinephrine regulation of 
fetal heart rate: Multiple mechanisms of action. Am. J. Obstet. 
Gynecol, 156:1254-1259. 
Cheung, C. Y. and R. A. Brace. 1988. Norepinephrine effects on fetal 
cardiovascular and endocrine systems. Am. J. Physiol. 254;H734-
H741. 
Chez, R. A., R. A, Ehrenkranz, G, K. Oakes, A. M. Walker, L. A. 
Hamilton, Jr., S. C. Brennan and M. K. McLanghlin. 1978. Effects 
of adrenergic agents on ovine umbilical and uterine blood flows. 
Pages 1-17 in L. D. Longo and D. D. Reneau, eds. Fetal and 
Newborn Cardiovascular Physiology. Vol. 2. Garland STPM Press, 
New York. 
274 
Clark, K. E. , H. A. Baker, R. Bhatnager, D. E. Van Orden and M J. Brody. 
1978. Prevention of estrogen-induced uterine hyperemia by a-
adrenergic receptor-blocking agents. Endocrinology 122:903-909. 
Clark, K. E., E. G. Mills, T, E. Otte and S. J. Stys. 1980. Effect of 
serotonin on uterine blood flow in pregnant and nonpregnant sheep. 
Life Sci. 27:2655-2661. 
Clement, D., P. M. Vanhoutte and I. Leusen, 1969. Capacitance 
reactions of isolated veins to monoamines and acetylcholine. 
Arch, Int. Physiol, Biochem, 77:73-87, 
Cohen, M, L,, R, W, Fuller and K, S, Wiley. 1981. Evidence for S-HTg 
receptors mediating contraction in vascular smooth muscle, J, 
Pharamcol, Exp, Ther, 218:421-425, 
Cohen, R, A. 1986. Contraction of isolated canine coronary arteries 
persistent to S2-serotonergic blockade. J. Pharmacol. Exp. Ther. 
237:548-552. 
Cohen, R. A., J. T. Shepherd and P. M. Vanhoutte. 1983, 5-
Hydroxytryptamine can mediate endothelivim-dependent relaxation of 
coronary arteries. Am, J, Physiol, 245:H1077-H1080. 
Cohen, W. R., G. J, Pisecki, H, E, Cohn, J, B, Young and B. T. Jackson. 
1984, Adrenal secretion of catecholamines during hypoxemia in 
fetal lambs. Endocrinology 114:383-390, 
Conn, P, J. and E. Sanders-Bush. 1984. Selective S-HTg antagonists 
inhibit serotonin-stimulated phosphatidylinositol metabolism in 
cerebral cortex. Neuropharmacology 23:993-996. 
Conn, P. J. and E. Sanders-Bush. 1987. Relative efficacies of 
piperazines at the phosphoinositide hydrolysis-linked serotonergic 
(5-HT2 and 5-HTic) receptors. J. Pharmacol, Exp, Ther, 242:552-
557, 
Conn, P, J., E. Sanders-Bush, B. J. Hoffman and P. R. Hartig. 1986. A 
unique serotonin receptor in choroid plexus is linked to 
phosphatidylinositol turnover. Proc. Natl. Acad. Sci. U. S. A. 
83:4086-4088. 
Coughlin, S, R,, M. Moskowitz and L, Levine. 1984. Identification of a 
serotonin type 2 receptor liked to prostacyclin synthesis in 
vascular smooth muscle cells. Biochem. Pharmacol. 33:692-695. 
Curro, F, A., S. Greenberg, T. S. Verbeuren and P. M. Vanhoutte. 1978. 
Interaction between alpha-adrenergic and serotonergic activation 
of canine saphenous veins. J. Pharmacol. Exp. Ther. 207:936-949. 
Dahlstrom, A and K. Fuxe. 1964. Evidence for the existence of 
275 
monoamine-containing neurons in the central nervous system. I. 
Demonstration of monoamines in the cell bodies of brain stem 
neurons. Acta Physiol. Scand. 62:1-55. 
de Coureelles, D., J. E, Leysen, F. De Clarck, H. Van Belle and P. A. 
Janssen. 1985. Evidence that phospholipid turnover is the signal 
transducing system coupled to serotonin-S2 receptor sites. J. 
Biol. Chem. 260:7603-7608, 
De Vivo, M. and S. Maayani. 1986. Characterization of the 5-
hydroxytryptamine^A receptor-mediated inhibition of forskolin-
stimulated adenylate cyclase activity in guinea pig and rat 
hippocampal membranes. J. Pharmacol. Exp. Ther. 238:248-253. 
Dilts, P. V. Jr., C. R. Brinkman, III, T. H. Kirschbaum and N. S. 
Assali. 1969. Uterine and systemic hemodynamic 
interrelationships and their responses to hypoxia. Am. J. Obstet. 
Gynecol. 103:138-157. 
Dompert, W. U,, T. Glaser and J. Traber. 1985. ^H-TVX Q 7821: 
Identification of S-HT^ binding sites as target for a novel 
putative anxiolytic. Naunyn-Schmiedeberg's Arch. Pharmacol. 
328:467-470. 
Donatsch, P., G. Engel, B. P. Richardson and P. A. Stadler. 1984. ICS 
205-930: A highly selective and potent antagonist at peripheral 
neuronal 5-hydroxytryptamine (5-HT) receptors. Br. J. Pharmacol. 
81:34-40. 
Doyle, V. M., J. A. Creba, U. T. Ruegg and D. Hoyer. 1986. Serotonin 
increses the production of inositol phosphates and mobilizes 
calcium via 5-HT2 receptor in A^r^ smooth muscle cells. Arch. 
Pharmacol. 333:98-102. 
Dyer, D. C. 1970a. The pharmacology of isolated sheep umbilical cord 
blood vessels. J. Pharmacol. Exp. Ther. 175:565-570. 
Dyer, D. C. 1970b. An investigation of the mechanism of potentiation 
by cocaine of responses to serotonin in sheep umbilical blood 
vessels. J. Pharmacol. Exp. Ther. 175:571-576. 
Dyer, D. C. 1974. Evidence for the action of d-lysergic acid and 
diethylamide, mescaline and bufotenine on 5-hydroxytryptamine 
receptors in umbilical vasculature. J. Pharmacol. Exp. Ther. 
188:336-341. 
Dyer, D. C. 1983. Interaction of serotonergic agonists and antagonists 
on umbilical arteries. Pharmacologist 25:137. 
Dyer, D. C. and E. D. Gough. 1971. Comparative actions of selected 
vasoactive drugs on isolated human uterine arteries. Am. J. 
276 
Obstet. Gynecol. 111:820-825. 
Dyer, D. C. and L. J. Weber. 1971. 5-Hydroxytryptamine and monoamine 
oxidase in adult and foetal sheep blood vessels. J. Pharm. 
Pharmacol. 23:549-550. 
Dyer, D. C., D. E. Nichols, D. B. Rusterholz and C. F. Burfknecht. 
1973. Comparative effects of steroisomers of psychotomimetic 
phenylisopropylamines. Life Sci. 13:885-896. 
Eberhard, D. A. and R. W. Holz. 1987. Cholinergic stimulation of 
inositol phosphate formation in bovine adrenal chromaffin cells: 
Distinct nicotinic and muscarinic mechanisms. J. Neurochem. 
49:1634-1643. 
Edvinsson, L., A. Degueurce, D. Duverger, E. T. Mackoenzie and B. 
Scatton. 1983. Central serotonergic nerves project to the pial 
vessels of the brain. Nature (Lond.) 306:55-57. 
Engel, G., M. Gothert, E. Muller-Schweinitzer, E. Schlicker, L. Sistonen 
and P. A. Stadler. 1983. Evidence for common pharmacological 
properties of ®H-5-hydroxytryptamine binding sites, presynaptic 5-
hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 
5-hydroxytryptamine receptors on sympathetic nerves. Naunyn-
Schmiedeberg's Arch. Pharmacol. 324:116-120. 
Engel, G., M. Gothert, D. Hoyer and K. Hillenbrand. 1986. Identify of 
inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in 
the rat brain cortex with 5-HTib binding sites. Naunyn-
Schmiedeberg's Arch. Pharmacol. 332:1-7. 
Eyre, P. 1975. Atypical tryptamine receptors in sheep pulmonary vein. 
Br. J. Pharmacol. 55:329-333. 
Fargin, A., J. R. Raymond, M. J. Lohse, B. K. Kobilka, M. G. Caron and 
R. J. Lefkowitz. 1988. The genomic clone G-21 which resembles a 
beta-adrenergic receptor sequence encodes the S-HT^^ receptor. 
Nature (London) 335:358-360. 
Feniuk, W. 1984. An analysis of 5-hydroxytryptamine receptors 
mediating contraction of isolated smooth muscle. 
Neuropharmacology 23:1467-1472. 
Feniuk, W., P. P. A. Humphrey and A. D. Watts. 1983. 5-
Hydroxytryptamine-induced relaxation of isolated mammalian smooth 
muscle. Eur. J. Pharmacol, 96:71-78. 
Feniuk, W., P. P. A. Humphrey and A. D. Watts. 1984. 5-
Carboxamidotryptamine-a potent agonist at 5-hydroxytryptamine 
receptors mediating relaxation, Br. J. Pharmacol. 82:209-215. 
277 
Feniuk, W., P. P. A. Humphrey, M. J. Perren and A. P. Watts. 1985. A 
comparison of 5-hydroxytryptamine receptors mediating contraction 
in rabbit aorta and dog saphenous vein. Evidence for different 
receptor types obtained by use of selective agonists and 
antagonists. Br. J. Pharmacol. 86;697-704. 
Fiscus, R. R. and D. C. Dyer. 1981. Cyclic nucleotide and 
contractility in human and sheep umbilical arteries. Eur. J. 
Pharmacol. 73:283-291. 
Fiscus, R. R. and D. C. Dyer. 1982. Effects of indomethacin on 
contractility of isolated human umbilical artery. Pharmacology 
24:328-336. 
Fisher, S. K. and B. W. Agranoff. 1981. Enhancement of the muscarinic 
synaptosomal phospholipid labeling effect by the ionophore A23187. 
J. Neurochem. 37:968-977. 
Ford, S. P., L. J. Weber and F. Stormshak. 1977. Role of estradiol-17 
and progesterone in regulating constriction of ovine uterine 
arteries. Biol. Reprod. 17:480-483. 
Forster, C. and E. T. Whalley. 1982. Analysis of the 5-
hydroxytryptamine-induced contraction of the human basilar 
arterial strip compared with the rat aortic strip in vitro. 
Naunyn-Schmiedeberg's Arch. Pharmacol. 319;12-17. 
Fozard, J. R. 1984a. MDL 72222, a potent and highly selective 
antagonist at neuronal 5-hydroxytryptamine receptors Naunyn-
Schmiedeberg's Arch. Pharmacol. 326:36-44. 
Fozard, J. R. 1984b. Neuronal 5-HT receptors in the periphery. 
Neuropharmacology 23:1473-1486. 
Fozard, J. R. 1987. 5-HT: The enigma variations. Trends Pharmacol. 
Sci. 8:501-506. 
Fozard, J. R., A. T. M. Mobarok Ali and G. Newgrosh. 1979. Blockade of 
serotonin receptors on autonomic neurones by (-)-cocaine and some 
related compounds. Eur. J. Pharmacol. 59:195-210. 
Friedman, W. F. 1973. The intrinsic physiologic properties of the 
developing heart. Pages 21-54 in W. F. Friedman, M. Lesch and E. 
M. Sonnenflick, eds. Neonatal Heart Disease. Grune and Stratton, 
New York. 
Fu, L. H. W. and N. Toda. 1983. Analysis of the contractile response 
to serotonin and tryptamine of isolated dog cerebral, femoral and 
mesenteric arteries. Jpn. J. Pharmacol. 33:473-480. 
Fujiwara, S., T. Itoh and H. Suzuki. 1982. Membrane properties and 
278 
excitatory neuromuscular transmission in the smooth muscle of dog 
cerebral arteries. Br. J. Pharmacol. 77:197-208. 
Fuller, E. 0., J. W, Manning and D. 0. Nutter. 1978. A perfused 
uterine preparation for the study of uterine and fetal physiology. 
Pages 421-435 in L. D, Longo and D. P. Reneau, eds. Fetal and 
Newborn Cardiovascular Physiology. Vol. 2. Garland STPM Press, 
New York. 
Fuller, E. 0., P. M. Galletti, J. W. Manning and T. F. Fitzerald. 1979. 
Responses of the uterine circulation to sympathetic nerve 
stimulation. J, Dev. Physiol. 1:209-218. 
Fuller, R. W., W. R, Mason and B. B. Molloy. 1980, Structural 
relationships in the inhibition of [^H]-serotonin binding to rat 
brain membranes in vitro by 1-phenyl-piperazines. Biochem. 
Pharmacol. 29:833-839. 
Furchgott, R. F. 1966. The use of y3-haloalkylamines in the 
differentiation of receptors and in the determination of 
dissociation constants of receptor-agonist complexes. Pages 21-
55 in N, J. Harper and A. B. Simmonds, eds. Advances in Drug 
Research. Vol. 3. Academic Press, London. 
Furchgott, R. F. 1972. The classification of adrenoceptors (adrenergic 
receptors). An evaluation from the standpoint of receptor theory. 
Pages 283-335 in H. Blaschko and E, Muscholl, eds. Handbook of 
Experimental Pharmacology, Catecholamines. Vol. 33. Springer-
Verlag, New York. 
Furchgott, R. F., A. Jurkiewicz and N, H. Jurkiewicz. 1973, Antagonism 
of propranolol to isoproterenol in guinea pig trachea: Some 
cautionary findings. Pages 295-300 in E. Usdin and S, H, Snyder, 
eds. Frontiers in Catecholamine Research, Pergamon Press Inc,, 
Elmsford, New York, 
Gaddum, J, H, and Z, P, Picarelli, 1957, Two kinds of tryptamine 
receptors, Br, J, Pharmacol, 12:323-328, 
Gautieri, R, F, and H, P, Ciuchta, 1962, Effect of certain drugs on 
perfused human placenta: I, Narcotic analogesies, serotonin and 
relaxin, J, Pharm. Sci. 51:55-58. 
Gershon, M. D., C. F. Dreyfus, V, M. Pickel, T. H. Joh and D, J. Reis. 
1977, Serotonergic neuron in the peripheral nervous system: 
Identification in gut by immunohistochemical localization of 
tryptophan hydroxylase, Proc, Natl, Acad, Sci, U, S, A, 74:3086-
3089, 
Glennon, R, A, 1987, Central serotonin receptors as target for drug 
research. J. Med. Chem, 30:1-12. 
279 
Glennon, R. A. and E. C. Mack. 1978. Serotonin receptor affinities of 
several hallucinogenic phenalkylamine and N,N-dimethyItryptamine 
analogues. J. Med. Chem. 21:822-905. 
Glennon, R. A. and R. A. Rosecrans. 1983. Antagonism of the effects of 
the hallucinogen DOM and the purported 5-HT agonist quipazine by 
S-HTg antagonists. Eur. J. Pharmacol. 91:189-195. 
Glennon, R. A., S. M. Liebowitz and G. M. Anderson. 1980. Serotonin 
receptor affinities of psychoactive phenalkylamine analogs. J. 
Med. Chem. 23:294-301. 
Glennon, R. A., R. Young, F, Bennington and R. D. Morin. 1982. 
Behavioral and serotonin receptor properties of 4-substituted 
derivatives of the hallucinogen l-(2,5-dimethoxyphenyl)-2-
aminopropane. J. Med. Chem. 25:1982-1989. 
Glennon, R. A., R. Young and J. A. Rosecrans. 1983. Antagonism of the 
effects of the hallucinogen DOM and the purported 5-HT agonist 
quipazine by 5-HT2 antagonists. Eur. J. Pharmacol. 91:189-196. 
Glennon, R. A., M. Titeler and J. D. Mckenney. 1984. Evidence for 5-
HTg involvement in the mechanism of action of hallucinogenic 
agents. Life Sci. 35:2505-2511. 
Godfraind, T. 1983. Actions of nifedipine on calcium fluxes and 
contraction in isolated rat arteries. J. Pharmacol. Exp. Ther. 
224:443-450. 
Goldberg, N. D. 1975. Cyclic nucleotide and cell function. Pages 185-
202 in G. Weissmann and R. Claiborne, eds. Cell Membranes: 
Biochemistry, Cell Biology and Pathology. H. P. Publishing, New 
York. 
Gozlan, H., S, El Mestikawy, L. Pichat, J. Glowinski and M. Hamon. 
1983. Identification of presynaptic serotonin autoreceptors using 
a new ligand: %-PAT. Nature 305:140-142. 
Guenther, A. E., A. J. Conley, D. E. Van Orden, D. B. Farley and S. P. 
Ford. 1988. Structural and mechanical changes of uterine 
arteries during pregnancy in the pig. J. Anim. Sci. 66:3144-
3152. 
Hahim, I., J. M. Robson and J. B. Senior. 1966. The 5-
hydroxytryptamine content of the placenta, foetus, and some 
maternal tissues during pregnancy in the rat. Br. J. Pharmacol. 
26:237-244. 
Hall, M. D., S. El Meatikawy, M. B. Emerit, L. Pichat, M. Hamon and H. 
Gozlan. 1985. [^H]8-hydroxy-2-(Di-n-propylamino)tetralin binding 
to pre- and post-synaptic 5-hydroxytryptamine sites in various 
280 
regions of the rat brain. J, Neurochem. 44:1685-1696. 
Hartig, P. R. 1989. Molecular biology of 5-Ht receptors. Trends 
Pharmacol. Sci. 10:64-69. 
Heuring, R. E. and S. J. Peroutka. 1987. Characterization of a novel 
^H-5-hydroxytryptamine binding site subtype in bovine brain 
membranes. J. Neurosci. 7:894-903. 
Heuring, R. E., J. R. Schlegel and S. J. Peroutka. 1986. Species 
variation in RU 24969 interactions with non-SHT^k binding sites. 
Eur. J. Pharmacol. 122:279-282. 
Hoffman, B. J., M. D. Karpa, J. R. Lever and P. R. Hartig. 1985. N^-
methyl-2-^"l LSD MIL), a preferred ligand for serotonin 5-
HT2 receptors. Eur. J. Pharmacol. 110:147-148. 
Hollenberg, N. K. 1988. Serotonin and vascular responses. Ann. Rev. 
Pharmacol. Toxicol. 28:41-59. 
Hoyer, D. 1988. Molecular pharmacology and biology of S-HT^c 
receptors. Trends Pharmacol. Sci. 9:89-94. 
Hoyer, D., G. Engel and H. 0. Kalkman. 1985. Molecular pharmacology of 
5-HTi, and S-HTg recognition sites in rat and pig brain membrane: 
Radioligand binding studies with [^H]5-HT, [^H]8-0H-DPAT, (-) 
[^"H] iodocyanopindolol, [®H]mesulergine and [®H]ketanserin. Eur. 
J. Pharmacol. 118:13-23. 
Hoyer, D., A. Pazos, A. Probst and J. M. Palacios. 1986. Serotonin 
receptors in the human brain: I. Characterization and 
autoradiographic localization of S-HT^^ recognition sites. 
Apparent absence of 5-HTib recognition sites. Brain Res. 376:85-
96. 
Huang, J. T. and B. T. Ho. 1972. The pressor action of 2,5-dimethoxy-
4-me thy1-amphetamine in rats. J. Pharm. Pharmacol. 24:656-657. 
Humphrey, P. P. A. 1984. Periphral 5-hydroxytryptamine receptors and 
their classification. Neuropharmacology 91:189-196. 
Hurwitz, L., L. J. McGuffee, S. A. Little and H. Blumberg. 1980. 
Evidence for two distinct types of potassivun-activated calcium 
channels in an intestinal smooth muscle. J. Pharmacol. Exp. Ther. 
214:574-580. 
Hurwitz, L., L. J. McGuffee, P. M. Smith and S. A. Little. 1982. 
Specific inhibition of calcium channels by calcium ions in smooth 
muscler. J. Pharmacol. Exp. Ther. 220:382-388. 
Iwamoto, H. S., A. M. Rudolph, B. L. Mirkin and L. C. Keil. 1983. 
281 
Circulatory and humoral responses of sympathetomized fetal sheep 
to hypoxemia. Am. J. Physiol. 245;H767-H772. 
Janis, R. A. and D. J. Triggle. 1983, New developments in Ca^"*" channel 
antagonists. J. Med. Chem. 26:775-785. 
Jones, C. T. and J. W. K. Ritchie. 1983. The effects of adrenergic 
blockade on fetal response to hypoxia. J. Dev. Physiol. 5:211-
222. 
Jones, J. B. and A. Rowesel. 1973. Fetal 5-hydroxytryptamine levels in 
late pregnancy. Br. J. Obstet. Gynecol. 80:687. 
Julius, D., A. B. MacDermott, R. Axel and T. Jessel. 1988. Molecular 
characterization of a functional cDNA encoding the serotonin^; 
receptor. Science 241:558-564. 
Kalkman, H. 0., Y. M. Harms, E. M. Van Gelderen, H. D. Batink, P. B. M. 
W. M, Timmermans and P. A. Van Zwieten. 1983, Hypertensive 
activity of serotonin antagonists; Correlations with a^-
adrenoceptor and serotonin receptor blockade. Life Sci. 32:1499-
1505. 
Kaumann, A. J. 1983. A classification of heart serotonin receptors. 
Naunyn-Schmiedeberg's Arch. Pharmacol. 322(Suppl.):R42. 
Kenakin, T. P. 1980. Effects of equilibration time on the attainment 
of equilibrium between antagonists and drug receptors. Eur, J. 
Pharmacol. 66: 295-306, 
Kenakin, T, P. 1984. The classification of drugs and drug receptors in 
isolated tissues. Pharmacol. Rev. 36:165-222. 
Kenakin, T. P, and D, Beek, 1980, Is prenalterol (H133/80) really a 
selective beta-1 adrenoceptor agonist? Tissue selectivity 
resulting from differences in stimulus-response relationships, J. 
Pharmacol, Exp, Ther, 213;409-412, 
Kenakin, T. P. and D. Beek. 1982. A quantitative analysis of histamine 
H^-receptor-mediated relaxation of rabbit trachea. J. Pharmacol. 
Exp. Ther. 220:353-357. 
Kendall, D. A. and S. R. Nahorski. 1984, Inositol phospholipid 
hydrolysis in rat cerebral cortical slices: II, Calcium 
requirement, J, Neurochem, 42:1388-1394, 
Kendall, D, A, and S, R, Nahorski, 1985, Dihydropyridine calcium 
channel activators and antagonists influence depolarization-
evoked inositol phospholipid hydrolysis in brain. Eur. J. 
Pharmacol. 115:31-36. 
282 
Kilpatrick, G. J., B. J. Jones and M. B. Tyers. 1987. Identification 
and distribution of 5-HT3 receptors in rat brain using radioligand 
binding. Nature (Lond.) 330:746-748. 
Klinge, E., 0. Pentilla and A. Tissari. 1964. The content of 5-
hydroxytryptamine in human uterine and placenta tissue, and their 
5-hydroxytryptophan decarboxylase and monoamine oxidase activities 
in normal and toxemic pregnancies. Acta Obstet. Gynecol. Scand. 
43:107-115. 
Kristic, M. K. and D. Djurkovic. 1980. Analysis of cardiovascular 
responses to central administration of 5-hydroxytryptamine in 
rats. Neuropharmacology 19:455-463. 
Krupp, P. and I, Krupp. 1960. Serotonin and toxemia of pregnancy. 
Obstet. Gynecol. 15:237 
Kuhn, D. M., W. A. Wolf and W. Lovenberg. 1980. Review of the role of 
the central serotonergic neuronal system in blood pressure 
regulation. Hypertension 2:243-255. 
Kuno, M. and P. Gardner. 1987. Ion channels activated by inositol 
1,4,5 -triphosphate in plasma membrane of human T-lymphocytes. 
Nature 326:301-304. 
Kwong, L. L., E. R. Smith, J. M. Daridson and S. J. Peroutka. 1986. 
Differential interactions of "prosexual" drugs with 5-
hydroxytryptamine^^ and alphlg-adrenergic receptors. Behav. 
Neurosci. 100:664-668. 
Lambert, G. A., E. Friedman, E. Buchweitz and S. Gershon. 1978. 
Involvement of 5-hydroxytryptamine in the central control of 
respiration, blood pressure and heart rate in the anesthetized 
rat. Neuropharmacology 17:807-813. 
Lebowitz, E. A., J. S, Novick and A. M. Rudolph. 1972. Development of 
myocardial sympathetic innervation in the fetal lamb. Pediat. 
Res. 6:887-893. 
Lees, M. M,, S. H. Taylor, D. B. Scott and M. G. Kerr, 1967. A study 
of cardiac output at rest throughout pregnancy. J. Obstet. 
Gynecol. Br. Commonw. 74:319-328. 
Lesinski, J., S. T. Kurzepa and E. Samojllk. 1967. Influence of 
phenelzine on 5-hydroxytryptamine levels in rat placenta and 
fetus. Am. J. Obstet. Gynecol. 97:249-253. 
Lester, H. A. 1988. Heterologous expression of excitability proteins: 
Route to more specific drugs? Science 241:1057-1063. 
Lewis, A. B., W. W. Evans and W. Sischo. 1982. Plasma catecholamine 
283 
responses to hypoxemia in fetal lambs. Biol. Neonate 41:115-122. 
Lewis, A. B., W, J. Wolf and W. Sischo. 1984. Cardiovascular and 
catecholamine responses to successive episodes of hypoxemia in the 
fetal. Biol. Neonate 45:105-111. 
Leysen, J. E., F. Awouters, L. Kenis, P. M. Laduron, J. Vanderberg and 
P. A. J. Janssen. 1981. Receptor binding profile of R 41468, a 
antagonist at S-HTg receptors. Life Sci. 28:1015-1022. 
Leysen, J. E., C. J. E. Niemegeers, J. M. Van Nueten and P. M. Laduron. 
1982. (®H) Ketanserin (R 41468), a novel selective ^H-ligand for 
serotoning receptor binding sites. Binding properties, brain 
distribution, and functional role. Mol. Pharmacol. 21:301-314. 
Leysen, J. E., D. de Chaffoy de Courcelles, F. De Clarck, C. J. E. 
Niemegeers and J. M. Van Nueten. 1984. Serotonin Sg receptor 
binding sites and functional correlates. Neuropharmacology 
23:1493-1501. 
Lyon, R. A., K, H. Davis and M. Titeler. 1987. ®H-DOB (4-bromo-2,5-
dimethoxyphenylisopropylamine) labels a guanyl nucleotide-
sensitive state of cortical 5-HT2 receptors. Mol. Pharmacol. 
31:194-199. 
Maayani, S., C. W. Wilkinson and J. S. Stollak. 1984. 5-
Hydroxytryptamine receptor in rabbit aorta:Characterization by 
butyrophenone analogs. J. Pharmacol. Exp. Ther. 229:346-350. 
Maggi, C. A., S. Manzini and A. Meli. 1983. Contribution of cellular 
and extracellular Ca^"*" during 5 -hydroxytryptamine - induced 
contractions of rabbit ear artery. Eur. J. Pharmacol. 94:251-
260. 
Mak, K. K. -W., N. M. Gude, W. A. W. Walters and A. L. A. Boura. 1984. 
Effects of vasoactive autacoids on the human umbilical-fetal 
placental vasculature. Br. J. Obstet. Gynecol. 91:99-106. 
Maloney, J. E., J. Cannata, M. H. Dowling, W. Else and B. Ritchie. 
1977. Baroreflex activity in conscious fetal and newborn lambs. 
Biol. Neonate 31:340-350. 
Marcinkiewicz, M., D. Verge, H. Gozlan, L. Pitchat and M. Hamon. 1984. 
Autoradiographic evidence for the heterogeneity of S-HT^ sites in 
the rat brain. Brain Res. 291:159-163. 
Markstein, R. , D. Hoyer and G. Engel. 1986. 5receptors mediate 
stimulation of adenylate cyclase in rat hippocampus. Naunyn-
Schmiedeberg's Arch. Pharmacol. 333:335-341. 
Martensson, L. and A. M. Carter. 1982. Effect of norepinephrine on 
284 
circulation in the genital tract of early and late pregnant guinea 
pigs. J. Reprod. Fertil. 66:23-29. 
Martin, L. L. and E. Sanders-Bush. 1982. Comparison of the 
pharmacological characteristics of S-HTj and 5-HT2 binding sites 
with those of serotonin autoreceptors which modulate serotonin 
release. Naunyn-Schmiedeberg's Arch. Pharmacol. 321:165-170. 
Mawe, G. M., T. A. Branchek and M. D. Gershon. 1986. Peripheral neural 
serotonin receptors: identification and characterization with 
specific antagonists and agonists. Proc. Natl. Acad. Sci. U. S. 
A. 83:9799-9803. 
McGrath, J. C., S. J. MacLennan and K, Stuart-Smith. 1985. 
Characterization of the receptor mediating contraction of human 
umbilical artery by 5-hydroxytryptamine. Br. J. Pharmacol. 
84:199-202. 
Meisheri, K. D., D. Hwang and C. VanBreemen. 1981. Evidence for two 
separate Ca^^ pathways in smooth muscle plasmalemma. J. Membr. 
Biol. 59:19-25. 
Meschia, G. 1983. Circulation to female reproductive organs. Pages 
241-269 in J. T. Shepherd and F. M. Abboud, eds. Handbook of 
Physiology, Section 2: Cardiovascular System. Vol. 3, Part 1. 
American Physiology Society, Bethesda, Maryland. 
Molderings, G. J,, K. Fink, E. Schlicker and M. Gothert. 1987. 
Inhibition of noradrenaline release via presynaptic 5-HTiB 
receptors of the rat vena cava. Naunyn-Schmiedeberg's Arch. 
Pharmacol. 336:245-250. 
Moll, W. and R. Gotz. 1985. Pressure-diameter curves of mesometrial 
arteries of gniuea pigs demonstrate a non-muscular, oestrogen-
inducible mechanism of lumen regulation. Eur. J. Physiol. 
404:332-338. 
Moon, S. L. and D. P. Taylor. 1985. In vitro autoradiography of %-
busprione and ®H-2-deoxyglucose after buspirone administration. 
Soc. Neurosci. Abstr. 11:114. 
Morishita, H. 1979. Distribution and characterization of the 
adrenoceptors in dog coronary arteries. Arch. Int. Pharmacodyn. 
Ther. 239:195-207. 
Nair, X. and D. C. Dyer. 1973. Effects of metabolic inhibitors and 
oxygen on responses of human umbilical arteries. Am. J. Physiol. 
225:1118-1122. 
Nakaki, T., B. L. Roth, D. M. Chuang and E. Costa. 1985. Phasic and 
tonic components in 5-HT2 receptor-mediated rat aorta contraction: 
285 
Participation of Ca^"*" channels and phospholipase C. J. Pharmacol. 
Exp. Ther. 238:480-485. 
Neale, R. F., S. L. Fallon, W. C. Boyar, J. W. F. Wasley, L. L. Martin, 
G. A. Stone, B. S. Glaeser, C. W. Sinton and M. Williams. 1987. 
Biochemical and pharmacological characterization of COS 12066B, a 
selective serotonin-IB agonist. Eur. J. Pharmacol. 136:1-9. 
Neijt, H. C., I. J. te Duits and H. P. M. Vijverberg. 1988. 
Pharmacological characterization of serotonin S-HTg receptor 
mediated electrical response in cultured mouse neuroblastoma 
cells. Neuropharmacology 27:301-307. 
Neild, T. 0. 1987. Actions of neuropeptide Y on innervated and 
denervated rat tail arteries. J. Physiol. 386:19-30. 
Norman, A. B., G. Battaglia, A. L. Morrow and I. Creese. 1985. WB 
4101 labels serotonin receptors in rat cerebral cortex. Eur. 
J. Pharmacol. 106:461-462. 
Oriowo, M. A., J. A. Sevan and R. D, Sevan. 1989. Variation in 
sensitivity of six cat and six rat arteries to norepinephrine can 
be related to deferences in agonist affinity and receptor reserve. 
J. Pharmacol. Exp. Ther, 251:16-20. 
Pappano, A. J. 1977. Ontogenetic development of autonomic 
neuroeffector transmission and transmitter reactivity in embryonic 
and fetal hearts. Pharmacol. Rev. 29:3-33. 
Park, M. K., C. Rishor and D. C. Dyer. 1972. Vasoactive action of 
prostaglandins and serotonin on isolated human umbilical arteries 
and veins. Can. J. Physiol. Pharmacol, 50:393-399. 
Paton, W, D. M. and D, R. Waud. 1967. The margin of safety of 
neuromuscular transmission. J. Physiol. (London) 191:59-90. 
Pazos, A. and J. M, Palacios. 1985. Quantitative autoradiographic 
mapping of serotonin receptors in the rat brain. I. Serotonin-1 
receptors. Brain Res. 346:205-230. 
Pazos, A, D. Hoyer and J. M. Palacios. 1984a. Mesulergine, a selective 
serotonin-2 ligand in the rat cortex, does not label these 
receptors in porcine and human cortex: Evidence for species 
differences in brain serotonin-2 receptors. Eur. J. Pharmacol. 
106:531-538. 
Pazos, A., D. Hoyer and J. M. Palacios. 1984b. The binding of 
serotonergic ligands to the porcine choroid plexus: 
Characterization of a new type of serotonin recognition site. 
Eur. J. Pharmacol. 106:539-546. 
286 
Pedigo, N. W., H. I. Yamamura and D. L. Nelson. 1981. Discrimination 
of multiple [%]5-hydroxytryptamine binding sites by the 
neuroleptic spiperone in rat brain. J. Neurochem. 36:220-226. 
Penfold, P., L. Drury, R. Simmonds and F, E. Hytten. 1981. Studies of 
a single placental cotyledon in vitro; I The preparation and its 
viability. Placenta 2:149-154. 
Peroutka, S. J. 1984. 5-HTi receptor sites and functional correlates. 
Neuropharmacology 23:1487-1492. 
Peroutka, S. J. 1986. Pharmacological differentiation and 
characterization of S-HT^g, and S-HT^c binding sites in rat 
frontal cortex. J. Neurochem. 47:529-540. 
Peroutka, S. J. 1988. 5-Hydroxytryptamine receptor subtypes. Ann. 
Rev. Neurosci. 11:45-60. 
Peroutka S. J., and S. H. Snyder. 1979. Multiple serotonin receptors: 
differential binding of [®H]5-hydroxytryptamine, [gH]lysergic acid 
diethylamide and [®H]spiroperidol. Mol. Pharmacol. 16:687-699. 
Peroutka, S. J., R. M. Leboritz and S. H, Snyder. 1981. Two distinct 
central serotonin receptors with different physiological 
functions. Science 212:827-829. 
Peroutka, S. J., S. Huang and G. S. Allen. 1986. Canine basilar artery 
contractions mediated by 5-hydroxytryptamine^^ receptors. J. 
Pharmacol. Exp. Ther. 237:901-906. 
Peroutka, S. J., A. Hamik, M. A. Harrington, A. J. Hoffman, C. A. 
Mathis, P. A. Pierce and S. S. H. Wang. 1988. (R)-(-)-["Br]4-
bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine 
binding site in brain membranes. Mol. Pharmacol. 34:537-542. 
Pierce, P. A. and S. J. Peroutka. 1988. Antagonism of 5-
hydroxytryptamineg receptor-mediated phosphatidylinositol turnover 
by d-lysergic acid diethylamide. J. Pharmacol. Exp. Ther. 
247:918-925. 
Pierce, P. A. and S. J. Peroutka. 1989. Evidence for distinct 5-
hydroxytryptamineg binding site subtypes in cortical membrane 
preparations. J. Neurochem. 52:656-658. 
Pritchett, D. B., A. W. Bach, M. Wozny, 0. Taleb, R. Dal Toso, J. C. 
Shin and P. H. Seeburg. 1988. Structure and functional 
expression of cloned rat serotonin 5-HT-2 receptor. EMBO J. 
7:4135-4140. 
Raiteri, M. , G. Maura, G. Bonanno and A. Pittaluga. 1986. Differential 
pharmacology and function of 5-HTi receptors modulating 
287 
transmitter release in rat cerebellum. J. Pharmacol. Exp. Ther. 
237:644-648. 
Rankin, J. H. G,, G. Meschia, E. L. Makowski and F. C. Battaglia. 1971. 
Relationship between uterine and umbilical venous P02 in sheep. 
Am. J. Physiol. 220:1688-1692. 
Richardson, B. P., G. Engel, P. Donatsch and P. A. Stadler. 1985. 
Identification of serotonin M-receptor subtypes and their specific 
blockade by a new class of drugs. Nature 316:126-131. 
Robillard, J. E. and R. E. Weitzman. 1980. Development aspects of the 
fetal renal response to exogenous arginine vasopressin. Am. J. 
Physiol. 238;F407-F414. 
Robinson, S. E. 1982. Interaction of the median raphe nucleus and 
hypothalamic serotonin with cholinergic agents and pressor 
responses in the rat. J. Pharmacol. Exp. Ther. 223:662-668. 
Robson, J. M. and J, B. Senior. 1964. The 5-hydroxytryptamine content 
of the placenta and foetus during pregnancy in mice. Br. J. 
Pharmacol, 22:380-387. 
Robson, J. M. and F. M. Sullivan. 1966. Analysis of actions of 5-
hydroxytryptamine in pregnancy. J. Physiol. 184:717-722. 
Romero, T., J. Covell and W. F. Friedman. 1972. A comparison of 
pressure volume relations of the fetal, newborn and adult heart. 
Am. J. Physiol. 222:1285-1292. 
Rosenfeld, C. R. 1977. Distribution of cardiac output in ovine 
pregnancy. Am. J. Physiol. 232:H231-235. 
Rosenfeld, C. R., F. H. Morriss, Jr., E. J, Makowski, G. Meschia and F. 
C. Battaglia. 1974. Circulatory changes in the reproductive 
tissues of ewes during pregnancy. Gynecol. Invest. 5:252-268. 
Roth, B. L., T. Nakaki, D. M. Chuang and E. Costa. 1984. Aorta 
recognition sites for serotonin (5-HT) are couples to 
phospholipase C and modulate phosphatidylinositol turnover. 
Neuropharmacology 23:1223-1225. 
Roth, B. L., T. Nakaki, D. M. Chuang and E. Costa. 1986. 5-
Hydroxytryptamineg receptors coupled to phospholipase C in rat 
aorta: Modulation of phosphoinositide turnover by phorbol ester. 
J. Pharmacol. Exp. Ther. 238:480-485. 
Rudolph, A. M. and M. A. Heymann. 1974. Fetal and neonatal circulation 
and respiration. Ann. Rev. Physiol. 36:187-207. 
Ryan, M. D., K. E. Clark and M. J. Brody. 1974. Neurogenic and 
288 
mechanical control of canine uterine vascular resistance. Am. J. 
Physiol. 227:547-555. 
Sanders-Bush, E. and P. J. Conn. 1987. Neurochemistry of serotonin 
neuronal systems: Consequences of serotonin receptor activation. 
Pages 95-103 in H. Y. Meltzer, ed. Psychopharmacology: The Third 
Generation of Progress. Raven Press, New York. 
Sanders-Bush, E., K. D. Burris and K. Knoth. 1988, Lysergic acid 
diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial 
agonists at serotonin receptors linked to phosphoinositide 
hydrolysis. J. Pharmacol. Exp. Ther. 246:924-928. 
Saxena, P. R. and P. D. Verdouw. 1985. 5-Carboxamidetryptamine, a 
compound with high affinity for 5-hydroxytryptamine^ binding 
sites, dilates arterioles and constricts arteriovenous 
anastomoses. Br. J. Pharmacol. 84:533-544. 
Schmidt, A. W. and S. J. Peroutka. 1989. 5-Hydroxytryptamine receptor 
"families". FASEB J. 3:2242-2249. 
Schnellmann, R. G., S. J. Waters and D. L. Nelson. 1984, [^H]-5-
hydroxytryptamine binding sites: Species and tissues variation, 
J. Neurochem. 42:65-70. 
Schoeffter, P., C, Waeber, J. M. Palacios and D. Hoyer. 1988. The 5-
hydroxytryptamine S-HT^j receptor subtype is negatively coupled to 
adenylate cyclase in calf substantia nigra. Naunyn-Schmiedeberg's 
Arch. Pharmacol, 337:602-608, 
Shenker, A,, S, Maayani, H, Weinstein and J, R, Green, 1985, Two 5-HT 
receptors linked to adenylate cyclase in guinea pig hippocampus 
are discriminated by 5-carboxamidotryptamine and spiperone, Eur, 
J, Pharmacol, 109:427-429, 
Shinebourne, E. A,, E, K, Vapaavouri, R, L, Williams, M. A, Heymann and 
A, M. Rudolph. 1972. Development of baroreflex activity in 
unanesthetized fetal and neonatal lambs. Circ. Res. 31:710-718. 
Sills, M. A., B. B, Wolff and A. Frazer. 1984. Determination of 
selective and nonselective compounds for the S-HT^g receptor 
subtypes in rat frontal cortex. J. Pharmacol. Exp. Ther. 231:480-
487. 
Silver, M., D, H, Steven and R, S, Comline, 1973, Placental exchange 
and morphology in ruminants and the mare. Pages 245-471 in K. S. 
Comline, K, W. Cross, G, S. Dames and P. W. Nathaniels, eds. 
Foetal and Neonatal Physiology. Cambridge Univ. Press, Cambridge, 
UK. 
Slack, B. E., J. E. Bell and D. J. Benos. 1986. Inositol-1,4,5,-
289 
triphosphate injection mimics fertilization potentials in sea 
urchin eggs. Am. J. Physiol. 250:C340-C344. 
Smith, L. M. and S. J. Peroutka. 1986. Differential effects of 5-
hydroxytryptamine^^ selective drugs on the 5-HT behavioral 
syndrome. Pharmacol. Biochem. Behav. 24:1513-1519. 
Snyder, S. H., L. Faillace and L. Hollister. 1967. 2,5-Dimethoxy-4-
methylamphetamine (STP): A new hallucinogenic drug. Science 
158:669-670. 
Sole, M. J., A. Shum and G. R. Van Loon. 1979. Serotonin: Metabolism 
in the normal and failing heart. Circ. Res. 45:629-634. 
Spedding, M. 1985. Calcium antagonist subgroups. Trends Pharmacol. 
Sci. 6:109-114. 
Spivack, M. 1943. On the presence or absence of nerves in the 
umbilical blood vessels of man and guinea pig. Anat. Rec. 85:85-
109. 
Stark, R. I., S. L. Wardlaw, S. S. Daniel, M. K. Husain, U. M. Sanocka 
and R. L. V. Wiele. 1982. Vasopressin secretion induced hypoxia 
in sheep: Developmental changes and relationship to beta-
adrenergic release. Am. J. Obstet. Gynecol, 143:204-212. 
Stegner, H., R. D. Leake, S. M. Palmer, G. Oakes and D. A. Fisher. 
1984. The effect of hypoxia on neurohypophyseal hormone release 
in fetal and maternal sheep. Pediat. Res. 18:188-191. 
Steven, D. H. 1975. Anatomy of the placenta barrier. Pages 25-56 in 
D. H. Steven, ed. Comparative Placentation. Academic Press, New 
York. 
Stice, S. L., S. P. Ford, J. P. Rosazza and D. E. VanOrden. 1987. Role 
of 4-hydroxylated estradiol in reducing Ca^"*" uptake of uterine 
arterial smooth muscle cells through potential-sensitive channels. 
Biol. Reprod. 36:361-368. 
Tadepalli, A. S., E. Friedman and S. Gershon. 1975. Cardiovascular 
actions of 2,5-dimethoxy-4-methylamphetamine (DOM) in the cat. 
Eur. J. Pharmacol. 31:305-312. 
Taylor, E. W., S. D. Duckies and D. L. Nelson. 1986. Dissociation 
constants of serotonin agonists in the canine basilar artery 
correlate to Ki values at the S-HTi^ binding site. J. Pharmacol. 
Exp. Ther. 236:118-125. 
Thandroyen, F. T., S. Saman and L. H. Opie. 1985. Serotonin and the 
heart: Pharmacological evaluation with the S2-serotonergic 
antagonist ketanserin. Pages 87-94 in P. M. Vanhoutte, ed. 
290 
Serotonin and the Cardiovascular System. Raven Press, New York. 
Thorbert, G., P. Aim, C. Owman and N. -0. Sjoberg. 1977. Regional 
distribution of autonomic nerves in guinea pig uterus. Am. J. 
Physiol. 233:C25-C34. 
Thorbert, G., P. Aim, C. Owman and N. -0. Sjoberg and B. Sporrong. 
1978. Regional changes in structural and functional integrity of 
myometrial adrenergic nerves in pregnant guinea pig, and their 
relationship to the localization of the conceptus. Acta Physiol. 
Scand. 103:120-131. 
Titeler, M., K. Herrick, R. A. Lyon. J. D. Mckenney and R. A. Glennon. 
1985. ®H-DOB: A specific agonist radioligand for S-HTg serotonin 
receptors. Eur. J. Pharmacol. 117:145-146. 
Tomita, H., R. A. Brace, C. Y. Cheung and L. D. Longo. 1985. 
Vasopressin dose-response effects on fetal vascular pressures, 
heart rate, and blood volume. Am. J. Physiol. 249:H974-H980. 
Tranzer, J. P., M. Da Prada and A. Fletcher. 1966. Ultra-structural 
localization of 5-hydroxytryptamine in blood platelets. Nature 
(London) 212:1574-1575. 
Tricklebank, M. D. 1985. The behavioral response to 5-Ht receptor 
agonists and subtypes of the central 5-HT receptor. Trends 
Pharmacol. Sci. 6:403-407. 
Tsmay, M. J. A., E. R. Lumbers and A. D. Stevens. 1979. The action of 
angiotensin II on the baroreflex response of the conscious ewe and 
the conscious fetus. J, Physiol. 288:467-479. 
Tulenko, T. N. 1979. Regional sensitivity to vasoactive polypeptides 
in the human umbilioplacental vasculature. Am. J. Obstet. 
Gynecol. 135:629-636. 
Tuncer, M., N. DoGan, S. Oktay and S. 0. Kayaalp. 1985. Receptor 
mechanisms for 5-hydroxytryptamine in isolated human umbilical 
artery and vein. Arch. Int. Pharmacodyn. 276:17-27. 
Tyce, G. M. 1985. Biochemistry of serotonin. Pager 1-13 in P. M. 
Vanhoutte, ed. Serotonin and the Cardiovascular System. Raven 
Press, New York. 
Van Nueten, J. M. 1983. 5-Hydroxytryptamine and precapillary vessels. 
Fed. Proc. 42:223-227. 
Van Nueten, J. M., P. A. J. Janssen, W. De Ridder and P. M. Vanhoutte. 
1982. Interaction between 5-hydroxytryptamine and other 
vasoconstrictor substances in the isolated femoral artery of the 
rabbit: Effect of ketanserin (R 41468). Eur J. Pharmacol. 
291 
77:281-287. 
Van Nueten, J. M., P. A. J. Janssen, J. Van Beek, R. Xhonneux, T. j. 
Verbeuren and P. M. Vanhoutte. 1981. Vascular effects of 
ketanserln (R 41468), a novel antagonist of S-HTg serotonergic 
receptors. J. Pharmacol. Exp. Ther. 218:217-230. 
Van Nueten, J. M., J. E. Leysen, F. De Clarck and P.M. Vanhoutte. 1984. 
Serotonergic receptor subtypes and vascular reactivity. J. 
Cardiovasc. Pharmacol. 6:5564-5574. 
Van Nueten, J. M. and P. M. Vanhoutte. 1981, Selectivity of calcium 
antagonism and serotonin antagonism with respect to venous and 
arterial tissues. Angiology 32:476-484. 
Van Nueten, J. M. and P. M. Vanhoutte. 1984, Serotonin and vascular 
function. Clin. Anaesthesiol. 1:363-381. 
VanBreemen, C., P. I. Aaronson, C. A. Cauvin, R. D, Loutzenhiser, A. W. 
Mangel and K. Saida. 1982. The calcium cycle in arterial smooth 
muscle. Pages 53-63 in S. F. Flaim and R. Zelis, eds. Calcium 
Blockers. Urban and Schwarzenberg, Baltimore. 
Vanhoutte, P. M. 1982a. Does 5-hydroxytryptamine play a role in 
hypertension? Trends Pharmacol. Sci. 3:370-373. 
Vanhoutte, P. M. 1982b. 5-Hydroxytryptamine, vasospasm and 
hypertension. Pages 163-174 in F. De Clarck and P. M. Vanhoutte, 
eds. 5-Hydroxytryptamine and Peripheral Reactions. Raven Press. 
New York. 
Vanhoutte, P. M. 1985. Peripheral serotonergic receptors and 
hypertension. Pages 123-133 in P. M. Vanhoutte, ed. Serotonin 
and the Cardiovascular System. Raven Press, New York. 
Vapaavuori, E. K. , E. A. Shineboume, R. L. Williams, M. A. Heymann and 
A. M. Rudolph. 1973, Development of cardiovascular responses to 
autonomic blockade in intact fetal and neonatal lambs, Biol, 
Neonate 22:177-184, 
Verdouw, P, D., H, M, Jennewein, J, Mierau and P, R, Saxena, 1985, N-
(3-acetylaminophenyl)piperazine hydrochloride (BEA 1654), a 
putative 5-HTi agonist, causes constriction of arteriovenous 
anastomoses and dilatation of arterioles, Eur, J, Pharmacol, 
107:337-346, 
Wehreberg, W, B,, D, P, Chaichareon, D, J, Dierschke, J, H. Rankin and 
0. J. Ginther. 1977. Vascular dynamics of the reproductive tract 
in the female rhesus monkey: Relative contributions of ovarian 
and uterine arteries. Biol. Reprod. 17:148-153. 
292 
Weiss, S., M. Sebben, D. Kemp and J. Bockaert. 1986. Serotonin 5-HTi 
receptors mediate inhibition of cyclic AMP production in neurons. 
Eur. J. Pharmacol. 120:227-230. 
Wenting, G. J., A. J. J. Woittiez, A. J. Man in't Veld and M. A. D. H. 
Schalekamp. 1984. 5-HT, alphl-adrenoceptors, and blood pressure: 
Effects of ketanserin in essential hypertension and autonomic 
insufficiency. Hypertension 6:100-109. 
Winkelmann, R. K., M. E. Goldyne and R. L. Linscheid. 1976. 
Hypersensitivity of scleroderma cutaneous vascular smooth muscle 
to 5-hydroxytryptamine. Br. J. Dermatol. 95:51-56. 
Winquist, R. J. and D. F. Bohr. 1983. Structural and functional 
changes in cerebral arteries from spontaneously hypertensive rats. 
Hypertension 5:292-297. 
Wiriyathian, S., J. C. Porter, R. P. Naden and C. R. Rosenfeld. 1983. 
Cardiovascular effects and clearance of arginine vasopressin in 
the fetal lamb. Am. J. Physiol. 245:E24-E31. 
Woods, J. R., Jr., A. Dandavino, K. Murayama, C. R, Brinkman, III, and 
N. S. Assali. 1977. Autonomic control of cardiovascular 
functions during neonatal development and in adult sheep. Circ. 
Res. 40:401-407. 
Yagaloff, K. A. and P. R. Hartig. 1985. ^"l-Lysergic acid 
diethylamide binds to a novel serotonergic site on rat choroid 
plexus epithelia cells. J. Neurosci. 5:3178-3183. 
Zhang, L. and D. C. Dyer. Unpublished data. Department of Veterinary, 
Iowa State University. 
293 
ACKNOWLEDGEMENTS 
I wish to express my deep appreciation to my major professor, Dr. 
Donald C. Dyer for his sharp guidance and encouragement throughout my 
graduate study, I am also very grateful to him for his method of 
teaching me the art and science of research and of how to be a 
professional, which will benefit me for the rest of my life. 
I would like to thank Dr. Frederick B. Hembrough for his personal 
commitment to the surgery involved in my dissertation, which 
significantly contributed to the successful outcome of the experiment. 
I would also like to thank the other members of my study committee: Dr. 
Richard L. Engen, Dr. Stephen P. Ford and Dr. Darrell L. Trampel, who at 
various times gave to me important advice and criticism during my 
graduate study at Iowa State University. 
My thanks are extended to Mr. Arthur R. Anderson for his 
assistance in working with me on various computer programs and to Linda, 
Marlene and Mary Jane for typing the manuscripts. 
I also owe my thanks to the fellow students Bruce, Ivan, Pan-
dong, Michael and Jennifer and to the staff members Bill, Dave, Bud and 
Jeannette for their friendship and help in various ways during my stay 
at Iowa State University. 
I appreciate that Jiangxi Agricultural University allowed me to 
come to the United States to pursue my Ph.D. study and that the 
Department of Veterinary Physiology and Pharmacology of Iowa State 
University provided me an opportunity to work as a teaching assistant 
for financial support. 
294 
I wish to express my deep gratitude to my wife, Shumei Yang, for 
the love and courage and to my daughter Sandra. 
Finally, I would like to dedicate this dissertation to my mother 
for all the love and support she gave to me. 
